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Abstract 
The generation of malodour in the human underarm (axilla) is caused by bacterial 
biotransformation of specific malodour precursor molecules contained within non-odorous 
apocrine gland secretions. The dipeptide-conjugated thioalcohol, (S)-(1-(2-hydroxyethyl)-
1-methylbutyl)-L-cysteinylglycine (Cys-Gly-3M3SH) is known to be secreted into the axilla 
and biotransformed into the highly volatile thioalcohol 3-methyl-3-sulfanylhexan-1-ol 
(3M3SH) by members of the axillary microbiota, consisting principally of the genera 
Corynebacterium and Staphylococcus. However, the exact bacterial species that carry out 
this biotransformation have not been thoroughly characterised. Additionally, the route by 
which malodour precursor molecules are transported across the bacterial cell membrane 
to the cytoplasm have not been assessed, and a general disagreement within the 
literature is evident regarding the intracellular catabolic fate of such molecules. 
Here, malodour precursor biotransformation data is presented from a library of skin 
isolated corynebacteria and staphylococci which identified significant variations in 
thioalcohol production across individual bacterial species and strains. Three 
Staphylococcus species, S. hominis, S. haemolyticus and S. lugdunensis were the 
strongest Cys-Gly-3M3SH biotransformers whereas all Corynebacterium spp. assessed 
showed weak or absent catabolism of this substrate. The molecular basis of uptake and 
biotransformation of dipeptide-conjugated malodour precursor compounds in the model 
organism Escherichia coli K-12 was assessed by creating and characterising peptide 
transporter deficient strains, which revealed novel phenotypes for several poorly studied 
peptide transporters in this organism. The relevant E. coli strains were then used as a 
background to overexpress and characterise putative dipeptide-conjugated malodour 
precursor transporters from a strong malodour producing S. hominis isolate. This revealed 
that a general S. hominis peptide transporter mediates Cys-Gly-3M3SH uptake. An in 
silico analysis of putative Cys-Gly-3M3SH catabolic genes revealed a novel cystathionine 
β-lyase-like gene present only in those Staphylococcus species able to biotransform Cys-
Gly-3M3SH, strongly suggesting an involvement in Cys-Gly-3M3SH biotransformation. 
This work provides major advances in understanding the molecular basis of human 
axillary malodour. 
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1.1  Skin structure and perspiration  
The skin is the largest organ of the human body, playing a critical role in thermoregulation. 
Excessive internal body temperatures (>40oC) result in protein denaturation, cell death 
and ultimately multiple organ failure (Wilke et al., 2007). It is the job of the skin to regulate 
core body temperature under excessive environmental temperature and during 
physiological stress, particularly during immune system activation in response to invading 
microbial pathogens. The primary means of regulating core body temperature is by 
perspiration (sweating). During sweating, thermal energy is released when the water 
component of sweat evaporates from the surface of the skin in a process known as 
evaporative cooling (Shelley & Hurley, 1975). This process has the net effect of lowering 
the temperature of the skin and underlying tissue. Sweating is controlled by the central 
nervous system, with the hypothalamus being the primary portion of the brain controlling 
this process by responding to fluctuations in core body temperature, stress, changes in 
the levels of certain hormones and the concentration of pyrogens present in the 
bloodstream (Holzle, 2002). The physical act of sweating is performed by sweat glands, 
which are tubular exocrine glands on the surface of mammalian skin. Most mammals have 
two types of sweat gland, apocrine and eccrine. A key difference between these sweat 
glands is that the apocrine gland opens into a hair follicle whereas the eccrine gland 
opens directly onto the surface of the skin. The apocrine/eccrine classification was 
devised in the early 1900s by Schiefferdecker (1922) and still stands today. A 
comprehensive review of apocrine and eccrine glands is provided below. An additional 
type of skin-associated exocrine gland is the sebaceous gland which is relatively evenly 
distributed across the skin, with the exception of the palms of the hands and soles of the 
feet. Sebaceous glands are at particularly high density on the scalp and face, where up to 
900 glands per cm2 of skin can be present (Folk & Semken, 1991). Sebaceous glands are 
proposed to lubricate the skin by secreting a waxy substance known as sebum which is 
thought to provide a physical defence barrier against invading microorganisms (Boutelier, 
1959), but sebaceous glands are not involved in sweating. 
1.1.1  The eccrine gland 
Located at the top, shallow portion of the dermis, the eccrine gland is almost exclusively 
involved in thermoregulatory sweating. In humans, chimpanzees and gorillas, it is 
distributed evenly across the entire surface of the skin, with particularly concentrated 
regions in the palms of the hands and soles of the feet (Robertshaw, 1985). In fact, on the 
palms of the hand, human skin can contain as many as 2000 eccrine glands per cm2. This 
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is significantly higher than other areas of the body such as the trunk and limbs which 
contain up to 10-fold fewer (Weiner & Hellmann, 1959). Estimations of the total number of 
eccrine glands on the entire surface area of human skin range from 1.6 to 4.0 x 106, 
which, when averaged out, equates to approximately 80 to 200 cm-2 skin (Kawahata, 
1950). As well as providing evaporative cooling, the eccrine gland is occasionally involved 
in an additional type of sweating termed emotional sweating. Emotional sweating is a 
specific stress reaction whereby sweat production is increased in response to an 
environmental stimulus such as pain, fear, mental stress or other physiological stimuli. It is 
thought to be controlled, at least in part, by the amygdala (Asahina et al., 2003). The few 
eccrine sweat glands involved in emotional sweating are innervated by cholinergic nerves, 
that is, they are activated specifically and exclusively by the neurotransmitter 
acetycholine. A specific example of this response is the observed heavy sweating on the 
palms of the hands and soles of the feet as a fight-or-flight response, which is carried out 
by a concentrated group of eccrine glands in these regions. This process is evident in 
many mammals, including humans, and serves to increase friction in the hands and feet 
to reduce slipping and aid in escape from predators (Adelman et al., 1975).  
Eccrine sweat consists mainly of water, but is very hypotonic as it contains high 
concentrations of ionic salts such as Na+, K+ and Cl-. NaCl is said to account for up to 90% 
of the osmotic activity of sweat (van Heyningen, 1952), but this varies considerably 
between individuals. In fact, sufferers of pancreatic cystic fibrosis have such altered 
electrolyte composition that a clinical diagnosis of the condition can be made on this basis 
alone (Naruse et al., 2004).  Eccrine sweat also contains small waste-product molecules 
such as lactate (Patterson et al., 2000), accounting for the slight acidity of eccrine sweat, 
of which, the pH varies between approximately 4.0 and 6.0 (Shelley et al., 1953). Along 
with electrolytes and lactate, eccrine sweat typically contains amino acids such as 
histidine, lysine and arginine (Hirokawa et al., 2007), oligosaccharides and urea (Mosher, 
1933), trace elements of metals such as zinc, copper, nickel and cadmium (Cohn & 
Emmett, 1978) and even novel antimicrobial peptides such as dermcidin (Schittek et al., 
2001). The total volume of sweat secreted by an individual is reported to be as much as 
10 litres per day (Kuno, 1965). Coincidentally, the dissipation of between 6 to 8 litres of 
sweat per day is equivalent to an evaporative heat loss of approximately 600 kcal m-2 skin 
hr-1, which is said to be a sufficient amount to allow Homo sapiens to carry out a full day’s 
work in a hot, dry, sun-exposed environment without suffering heat exhaustion, conditions 
similar to those observed in prehistoric equatorial climates (Weiner & Hemmlann, 1959). 
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1.1.2  The apocrine gland 
The apocrine gland is distinct from the eccrine gland both morphologically and by the 
pattern of distribution across the skin and spatial locality within the dermal layers. 
Apocrine glands are spongy in appearance and located subcutaneously, deep inside the 
dermis. In contrast to the eccrine gland, apocrine glands are relatively scarcely distributed 
across human skin, with particular clustering occurring almost exclusively in the armpit 
(axilla), but also within the nipples and areolae of the breast, ear canal and in the perianal 
and pubic regions (Kurosumi et al., 1984). The limited and concentrated spatial 
distribution of the apocrine gland is unique to only a handful of animals such as humans, 
chimpanzees and gorillas. The skin of most other primates and mammals is almost 
exclusively covered by apocrine glands. It is argued that the human apocrine gland is an 
evolutionary relic that was once involved in evaporative cooling but is now only retained 
by mammals that did not develop an eccrine gland system for thermoregulation 
(Montagna & Parakkal, 1974). The structure and spatial distribution of glands within the 
human axilla is shown in Fig. 1.1. In contrast to the eccrine gland, the apocrine gland has 
evolved solely to respond to emotional stimuli. Whereas the limited numbers of 
emotionally-responsive eccrine glands are activated exclusively by the neurotransmitter 
acetylcholine, all apocrine glands are innervated specifically by sympathetic adrenergic 
nerves, that is, they are activated by adrenaline (Hurley, 1953). This phenomenon was 
demonstrated empirically in the 1950’s in a series of experiments which involved injecting 
subjects with diluted adrenaline, noradrenaline or acetylcholine and measuring axillary 
sweat secretions (Shelley et al., 1953). In all subjects tested, specific apocrine sweating 
was exclusively observed following adrenaline or noradrenaline injection whereas eccrine 
sweating was specifically observed following injection of acetylcholine. In the same study, 
subjects were exposed to infra-red heat for a period of 30 min. An absence of apocrine 
secretion was noted but a significant amount of eccrine sweat was apparent, 
demonstrating that eccrine glands and not apocrine glands are involved in 
thermoregulation. The two main emotions that promote apocrine secretion are fear and 
pain. In an early study on the effect of fear (apprehension) on apocrine sweating, visible 
apocrine secretions were visible in several individual males immediately prior to minor 
dermatological surgery (Shelley et al., 1953). In the same study, the effect of pain on 
apocrine sweating was studied using pregnant women in different stages of labour. It was 
observed that as the uterine contractions intensified, so did apocrine secretions, directly 
correlating with an increased level of pain. 
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Figure 1.1. The glandular composition of the human axilla. Adapted from Gallik (2013). 
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The chemical composition of apocrine and eccrine sweat is very similar, but apocrine 
sweat additionally contains a relatively high concentration of lipids (20 mg/ml), most of 
which are cholesterol or triglyceride (76.2%) or fatty acid (19.2%) (Leyden et al., 1981). 
Proteins are also a significant component, accounting for approximately 10% of apocrine 
sweat (Gower, 1988). These specific secretions give apocrine sweat a characteristic milky 
and viscid appearance that dries with a glue-like consistency (Folk & Semken, 1991). The 
pH of apocrine sweat ranges from approximately 5.0 to 6.5, making it slightly more 
alkaline than eccrine sweat due to the apparent absence of lactate (Shelley et al., 1953). 
Importantly in the context of this work, trace amounts of many other small molecules and 
compounds that are particularly significant for characteristic human body odour are also 
secreted in apocrine sweat and will be discussed in detail later. 
1.2 The evolutionary origins and historical significance of body 
odour 
The production of body odour is well accepted to be an evolutionary trait, with strong 
historical associations with ancestral mate selection, sexual attraction and kin recognition. 
It is well documented that newborn infants can correctly identify their own mothers breast 
(Russell, 1976) and axillary scent (Cernoch & Porter, 1985) by olfactory signals, 
presumably provided by the concentrated cluster of apocrine glands in those regions, 
particularly the axillae. These studies outline the apparent role of body odour in non-verbal 
communication between mothers and their infants, with particular emphasis on those 
odours emanating from clusters of apocrine glands. 
The role of axillary body odour in sexual attraction has been described since the mid-
1800s when anthropologists began to suggest that the function of the human axilla was to 
produce scent or odour deemed to be attractive to members of the opposite sex. In 1840, 
Thomas Laycock remarked on human body odour: 
“The principal seat of this odour is in the follicles of the axillae, and is not given off before 
puberty. It is most powerful in individuals who are continent, or with strong sexual powers, 
and in some it is very pleasant.” 
Similarly in 1901, Albert Hagen, stated:  
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“The axillary scent in man seems to be superior to the scent of the sexual organ or any 
other part of the body...as had already been described, the apocrine glands in the axillae, 
to which the axillary scent is essentially due, develop first a few years before the onset of 
puberty and undergo some cyclic or temporary changes concomitantly with the 
menstruation or pregnancy. This also supports the existence of sexual significance of the 
axillary scent.” (Stoddart, 1991) 
In human development, the apocrine gland is visible by the third trimester of pregnancy, 
developing first as a coiled rod of cells (Stoddart, 1991). By age four, the human apocrine 
gland begins to enlarge. By age seven, the muscle fibres required to expel apocrine 
secretions begin to develop in the basal cells. Apocrine gland secretion is not observed 
until puberty but continues from this point throughout life. Further support for the notion of 
the axillary apocrine gland as a scent organ followed throughout the 20th century, with 
observations that the apocrine gland develops slightly earlier and to a higher density in 
females than males (Schiefferdecker, 1922). This observation strongly suggested to 
researchers that the apocrine gland is involved in sexual attraction with odours emanating 
from the axillary region, particularly in sexually active females, serving as a signal to 
attract a sexual partner. This opinion has continued to be favourable into the present day. 
Rikowski & Grammar (1999) demonstrated that males perceive the body odour of facially 
attractive women as more pleasant than less facially attractive women. However, the 
historical opinion that ‘attractive’ human body odour is stronger in females during their 
most fertile periods has been significantly challenged, particularly by Thornhill & 
Gangestad (1999) who demonstrated that there are no differences between the perceived 
attractiveness of female body odour at different stages of the menstrual cycle, suggesting 
that female fertility does not influence body odour profile. An interesting hypothesis has 
also been proposed by Wedekind et al. (1995), who suggest that sexual attractiveness 
through body odour, though not necessarily axillary odour, is partly controlled by products 
of the major histocompatibility complex (MHC), a large set of cell-surface molecules 
controlling a significant part of the immune system. Wedekind demonstrated that subjects 
rate the relative pleasantness of other individuals’ body odour as more attractive if they 
have an MHC profile discordant to their own. The reasons for this have not been fully 
elucidated, but it is hypothesised that selecting a mate with a different MHC profile would 
promote MHC heterozygosity, in turn serving to increase protection against rapidly 
evolving pathogens and also, more simply, prevent inbreeding within the population. The 
‘inbreeding avoidance hypothesis’ is particularly favoured for mice, where a distinct fitness 
disadvantage is observed in those populations with severe inbreeding (Meagher et al., 
2000). Fittingly, it has also been demonstrated that the MHC profile influences the mate 
choice of mice, who, just like humans, tend to look for mates with dissimilar MHC 
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phenotypes (Wedekind & Penn, 2000). Interestingly, Wedekind et al. (1995) also 
described that mice are able to recognise human MHC scents from urine samples and 
subsequently ascertained that the converse was also true, demonstrating that humans 
can distinguish between two genetically identical mice differing only in their MHC profile 
by scent alone. 
Clearly therefore, there appears to be strong positive selection for particular body odour 
profiles to develop in humans. The odour profiles generated, particularly in the axillae, 
seem to be geared towards enhancing reproductive biology. From studies on kin 
recognition, the odour profiles appear to be extremely individualistic and it is likely that 
they are more closely controlled than one would imagine.  
1.3  The origins of axillary (mal)odour 
The term ‘axillary malodour’ has crept into existence and everyday use over the past 
century. It is now generally applied to odour emanating from the axillary region of humans. 
For this reason, the term axillary malodour will be used henceforth in this context.  Despite 
reports dating back to the 1800’s regarding axillary odour, it was not until the 1950’s that 
the biological origins of axillary malodour began to be unravelled. Prior to 1953 there was 
no knowledge of microbiological involvement in producing odorous compounds directly 
from human apocrine gland secretions, which is now the generally accepted route to 
human axillary malodour. It was the pioneering work of Walter B Shelley that first 
described this in detail. Shelley et al. (1953) began by demonstrating that apocrine sweat 
was a sterile fluid immediately after secretion onto the surface area of the axilla. Multiple 
vials of sterile and non-sterile apocrine sweat were then prepared, along with several vials 
of independently isolated eccrine sweat to serve as a control. All vials were incubated at 
room temperature for 2 weeks and subjective odour measurements taken by two 
independent panellists at appropriate time intervals. It was observed that only those vials 
containing non-sterile apocrine sweat produced an odour, which appeared very rapidly 
following only 6 hours incubation. Vials containing eccrine sweat remained completely 
odourless. Apocrine-associated odour production could be inhibited, although not 
completely, by applying an antibacterial wash to the axilla prior to isolating apocrine sweat 
samples. Shelley concluded that bacterial biotransformation must be responsible for the 
odour produced in the non-sterile apocrine sweat samples and that specific components 
of apocrine sweat must serve as primary substrates for production of such odour. A later 
study by Shehadeh & Kligman (1963) narrowed down the bacteria responsible for this 
phenotype to Gram-positive organisms. Cultures of the most commonly isolated axillary 
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bacteria were prepared in rich growth media and transferred to glass capillary tubes. 
Human-isolated apocrine secretions were subsequently added to the bacterial cultures 
and incubated for 48 hours, followed by subjective odour analysis. It was observed that 
Gram-positive bacteria, particularly coagulase negative staphylococci along with 
diphtheroids (non-pathogenic corynebacteria) produced the most pungent smell 
characteristic of typical axillary malodour, whereas all Gram-negative bacteria produced 
little or no characteristic axillary malodour. 
1.3.1 The microbiota of the human axilla and its correlation with 
malodour 
Studies through the latter part of the 20th century attempted to fully characterise the 
composition of the axillary microbiota in order to specifically identify which bacteria were 
responsible for malodour. Aly & Maibach (1977) observed a significant coryneform 
domination of the axilla when they noted that coryneforms represented, on average 
(n=66), 96% of the total bacteria in this region. The term coryneform was coined by 
Cowan (1968) and covers all non-sporulating, pleiomorphic rod-shaped bacteria. 
Historically, it has been used interchangeably with corynebacteria, despite the observation 
that only around 60% of skin coryneforms belong to the genus Corynebacterium (Pitcher, 
1983). Throughout the late 1960’s to the 1980’s studies confirmed that corynebacteria and 
the increasingly relevant genus Staphylococcus represented the dominant bacterial 
genera of the axillary microflora. Marples & Williamson (1969) identified that, on average, 
coagulase-negative cocci (likely consisting mainly of non-pathogenic staphylococci) and 
lipophilic coryneforms represented 85% of the total axillary flora. Kloos & Musselwhite 
(1975) found that coryneforms represented approximately 70% of the axillary population. 
A more refined study by Leyden et al. (1981) examined the previously reported 
corynebacterial domination of the axilla and began to assess, in detail, the axillary 
microbiota and its relationship with axillary odour. Through culture-based methods, 
Leyden compiled and averaged data on the prevalence and density of the axillary 
microbiota in both male (n=128) and female (n=77) subjects. This data is displayed in 
Table 1.1. In all subjects, members of the Micrococcaceae could be cultured, which, when 
broken down to the genus level, consisted solely of Staphylococcus spp., mainly S. 
epidermidis (51%) and S. saprophyticus (29%). It should be noted that this historic 
misassignment of staphylococci within the Micrococcaceae family has since been 
rectified. The overall density of these bacteria was approximately three-fold greater in 
females than in males. 
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When comparing the ratio of staphylococci and corynebacteria, Leyden’s data suggested 
that, on average, approximately 75% of the bacterial load within the axilla consisted of 
corynebacteria, with staphylococci accounting for the majority of the remaining 25%. 
Other minor component microbes of the axilla were identified as Gram-negative rods and 
Propionibacterium spp., but these bacteria were present at densities at least two log (base 
10)-fold lower than either staphylococci or lipophilic corynebacteria. The presence of 
corynebacteria in the human axilla was supported by Jackman & Noble (1983) who 
identified lipophilic diphtheroids (now an obsolete taxonomic term historically applied to 
mean a microorgansism which resembles the diphtheria-causing bacterium, C. 
diphtheriae) and large colony diptheroids, consisting exclusively of Corynebacterium spp., 
which, when taken together were present, but not always dominant, in almost all 
individuals assessed. It was also demonstrated that males, on average, are three times 
more likely to have a coryneform-dominated axilla than females. However, in absolute 
terms, Jackman & Noble disagreed with Leyden’s observation regarding the mean 
distribution of corynebacteria and staphylococci, and stated that coryneform- or coccal-
dominated floras were evenly split between a representative population.  
Leyden went on to relate this data to axillary malodour. He observed that individuals 
described as having apocrine odour, that is “the offensive pungent smell so typical of body 
odour”, reproducibly had a significantly higher density of total bacteria within their axillae 
(1.3 x 105 cm-2 compared to 4.8 x104 cm-2). These bacteria were principally lipophilic 
diphtheroids, whereas Micrococcaceae (staphylococci) that were associated with 
individual axillae did not exhibit typical malodour, but displayed a distinctive non-apocrine 
odour phenotype. Leyden was one of the first to suggest a correlation between axillary 
malodour and a high density of corynebacterial commensals within the axilla. Jackman 
and Noble supported this association, stating that individuals exhibiting strong axillary 
malodour have a coryneform-dominated axilla, which usually consists of greater than 1.6 x 
105 total coryneform bacteria cm-2 skin.  
Recent work using more sophisticated culture-based methods was carried out by Taylor et 
al. (2003). The approach of this study was similar to that of Leyden, whereby axillary 
samples were taken from multiple male and female volunteers and bacteria cultured in 
both aerobic and anaerobic growth media. The results revealed particular genus-specific 
differences between individuals, with the axillary region dominated by either staphylococci 
(52% of subjects) or aerobic coryneforms (34% of subjects). The remaining subjects 
(14%) had a propionibacteria-dominated axilla. Taylor then assessed the relationship 
between microbial counts and associated malodour using a malodour scoring system 
which allows trained assessors to subjectively assess axillary malodour intensity. The 
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microbial composition of each respective axilla is then correlated with malodour on a 5-
point hedonic scale. A significant association between malodour and high microbial counts 
was observed for total aerobes (aerobic coryneforms, staphylococci, micrococci and 
Malassezia spp., combined), aerobic coryneforms alone and micrococci alone. No 
significant correlation between malodour and high population densities of staphylococci, 
propionibacteria or Malassezia spp. was observed. In order to identify the most prominent 
Corynebacterium spp. within the axilla, Taylor isolated 16S rDNA from 61 aerobic 
coryneforms, originally isolated from cultured axillary samples. A significant proportion 
(67%) was identified with the highest similarity score to Corynebacterium G-2 CDC 
G5840, identified earlier as C. tuberculostearicum (Riegel et al., 1995). 7% (4 out of 61 
isolates) were identified as C. mucifaciens with other species such as C. afermentans, C. 
amycolatum, C. genitalium and C. riegelii each representing less than 4% of the total 
corynebacterial pool. This data provided further evidence that aerobic bacteria, particularly 
corynebacteria, were strongly associated with malodour, with C. tuberculostearicum being 
the most likely culprit based on its high prevalence relative to other aerobic coryneforms 
isolated from the axilla.  
Further attempts to characterise the axillary microbiota have adopted culture-independent 
metagenomic and molecular-based techniques. Callewaert et al. (2013) sampled the 
axillary microbiome of 53 individuals and used high-throughput next-generation DNA 
sequencing to characterise microbial populations of these samples. Again, similar to 
Taylor et al. (2003), Callewaert observed either a corynebacterial-dominated (39% of 
subjects) or staphylococcal-dominated axilla (61% of subjects). Species-level 
discrimination within these samples was not entirely possible, but within the 
staphylococcal-dominated axilla, S. epidermidis appeared to be the most abundant 
species but with distinct populations of S. hominis and an unspeciated Staphylococcus sp. 
also detected. Gender-specific differences were also apparent, with females more likely to 
have staphylococcal-dominated axillae than males. The staphylococcal-dominated axillae 
phenotype was echoed by Costello et al. (2009) who probed microbial colonisation of 
various sites on human skin, including the axilla. Egert et al. (2011) adopted a slightly 
different study focus and assessed, in detail, the bacterial population symmetry between 
the left and right axillae both intra- and inter-personally using a pool of 10 male volunteers. 
Statistically significant differences were observed between individuals but not between the 
left and right axillae of the same individual, a phenomenon reaffirmed in a later study 
(Callewaert et al., 2013). Within Egert’s study, species discrimination of axillary-isolated 
staphylococci and corynebacteria revealed a Staphylococcus species bias of S. 
epidermidis and S. hominis, whereas the majority of Corynebacterium species consisted 
of either C. tuberculostearicum (echoing the findings of Taylor et al., 2003) or C. 
25 

kroppenstedtii. In addition to the two major axillary-colonising genera, several samples of 
the Gram-positive anaerobic coccus Anaerococcus sp. DQ847450 were identified. This 
represented a novel axillary commensal, as members of this genus are commonly isolated 
exclusively from clinical samples (Song et al., 2007). These bacteria were presumably not 
isolated previously due to insufficient anaerobic culturing techniques. It is important to 
note that Egert’s analysis assessed pooled samples from only three individual axillae and 
therefore cannot be satisfactorily representative of a universal axillary microbiota. 
Although over the past decades there appears to have been a gradual switch from the 
view that the human axilla is completely dominated by corynebacteria to the position that 
the majority of axillae are marginally dominated by staphylococci, a consensus on the 
exact microbial make-up of the axilla remains unresolved. Collectively, microbiome 
studies show huge variation in the abundance of not only species but also genera across 
the skin microbiome, prohibiting the assertion of a ‘typical’ axillary carriage of bacteria. 
Nevertheless, a significant improvement in the ability to isolate and identify bacteria within 
this environmental niche has emerged, most likely brought about by improvements in 
bacterial isolation techniques, which, in their infancy, likely inadvertently excluded or 
prohibited the growth of certain bacteria and promoted the growth of others, leading to 
inherent bias in the final data. In fact, Leyden et al. (1981) remarked that the disparity in 
bacterial numbers observed in his study and the study of Aly & Maibach (1977) were likely 
due to environmental, hygiene or sampling differences. The advent of new methods to 
detect, enumerate and characterise the resident skin microbiota such as high-throughput 
DNA sequencing has undoubtedly also aided in the position that we are at today and is 
likely to play a central role in future species and strain discrimination of the axillary 
microbiota. 
1.4 The biochemical basis of axillary malodour 
It is now generally accepted that three classes of odorous molecule are responsible for 
axillary malodour. These are odorous steroids, volatile fatty acids (VFAs) and thioalcohols, 
which all exhibit a distinct and characteristic odour, culminating in what modern society 
would term ‘body odour’. The generation of these odorous molecules is, as reported 
previously (Shelley et al., 1953) dependent upon biotransformation of their constituent 
non-odorous precursor molecule(s) by members of the resident axillary microbiota. The 
three classes of odorous molecules are discussed below. 
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1.4.1  Odorous steroids 
The first class of malodorous molecules, odorous steroids, were discovered in the 1970’s, 
with 5α-androst-16-en-3-one (androstenone) being one of the first discovered on human 
skin (Gower, 1972), closely followed by its respective alcohol, 5α-androst-16-en-3α-ol 
(androstenol) (Brooksbank et al., 1974). 4,16-Androstadien-3-one (androstadienone) is 
also present at detectable levels (Gower et al., 1994). These molecules are collectively 
termed 16-androstenes (Table 1.2). Androstenone, an important porcine pheromone, was 
subsequently isolated directly from the human axilla (Claus & Alsing, 1976), where, at the 
time, it was thought to be one of the key contributors to axillary malodour. The postulated 
odourless precursor molecules of 16-androstenes were testosterone, 5α-
dihydrotestosterone (DHT) and pregnenolone, but none of these molecules appeared to 
be converted to appreciable levels of 16-androstenes by incubation with mixed 
populations of aerobic corynebacteria (Nixon et al., 1986, Gower et al., 1986). The 
average olfactory thresholds for the commonly isolated odorous axillary steroids, 
androsterone and androstenol are 0.18 parts per billion (ppb) and 6.2 ppb, respectively 
(Amoore et al., 1977). It has been stated that the physiological concentrations of such 
molecules are in the low pmol cm-2 axillary skin (Gower et al., 1994). This means that 
theoretically, odorous steroids are present at a high enough concentration to contribute to 
axillary malodour.  Direct bacterial biotransformation of 16-androstene precursor 
molecules has been shown by Tue et al. (1998) who demonstrated that corynebacteria 
were able to biotransform testosterone into androstenedione and androstanedione. 
However, testosterone and other precursors of these odorous steroids are not present at 
significant concentrations in human axillary secretions. In a later study it was 
demonstrated that no single Corynebacterium spp. was able to perform all of the 
necessary biochemical reactions required to biotransform a common axillary steroid 
precursor, 5,16-androstadien-3-ol, into the full complement of odorous steroid products, 
identifiable by gas chromatography-mass spectrometry (GC-MS) (Austin & Ellis, 2003). 
Those bacteria that were able to produce detectable levels of odorous molecules did so 
only after prolonged (48 h) incubation and were found to be present at insignificant levels 
within the axillary microbiota. 
When the field of odorous axillary steroids is assessed as a whole, it becomes apparent 
that there are no reports linking 16-androstenes to underarm odour when assessing total 
body odour as a whole, in vivo. Zeng et al. (1991) undertook an organoleptic evaluation of 
human axillary odour using GC-MS and asked panellists to identify characteristic body 
odour-type notes. Despite identifying distinct peaks for 16-androstenes, the panellists did 
not identify these molecules as being characteristic of axillary malodour. This is possibly 
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because it has been reported that humans demonstrate a significant qualitative variation 
in the perceived olfactory odour notes of these molecules, particularly androstenone, 
which has been described by some panellists as ‘sweaty and urinous’ and by others as 
‘floral and sweet’. 
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Table 1.2. Major odorous steroid molecules identified in non-sterile axillary secretions 
Molecule Chemical structure Reference 
5α-androst-16-en-3-one 
 
(androstenone) 
 
Gower (1972) 
5α-androst-16-en-3α-ol 
 
(androstenol) 
 
Brooksbank et al. (1974) 
4,16-androstadien-3-one 
 
(androstadienone) 
 
Gower et al. (1994) 
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Additionally, it is estimated that up to 50% of individuals are specifically anosmic to 
androstenone, that is, they have no olfactory perception of this molecule (Amoore et al., 
1977). Therefore, odour intensity and descriptors applied to 16-androstenes are likely to 
be subjective and unique to the individual assessor and may therefore be unimportant in 
defining the highly characteristic and orthodox smell of axillary malodour.  Due to these 
insights, the notion that odorous steroids are a major contributor to axillary malodour has 
quickly lost favour and it is now widely accepted that they play a minor or insignificant role 
(James et al., 2013). 
1.4.2  Volatile fatty acids (VFAs) 
Short-to-medium chain (C2-C11) VFAs (Table 1.3) have been routinely isolated from the 
human axilla and are commonly accepted to be involved in malodour. Short-chain VFA 
malodorants, commonly defined as acetic (C2) and propionic (C3) acid are thought to be 
produced via microbial fermentation of glycerol and lactic acid, both naturally present on 
the surface of the skin. Lactic acid is particularly abundant on skin with a reported 
concentration of 2.48 ± 0.17 mM (Petersen, 1999). Both glycerol and lactic acid can be 
broken down efficiently by Propionibacterium avidum, a widely isolated skin commensal 
(Bojar & Holland, 2004) into significant quantities of propionic acid (James et al., 2004). 
Similarly, branched aliphatic amino acids such as leucine, isoleucine and valine have the 
potential to be metabolised by commensal bacteria to other short-chain VFAs (C4-C5), 
including 3-methylbutanoic acid (isovaleric acid). Isovaleric acid is demonstrably produced 
directly from amino acid catabolism by both propionibacteria (Thierry et al., 2002) and 
multiple Staphylococcus spp. (James et al., 2004, James et al., 2013). However, due to 
the widespread distribution of short-chain VFA precursor substrates (glycerol, lactic acid 
and branched-chain amino acids) not only within the axilla, but across the entire surface of 
the skin, along with the plethora of microorganisms with the inherent ability to metabolise 
these simple molecules, short-chain VFAs are likely to be a feature of general sweat 
malodour and not specifically characteristic of underarm malodour. 
Medium-chain VFAs have a more prominent role in axillary malodour. Using a GC-MS 
approach, Zeng et al. (1991) identified key axillary malodorants by asking panellists to 
distinguish typical axillary malodour scents collected from the axillary extracts of six male 
donors. The molecules responsible for these scents were then identified by isolating the 
region of the chromatogram where the panellists identified strong characteristic odours.  
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Table 1.3. Selected high-odour impact VFAs isolated from hydrolysed human axillary 
extracts 
Molecule Chemical structure Reference 
Acetic acid 
 
James et al. 
(2004) 
Propionic acid 
 
James et al. 
(2004) 
3-methylbutanoic acid 
(Isovaleric acid) 
 
James et al. 
(2004) 
(E)-3-methyl-2-hexenoic 
acid 
E-(3M2H) 
 
Zeng et al. 
(1991) 
Natsch et al. 
(2003) 
(Z)-3-methyl-2-hexenoic 
acid 
Z-(3M2H) 
 
Zeng et al. 
(1991) 
 
Natsch et al. 
(2003)
3-methylhexanoic acid 
(3MH) 
 
Zeng et al. 
(1991)
7-octenoic acid 
 
Zeng et al. 
(1991)
 
 
n-hexanoic acid 
 
 
 
Zeng et al. 
(1991)
4-ethylpentanoic acid 
 
 
Zeng et al. 
(1991)
2-methylheptanoic acid 
 
Zeng et al. 
(1991)
3-hydroxy-3-
methylhexanoic acid  
(HMHA) 
 
Natsch et al. 
(2003) 
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Several odorous compounds were identified within the extracts, with the most abundant 
molecule being 3-methyl-2-hexenoic acid, of which, both the E- and Z- isomer were 
identified, but with (E)-3-methyl-2-hexenoic acid being the major component (10-fold more 
abundant). For simplicity, (E)-3-methyl-2-hexenoic acid will henceforth be referred to as 
3M2H. 3M2H was described by odour assessors as sweaty, burnt, acrid and musty. Other 
high-impact malodorants were also identified in lower quantities relative to 3M2H, some of 
which exhibited particularly strong odour properties. Of the molecules identified, those 
exhibiting unsaturation or branching appeared to have the strongest odour. Some of these 
molecules are shown in Table 1.3. Exhibiting both unsaturation and branching, 3M2H 
displays one of the highest odour impacts of all the identified molecules. Historically, 
3M2H was described as a characteristic odour of clinical patients suffering from 
schizophrenia (Smith et al., 1969), but the same group later reported that it was also 
present in healthy patients (Gordon et al., 1973). Within Zeng’s study, four independent 
odour assessors agreed that characteristic underarm malodour emanated from the acid-
fraction of the extracted axillary material and not the steroidal fraction, strongly suggesting 
that VFAs, particularly 3M2H and not odorous steroids, as previously described, are major 
contributors to characteristic axillary malodour.  
At this time, the biochemical and microbiological route to VFA production was unknown. 
Given that apocrine secretions are odourless (Shelley et al., 1953) it was postulated that 
odorous VFAs, specifically 3M2H, would be initially conjugated to a molecule or protein 
present in apocrine secretions and subsequently metabolised by the axillary microbiota 
once secreted into the axilla. Originally it was believed that these molecules were non-
covalently attached to either of two proteins identified in apocrine sweat, Apocrine 
Secretion Odor-Binding proteins 1 and 2 (ASOB1 and ASOB2), with the offending 3M2H 
being liberated by an as yet undefined complement of bacterial proteases (Spielman et 
al., 1995). Subsequently, Zeng et al. (1996), showed that ASOB2 was a homologue of 
ApoD, a lipocalin protein and part of the α2µ-microglobulin superfamily; a large group of 
carrier proteins with the capacity to bind small hydrophobic molecules, including lipids 
(Flower, 1996). This raised the possibility that malodour precursor molecules were 
transported to the axilla by a similar mechanism to some mammalian odorants. Typically, 
mammalian odour molecules that play a key role in chemoattraction and chemical 
signalling are carried to the desired cutaneous location by a subclass of lipocalins, the 
odorant binding proteins (OBPs) (Tegoni et al., 2000) where they are subsequently 
liberated by commensal microorganisms in these regions. 
This hypothesis was challenged by Natsch et al. (2003), who used a sophisticated GC-MS 
approach to demonstrate that 3M2H, along with a newly-identified and highly abundant 
32 

VFA, 3-hydroxy-3-methylhexanoic acid (HMHA), were initially conjugated to an L-
glutamine amino acid within sterile apocrine secretions. 3M2H and HMHA were shown to 
bind to the Nα-atom of L-glutamine and these VFA malodour precursor molecules were 
given the functional titles 3M2H-Gln and HMHA-Gln, respectively. From the structure of 
these molecules, it was predicted that Nα-acylglutamine aminoacylase activity would be 
required to release the odorous molecule from its respective precursor. This was indirectly 
demonstrated when axillary isolated Corynebacterium spp., namely C. jeikeium, C. bovis 
and C. striatum were shown to release appreciable quantities of 3M2H and HMHA from 
their respective glutamine-conjugated precursor molecules. This activity was not apparent 
in S. epidermidis, S. capitis or Micrococcus luteus. The putative zinc-dependent Nα-
acylglutamine aminoacylase was subsequently cloned from C. striatum axillary isolate 20 
(Ax20) and recombinantly expressed in E. coli. Pure recombinant enzyme displayed 
activity towards both 3M2H-Gln and HMHA-Gln but interestingly showed the highest Vmax 
and Km towards a synthetic substrate, Nα-decanoyl-Gln. Nevertheless, this work 
represented the first direct demonstration that 3M2H and HMHA are released via bacterial 
Nα-acylglutamine aminoacylase activity. The involvement of HMHA and 3M2H in axillary 
malodour was supported by Troccaz et al. (2009), who described the minimum olfactory 
values for these molecules, that is, the lowest detectable levels for the human nose of 
each molecule in gas phase, averaged across 30 individual odour assessors. The lowest 
detectable level (pg L-1 air) of 3M2H was 202.0 and for HMHA, 175.0, which equates to 
0.202 and 0.175 parts per trillion, respectively. With reported concentrations of HMHA-Gln 
averaging 113.5 mg L-1 sweat (Troccaz et al., 2009), clearly an extremely small 
percentage of the precursor needs to be biotransformed to release the levels of VFA 
required to activate the human olfactory system. A plethora of other Nα-acylglutamine 
aminoacylase-hydrolysable Gln-conjugated VFAs were subsequently identified in axillary 
sweat isolated from multiple sweat donors (Natsch et al., 2006). These were present in 
extremely variable quantities inter-individually, leading to the suggestion that an 
individuals’ unique combination of VFAs made up their body odour ‘footprint’. 
Despite the isolation of two important VFAs, 3M2H and HMHA and their respective 
glutamine-conjugated precursors in the human axilla, precursor biotransformation by a 
physiologically relevant and abundant population of axillary bacteria has yet to be 
demonstrated. From the limited information available and already discussed, the strong 
HMHA and 3M2H producing corynebacteria isolated by Natsch, principally C. jeikeium, C. 
bovis and Corynebacterium sp. Ax20 (initially speciated as C. striatum but latterly 
identified as C. glaucum (Natsch & Granier, 2014)) have not been associated with the 
axillary microbiota (Taylor et al., 2003, Egert et al., 2011). Additionally, those high density 
Corynebacterium spp. identified in the axillary region, namely C. tuberculostearicum and 
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C. mucifaciens have never been directly linked to axillary malodour biochemically, 
suggesting that they do not generate significant quantities of 3M2H or HMHA from their 
respective Gln-conjugated precursors. These collective observations question how 
physiological concentrations of VFAs arise in the axilla and hints that the most active VFA 
producing bacterial species within the axilla have yet to be isolated. 
1.4.3  Thioalcohols 
1.4.3.1 Identification of thioalcohols as components of axillary 
malodour and characterisation of their precursor conjugates 
An organic sulphur compound containing a free carbon-bonded sulfhydryl (SH) group is 
termed a thioalcohol or simply, a thiol. The word derives from an amalgamation of the 
Greek word ‘thion’ meaning sulphur and ‘alcohol’, with a thioalcohol being the sulphur 
analogue of its respective alcohol. Thioalcohols have previously been implicated in 
several common odour pathways including cat urine, wherein the amino acid S-(3-
hydroxy-1,1-dimethylpropyl)-L-cysteine (felinine) is biotransformed to the thioalcohol 3-
methyl-3-sulfanylbutan-1-ol by the action of bacteria present within or in the immediate 
vicinity of the urine (Westall, 1953). Similar odorous molecules are released during wine 
fermentation (Tominaga et al., 1998) and also in passion fruit juice, where 3-
sulfanylhexan-1-ol and 3-methyl-3-sulfanbutan-1-ol are released from cysteine-conjugated 
precursors present in the juice by the action of bacterial enzymes (Tominaga & 
Dubourdieu, 2000). Thioalcohols also play a role in the flavouring process of many foods 
and beverages; 3-methyl-2-butene-1-thiol for example, is an important ingredient defining 
the flavour of coffee. Conversely though, they can be connected to the ‘off’ flavour of 
foods and drinks including beer, wherein 3-methyl-2-butene-1-thiol is produced from the 
metabolism of hop bitter in the presence of light and riboflavin creating a characteristic 
‘skunky’ flavour, explaining why beer is generally brewed and packaged in dark vessels 
(Vermeulen et al., 2005). 
The identification of thioalcohols as a marker of body odour was originally described in a 
patent application (Lyon et al., 1991), but specific details were vague. The first detailed 
reports of the presence of thioalcohols in axillary sweat were made independently by three 
research groups in the same year (Hasegawa et al., 2004, Natsch et al., 2004, Troccaz et 
al., 2004). Natsch had asked panellists to olfactorily assess hydrolysed axillary secretions 
and identify key body odour notes. The odorous compounds within these samples were 
then isolated using GC-MS. Among the offending compounds were the previously isolated 
34 

VFAs 3M2H and HMHA along with distinct peaks for a series of as yet unidentified 
molecules. The most abundant of these (present at approximately 70% abundance 
compared to HMHA and 3M2H) was subsequently identified as 3-methyl-3-hexan-1-ol 
(3M3SH). Other thioalcohols present in the sample but at lower concentrations were 2-
methyl-butan-1-ol, 3-pentan-1-ol and 3-sulfanhexan-1-ol. The chemical structure of these 
molecules is displayed in Table 1.4. Subjective descriptors that have since been applied 
to 3M3SH are oniony, meaty and acrid sweat-like (Troccaz et al., 2004) and the 
consensus on the olfactory threshold of the molecule has settled between 1-3 pg L-1 air 
(Troccaz et al., 2009, Natsch et al., 2004) which equates to 1-3 parts per trillion. These 
values are approximately 100-fold lower than those of HMHA and 3M2H, confirming that 
the thioalcohol 3M3SH is much more pungent than the most highly abundant VFAs in the 
axilla and has been subsequently described as a high-impact, low threshold odorant 
(Barzantny et al., 2011).  
As was suggested in the 1950’s, axillary sweat is naturally odourless and it was therefore 
reasoned that thioalcohols, in a similar manner to VFAs, would be released by the 
apocrine gland as precursor conjugates. The odorous thioalcohol would then be liberated 
by the action of bacterial lyase enzymes. In similar biological systems, notably wine 
fermentation, distinctive sulphurous wine bouquets are produced by bacterial catabolism 
of S-hydroxyalkyl-L-cysteine-conjugates, naturally present in grapes, to their respective 
thioalcohols (Tominaga et al., 1998). Natsch et al. (2004) therefore postulated that S-
hydroxyalkyl-L-cysteine conjugates of axillary thioalcohols were the primary thioalcohol 
malodour precursor molecules released by the apocrine gland, but failed to provide any 
direct evidence for this. An alternative hypothesis was suggested by Starkenmann et al. 
(2005), who proposed that thioalcohol malodour precursor compounds would originate in 
the apocrine gland as glutathione (GSH) adducts. This suggestion was again based on 
knowledge of thioalcohol production during wine fermentation, whereby certain grapes 
containing GSH-conjugated thioalcohol compounds are sequentially hydrolysed by the 
host, first removing the glutamate residue and then the glycine residue to yield cysteine-S-
conjugates. These conjugated-intermediates are then further hydrolysed by 
microorganisms during the fermentation process to yield characteristic wine odours, a 
process typically performed by microbial carbon-sulphur lyase proteins, specifically 
cystathionine beta-lyase (C-S- β-lyase) (Grant-Preece et al., 2010). 
When a biochemical analysis of axillary sweat was undertaken by Starkenmann, rather 
than identifying cysteine-S-conjugates in sterile secretions the principal thioalcohol-
conjugated precursor molecules isolated were S-hydroxyalkyl-L-cysteinylglycine-
conjugates.  
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Table 1.4. High-odour impact thioalcohols isolated from hydrolysed human axillary 
extracts 
Molecule Chemical structure Reference 
3-methyl-3-
sulfanylhexan-1-ol  
 
(3M3SH)  
Natsch et al., (2004) 
Hasegawa et al., (2004) 
2-methyl-butan-1-ol 
 
Natsch et al., (2004) 
Hasegawa et al., (2004) 
3-pentan-1-ol 
 
Natsch et al., (2004) 
Hasegawa et al., (2004) 
3-methyl-hexan-1-ol 
 
Natsch et al., (2004) 
Hasegawa et al., (2004) 
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In Starkenmann’s study, axillary sweat was fractionated using HPLC coupled to gas 
chromatography (HPLC/GC) and each fraction biotransformed by bacterial isolates to 
identify distinct zones of axillary odour. One fraction was shown to produce a strong 
thioalcohol-associated odour, confirming the presence of thioalcohol precursor molecules 
in the pre-biotransformed fraction. A non-biotransformed portion of this fraction was then 
analysed using HPLC to identify the precursor molecules present. A distinct peak 
subsequently identified as S-[1-(2-hydroxyethyl)-1-methylbutyl]-(L)-cysteinylglycine (Cys-
Gly-3M3SH) (Fig. 1.2A) was isolated and confirmed as such when synthetic Cys-Gly-
3M3SH firmly matched the major peak identified in the isolated axillary sweat fraction. 
GSH-conjugated 3M3SH in axillary secretions was not present, suggesting that if it did 
originate as a GSH-adduct, a host-derived peptidase would be required to cleave the 
glutamate residue from the precursor prior to secretion by the apocrine gland. Additionally, 
no evidence was forthcoming for the presence of Cys-3M3SH in axillary sweat, signifying 
that the previous hypothesis by Natsch that cysteine-S-conjugated thioalcohols were the 
primary thiol precursor molecules released into the axilla, was incorrect. Further support 
for Cys-Gly-3M3SH as the principal 3M3SH precursor in axillary sweat was provided by 
Emter & Natsch (2008), who used a liquid chromatography-mass spectrometry (LC-MS) 
approach to confirm that the dipeptide conjugate was indeed the major thioalcohol 
precursor molecule. While they did identify the previously suggested Cys-3M3SH 
molecule, it was present at an 8-fold lower concentration that Cys-Gly-3M3SH and 
therefore described as a minor component. A later report suggested that female axillary 
sweat samples contained, on average, 7-fold more Cys-Gly-3M3SH per ml than male 
sweat and that the total amount of substrate released into the axilla fell in the µg-mg L-1 
range during excessive sweating (Troccaz et al., 2009). 
Given the observed differences in the relative abundance of Cys-Gly-3M3SH between 
individuals, it has been suggested that there could be a genetic basis for malodour 
precursor secretion in the human axilla. Historically it has been proposed that axillary 
odour is more pungent in Europeans and Africans than the Asian population (Matsunaga, 
1962), which intriguingly also correlates with an altered earwax phenotype. Accordingly, 
Martin et al. (2009) demonstrated that a single nucleotide polymorphism (SNP) in the 
human ABCC11 gene which conferred a G583A base substitution resulted in a clear non-
malodour phenotype in those individuals possessing the AA genotype. The ABCC11 
protein is an ATP-binding cassette (ABC) transporter and apical efflux protein normally 
active on the surface of secretory cells of apocrine sweat glands. It commonly acts to load 
malodour precursor compounds, including HMHA-Gln, 3M2H-Gln and Cys-Gly-3M3SH 
into vesicles for secretion via the apocrine gland into the axilla. 
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Figure 1.2. Chemical structures of model and physiological thioalcohol malodour 
precursor molecules. A – S-Benzyl-L-cysteine, B – S-Benzyl-L-cysteinylglycine,  
C – S-[1-(2-hydroxyethyl)-1-methylbutyl]-(L)-cysteinylglycine (Cys-Gly-3M3SH) 
S-Benzyl-L-cysteine 
B 
C 
S-Benzyl-L-cysteinylglycine 
A 
Cys-Gly-3M3SH 
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Individuals expressing the mutated form of this protein display a non-malodour phenotype 
due to malodour precursor compounds failing to reach the axilla. The wild-type ABCC11 
allele is prevalent among Europeans and Africans with the mutated G583A allele 
widespread mainly in individuals of East Asian descent, particularly Chinese, Korean and 
Japanese populations. The phenotypic effect of the G583A SNP was verified by Harker et 
al. (2014) who associated a significantly lower axillary odour in individuals homozygous 
for the mutated gene, which was biochemically connected to an almost complete absence 
of the malodorants HMHA, 3M2H and 3M3SH. The G583A SNP in ABCC11 represents 
the only currently known human SNP responsible for two individual phenotypic 
characteristics. The selective pressures governing inheritance of this particular gene 
remain undetermined. 
Given the low olfactory threshold for the thioalcohol 3M3SH (pg L-1) and the relative 
abundance of the Cys-Gly-3M3SH precursor, there is an obvious capacity for thioalcohol 
production by members of the axillary microbiota and the ability to carry out this process 
may provide a direct benefit to the bacterium. Beside the waste product 3M3SH, the net 
molecular gain would be one L-glycine residue and one molecule each of pyruvate and 
ammonia, giving a favourable reward of both carbon and nitrogen. In order to obtain these 
products however, the bacterium must also have the molecular capability to carry out the 
biotransformation process, which is discussed below. 
1.4.3.2 Molecular biotransformation of Cys-Gly-3M3SH and other 
thioalcohol-conjugates by axillary-isolated bacteria 
Analysis of thioalcohol-conjugate biotransformation by axillary bacteria has been largely 
limited to model malodour precursor substrates. Typically, the model substrate S-Benzyl-
L-cysteine (Fig. 1.2B) has been used due to initial, now inaccurate reports, suggesting 
that S-cysteine conjugates were the principal thioalcohol malodour precursor substrates in 
the axilla (Natsch et al., 2004). S-Benzyl-L-cysteine is known to be catabolised by many 
general C-S- β-lyase proteins, and therefore this activity was historically deemed to be a 
sufficient measure of the thioalcohol liberation potential of a bacterial isolate.  
James et al. (2013) showed that many bacteria were able to biotransform S-Benzyl-L-
cysteine into its respective thioalcohol product, benzyl-mercaptan. Activity was strongly 
associated with corynebacteria, where 67% of strains tested positive compared to only 
17% of staphylococci. When broken down to the species level, C. jeikeium and more 
excitingly, C. tuberculostearicum, appeared to show the highest activity, hinting that C-S- 
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β-lyase activity was strongest in a highly prevalent axillary species. Subsequently 
however, activity against this model substrate has been demonstrated for single strains of 
several Staphylococcus spp. including S. haemolyticus and S. hominis, along with several 
unspeciated strains of the same genus (Egert et al., 2011). 
Despite the prevalence and rigour of this work, studies using model substrates only have 
limited relevance and the conclusions drawn may not be transferable to the physiological 
situation, where, in the case of axillary malodour, the most prevalent thioalcohol precursor 
is Cys-Gly-3M3SH. To date, a detailed analysis of the microbial capacity to biotransform 
Cys-Gly-3M3SH has not been performed. Of the limited work in this area, early reports 
consisted of subjective analyses of total axillary secretions that had been biotransformed 
by several individual species of bacteria. S. haemolyticus Ax 4 was determined to produce 
the most acrid and intense sulphuric odour from these secretions which was subsequently 
correlated to the production of 3M3SH (Troccaz et al., 2004). The same odour profile was 
not associated with other axillary isolated bacteria including C. tuberculostearicum, C. 
minutissimum or S. epidermidis. It was later demonstrated by the same group that S. 
haemolyticus could directly biotransform purified Cys-Gly-3M3SH into 3M3SH, producing 
a total thioalcohol yield of 75%. C. xerosis and S. epidermidis both produced a lower 
3M3SH yield of 20% and 17% respectively (Starkenmann et al., 2005). Emter & Natsch 
(2008) later established that bacterial extracts of Corynebacterium isolate Ax20 were able 
to biotransform Cys-Gly-3M3SH relatively efficiently, to a total thioalcohol yield of 65%, 
whereas extracts of other axillary isolated bacteria such as C. jeikeium, S. epidermidis 
and C. bovis produced no appreciable levels of 3M3SH.  
Two conflicting hypotheses have been proposed regarding the catabolic fate of Cys-Gly-
3M3SH. Emter & Natsch (2008) discovered a novel corynebacterial zinc-dependent 
metallopeptidase in Corynebacterium sp. Ax20, subsequently named thiol precursor 
dipeptidase A (TpdA). TpdA was cloned from this organism, recombinantly expressed in 
E. coli and purified to homogeneity. When TpdA was combined with the C-S- β-lyase from 
Corynebacterium sp. Ax20 (previously implicated in thioalcohol liberation from S-cysteine-
conjugates (Grant-Preece et al., 2010)), 3M3SH was liberated from the dipeptide 
precursor in a sequential manner, i.e. the dipeptidase first cleaved the glycine residue, 
liberating Cys-3M3SH for catabolism to 3M3SH by C-S- β-lyase. Further characterisation 
of TpdA showed that the enzyme was active against a wide range of other simple 
dipeptide molecules along with Cys-Gly-3M3SH and a synthetic, model dipeptide 
malodour precursor substrate, S-Benzyl-L-cysteinylglycine (Fig. 1.2C), all at physiological 
concentrations. Interestingly, when the orthologous dipeptidase protein from C. jeikeium 
was cloned, very little activity against Cys-Gly-3M3SH was observed. This suggests that 
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not all corynebacterial TpdA homologues are adapted to catabolise this substrate. There 
are no TpdA homologues in staphylococci, which led to the proposal of an alternative Cys-
Gly-3M3SH biotransformation hypothesis by Troccaz et al. (2008) who had previously 
shown strong Cys-Gly-3M3SH biotransformation by S. haemolyticus. Troccaz suggested 
that a single enzymatic cleavage step was responsible for liberating 3M3SH from Cys-Gly-
3M3SH and postulated that C-S- β-lyase would be the enzyme responsible. Accordingly, 
SH_2636, the putative C-S- β-lyase from S. haemolyticus was cloned and recombinantly 
expressed, but showed negligible activity against Cys-Gly-3M3SH despite showing strong 
activity against its natural substrate, L-cystathionine. Similarly, James et al. (2013) cloned 
and recombinantly expressed the C-S- β-lyase from C. jeikeium NCIMB 40928 and 
demonstrated the enzyme had strong biotransformation activity against the model 
malodour precursor substrate S-Benzyl-L-cysteine along with a physiologically relevant 
substrate but minor component of axillary sweat, S-(3-hydroxy-1,2-dimethylpropyl)-L-
cysteine. However, activity of this enzyme against the physiologically relevant and 
abundant malodour substrate Cys-Gly-3M3SH was not assessed.  
While Cys-Gly-3M3SH is clearly a major component of axillary sweat, the exact 
biochemical route of thioalcohol liberation in the axilla remains unclear. Emter & Natsch 
(2008) showed strong in vitro activity of Corynebacterium sp. Ax20 and isolated the 
enzymes responsible, but failed to provide evidence of in vivo (whole cell) catabolism. 
Whereas Starkenmann et al. (2005) and Troccaz et al. (2009) demonstrated strong in vivo 
activity of S. haemolyticus Ax 4 against Cys-Gly-3M3SH, but failed to provide any direct 
biochemical evidence of the enzymes responsible. Crucially, no study has provided a 
convincing argument that any of the isolates that are able to biotransform Cys-Gly-3M3SH 
are present within the axillary microbiota at sufficient cell density to liberate the amount of 
thioalcohol required to appreciably activate the human olfactory system. 
When all studies are taken together, a model for Cys-Gly-3M3SH biotransformation by 
axillary bacteria can be proposed (Fig. 1.3). It begins with secretion of this molecule by the 
axillary apocrine gland. There is then a clear requirement for Cys-Gly-3M3SH to be 
transported into the bacterial cell prior to biotransformation, but this process is not 
understood in any bacterium. The intracellular catabolism of this molecule is thought to 
proceed either by a sequential dipeptidase and lyase step as suggested by Emter & 
Natsch (2008), or directly via a single C-S- β-lyase step as suggested by Troccaz et al. 
(2009).  
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Figure 1.3. Putative process of Cys-Gly-3M3SH biotransformation by axillary 
bacteria. 
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The complete process generates one molecule each of glycine pyruvate and ammonia per 
Cys-Gly-3M3SH molecule, which could all be utilised by the bacterium as a source of 
carbon or nitrogen. The thioalcohol waste product, 3M3SH is presumably transported or 
diffuses back across the cell wall on to the surface of the axilla where it readily evaporates 
due to the inherent high volatility of the molecule. Again, the 3M3SH export process is not 
understood in any bacterium. 
In summary, from subjective axillary odour analysis in the early 20th century, molecular 
detection techniques have advanced immeasurably to allow the discovery of malodours 
compounds and their precursors at pg L-1 level in the human axilla. It is now commonly 
accepted that Cys-Gly-3M3SH is one of the most prevalent malodour precursor molecules 
secreted by the apocrine gland. This molecule is microbially biotransformed to its highly 
pungent thioalcohol product, 3M3SH which is heavily implicated in characteristic human 
body odour. The exact microorganisms responsible for this process are not well 
characterised, although there is a general subjective association between axillary 
malodour and corynebacteria. There is clearly an important requirement to identify which 
bacteria are responsible for Cys-Gly-3M3SH biotransformation and understand not only 
the intracellular biotransformation process but also the mechanism of uptake of the 
precursor molecule in the relevant bacteria. 
1.5  E. coli as a model organism 
Escherichia coli (E. coli) is a Gram-negative bacterium belonging to the family 
Enterobacteriaceae. Environmentally, it thrives in the lower intestine of warm-blooded 
animals, including humans where it is commonly found as a commensal bacterium of the 
gut microbiota. E. coli is the most widely studied and characterised bacterium and is 
typically used for laboratory studies and genetic engineering. It can be grown on a wide-
variety of complex and minimal media with an approximate doubling time of 20 min when 
grown aerobically in rich media at 37oC (Tritz, 1987). The strain K-12 was originally 
isolated in 1922 (Riley et al., 2006) and quickly became the most widely used laboratory 
strain when the processes of conjugation and transduction were discovered (Lederberg & 
Tatum, 1946). E. coli K-12 was one of the first bacteria to be fully genome sequenced 
(Blattner et al., 1997) and the library of single, non-essential gene deletion mutants, the 
Keio Collection (Baba et al., 2006), has greatly aided the comprehensive genetic 
characterisation of this bacterium. 
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An alternative, widely-used model organism is Bacillus subtilis. Like E. coli, B. subtilis is 
genetically and biochemically well-characterised and has a highly annotated genome 
(Mader et al., 2011). B. subtilis is a Gram-positive bacterium and therefore more closely 
related to the majority of axillary isolates than E. coli. It is therefore important to be aware 
that although E. coli will be used in this instance, B. subtilis may also be an appropriate 
model organism in which to study malodour production. 
The direct application of E. coli as a model organism to study malodour production, 
specifically the molecular mechanism behind Cys-Gly-3M3SH biotransformation, has not 
been attempted before. It is clear that transport into the bacterium and enzymatic 
hydrolysis of the substrate are essential steps leading to 3M3SH liberation and 
subsequent volatilisation into the atmosphere. Structurally, Cys-Gly-3M3SH is a dipeptide 
analogue consisting of a cysteinylglycine backbone conjugated to a hydroxyalkyl moiety 
(Fig. 1.2A). Therefore, uptake is likely to occur via a specific peptide transporter with the 
ability to transport dipeptide analogues. Thus, a comprehensive review of peptide 
transport in E. coli is provided. 
 1.5.1  Molecular transport in E. coli 
In general terms, molecular transport is a vital bacterial process, facilitating import of 
essential molecules into the cytoplasm providing nutrients for the growing cell. Transport 
proteins are categorised into 5 distinct classes based on the energetics of substrate 
translocation and further subdivided into superfamilies based on their specific transport 
mechanism (Busch & Saier, 2002). The most abundant superfamily of bacterial transport 
proteins are the ATP-binding cassette (ABC) transporters with approximately 5% of the 
entire genome of E. coli encoding for these transport systems (Linton & Higgins, 1998). 
ABC transporters are found in both prokaryotes and eukaryotes and have a hugely 
diverse substrate specificity allowing for uptake of large, small, charged, uncharged, 
hydrophobic and hydrophilic molecules ranging from inorganic ions to complex 
polysaccharides, all of which need to cross the cellular membrane (Higgins, 2001). ABC 
transporters belong to the primary active transporter class, as defined by Busch & Saier, 
and move substrates across the membrane against the concentration gradient, with 
energy provided by the hydrolysis of ATP. 
Structurally, bacterial ABC transporters are multi-subunit proteins usually consisting of two 
transmembrane domains (TMDs), two adenosine triphosphatase (ATPase) domains and a 
single substrate-binding protein (SBP) (Higgins et al., 1986), although subtle variations of 
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this domain architecture are known to exist. In Gram-negative bacteria, the SBP is 
typically not membrane bound but freely patrols the periplasm, binding to a specific 
substrate and delivering it to the TMDs. In Gram-positive bacteria which lack a periplasm, 
the SBP is usually anchored to the outer surface of the cell membrane by attachment to 
membrane-bound lipids (Perego et al., 1991). This architecture is not true for all ABC 
transporters from Gram-positive bacteria however, as in the case of the glycine-betaine 
transporter from Lactococcus lactis, the SBP, OpuA, is directly fused to the TMDs 
(Bouvier et al., 2000). SBPs are highly specific for their cognate substrate(s) and typically 
bind with high affinity, in some cases at a substrate concentration lower than 1 µM 
(Madigan & Martinko, 2006). The TMDs are hydrophobic and contain multiple membrane 
spanning α-helices which form an internal pore through which the substrate passes. The 
substrate binding sites within the internal pore determine the substrate specificity of the 
transporter. Upon binding of the SBP-substrate complex to the TMDs, a conformational 
change is induced which subsequently initiates the hydrophilic ATPase domains, which 
are physically associated with the TMDs on the cytoplasmic side of the membrane, to 
hydrolyse adenosine triphosphate (ATP) to adenosine diphosphate (ADP) and phosphate 
(Pi) (Higgins, 2001). This process drives substrate translocation across the membrane, 
resulting in uptake of one molecule of substrate for a total of two ATP molecules 
hydrolysed (one per ATPase).  
Another notable superfamily of transport proteins is the Major Facilitator Superfamily 
(MFS). These proteins belong to the electrochemical or proton driven transporters, a class 
also referred to as secondary transporters and are the largest known class of secondary 
transporters (Pao et al., 1998). Like ABC transporters, MFS transporters are ubiquitous in 
all classifications of living organisms (Pao et al., 1998). Specifically within the genomes of 
microorganisms, the combined number of MFS and ABC transporters account for almost 
50% of all known solute transporters (Paulsen & Skurray, 1994). Structurally, they consist 
of a single membrane-imbedded polypeptide that utilises an electrochemical gradient such 
as H+ or Na+ to drive substrate translocation across the membrane against its 
concentration gradient (Saier, 2000a). MFS transporters can function to translocate a 
substrate into or out of the cell depending on the ionic concentration gradient (Saier, 
2000b), but individual transporters typically display directionality. A specific example of a 
well characterised bacterial MFS transporter is the lactose permease of E. coli, LacY, 
which co-transports an extracellular proton with lactose to facilitate substrate import into 
the cytoplasm of the cell (Abramson et al., 2003). 
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1.5.2  Peptide transport in E. coli 
Peptides are molecules consisting of amino acid monomers connected by peptide (amide) 
bonds. The smallest peptide is a dipeptide, consisting of two amide-bonded amino acids. 
Peptides can be distinguished from proteins based on the number of amino acid residues 
that form the molecule. A molecule containing 2-50 amino acids is said to be a peptide, 
whereas a molecule containing >50 amino acids is typically referred to as a protein (Sato 
et al., 2006). Peptide transport occurs in all organisms from microbes to man and is a vital 
route to supply amino acids for nutritional purposes. Uptake of peptides is an energetically 
favourable process as multiple amino acids can be transported at the same time without 
the energy cost of transporting them individually. Such amino acids can then fulfil the 
nutritional requirements of the cell or be used as building blocks to make proteins. There 
is also growing evidence that peptides are involved in intracellular signalling and 
metabolic adaptation (Detmers et al., 2001). 
Peptide transport in E. coli is relatively well characterised, with the two classes of 
transporters described in section 1.5.1 primarily involved uptake of these molecules. High 
affinity peptide transport is primarily achieved through two ABC peptide transporters; the 
dipeptide (Dpp) and oligopeptide (Opp) permeases. Lower affinity, high capacity peptide 
transport is achieved by MFS secondary transporter of the PTR-family, as discussed 
below. A graphical representation of these specific classes of E. colipeptide transporters
is shown in Fig. 1.4. 
1.5.2.1 The ABC peptide transporters of E. coli 
The Dpp dipeptide transporter is encoded by five individual genes, dppABCDF which are 
arranged in an operon. dppA encodes the SBP, dppB and dppC encode the TMDs and 
dppD and dppE encode the ATPase domains (Fig. 1.4). The X-ray crystal structure of the 
SBP has been solved both unbound (Dunten et al., 1993) and with Gly-Leu bound in the 
substrate binding pocket (Dunten & Mowbray, 1995), revealing that the SBP recognises 
the peptide backbone allowing for accommodation of a structurally diverse range of side 
chains within the binding pocket. Multiple studies have reported individual substrate 
specificities for Dpp, including Olson et al. (1991) who demonstrated that a proline 
auxotrophic dppA mutant was unable to utilise Pro-Gly as the sole source of proline and 
Payne et al. (1984), who showed that a dpp mutant and leucine auxotroph was unable to 
utilise several leucine-containing dipeptides as the sole source of leucine. De Felice et al. 
(1973) established that Gly-Val, Leu-Val, Val-Leu and Gly-Gly were also substrates for 
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Dpp. The substrate specificity of E. coli DppA was comprehensively substantiated by 
Smith et al. (1999) who concluded that the protein was promiscuous in dipeptide 
specificity and could also transport a limited range of L-Ala-containing tripeptides, 
although dipeptides were clearly the preferred substrate. Specific structural requirements 
of a Dpp-transported peptide are the presence of an unsubstituted α-amino group Payne 
(1971) and all residues to be in their L-isoform (Smith et al., 1999).  
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The genomic layout of the opp oligopeptide transporter is identical to dpp, with five 
individual genes, oppA oppBC and oppDF encoding the SBP, two TMDs and two ATPase 
domains, respectively (Fig. 1.4).  
The Opp system of E. coli has not been comprehensively analysed but the orthologous 
system in Salmonella enterica subspecies Typhimurium (S. typhimurium) has been 
extensively studied. The crystal structure of S. typhimurium OppA has been solved with 
Lys-Lys-Lys bound in the substrate binding pocket (Glover et al., 1995). This protein was 
able to bind peptides ranging from two to five amino acids in length with a structurally 
diverse range of side chains. Using Ala-Phe-[3H]Gly as a reporter substrate Guyer et al. 
(1986) demonstrated that OppA preferentially binds tripeptides, with sequentially 
decreasing affinity for tetra- and pentapeptides and no affinity for single amino acids or the 
limited range of dipeptides tested. It was subsequently shown that all five opp genes are 
required for Opp function, with insertion mutations in individual genes leading to disruption 
of peptide transport (Hiles et al., 1987). Similar to DppA, E. coliOppA has little side chain 
preference with a wide range of glycine-containing tripeptides sufficient to alleviate the 
effects of the toxic tripeptide triornithine (Naider & Becker, 1975).  
The sensitive to antimicrobial peptide (Sap) ABC transporter is an additional E. coli 
peptide transporter sharing an identical gene layout to opp and dpp. E. coli Sap remains 
uncharacterised but the orthologous multigene operon in S. typhimurium has been 
partially studied. In this organism, Sap is required for resistance to the antimicrobial 
peptides melittin and protamine, acting as an important virulence factor (Parra-Lopez et 
al., 1993). The Sap transport system allows these antimicrobials to be transported directly 
into the cytoplasm of the bacterium where they can be rapidly degraded by intracellular 
peptidases, rather than localise on the inner membrane where they act to disrupt the 
structural integrity of the cell.  
In the 1970s and 1980s, much attention was focussed on creating novel antimicrobial 
compounds that would be rapidly and efficiently transported into the bacterial cell. It was 
proposed that by attaching an antimicrobial compound to a peptide, the drug could be 
effectively smuggled into the bacterium through the high affinity ABC peptide transporters 
Dpp and Opp, in a Trojan horse-like manner. A proof-of-principle study was conducted by 
Ames et al. (1973) who demonstrated that histidinol-phosphate ester (HOLP) could be 
fused to Gly-Gly to create HOLP-Gly-Gly, which was transported into S. typhimurium by 
the Opp system. Similarly, a series of cytotoxic compounds attached to peptides of 
varying length were also transported by Opp, with the strongest level of transport 
49 

observed for tripeptide-conjugated antimicrobials. A similar study was successful in E. coli 
where it was demonstrated that two tripeptide-based antimicrobials were transported by 
Opp (Diddens et al., 1976). The natural tripeptide antibiotic, phaseolotoxin, is also 
transported by Opp in both E. coli and S. typhimurium (Staskawicz & Panopoulos, 1980), 
but publications on this novel antimicrobial delivery route quickly ceased in subsequent 
decades, possibly due to difficulties in bringing these compounds to market. 
1.5.2.2 The MFS peptide transporters of E. coli 
The MFS peptide transporters of E. coli belong to the proton-dependant oligopeptide 
transporter (POT) classification, which was originally described by Paulsen & Skurray 
(1994). The POT family was later renamed the Peptide Transporter (PTR) family (Steiner 
et al., 1995), as it was unclear whether all members of this group used co-transport of a 
proton to drive substrate translocation across the membrane. However, both POT and 
PTR nomenclature have been used interchangeably in subsequent literature and PTR 
family transporters are also more generally referred to as peptide symporters. PTR family 
proteins are characterised by the presence of a PTR2 (COG3104) domain. One of the first 
bacterial PTR family peptide transporters to be biochemically characterised was DtpT 
from Lactococcus lactis (Hagting et al., 1994, Hagting et al., 1997) but biochemical 
characterisation of the four E. coli PTR genes encoding the single subunit transporters 
DtpA, DtpB, DtpC and DtpD (Fig. 1.4) did not begin until the last decade.  
DtpA (historically called YdgR and more recently TppB), was originally characterised in S. 
typhimurium (Gibson et al., 1984). Previously, Barak & Gilbarg (1975) had isolated an E. 
coli oppABCDF mutant that was resistant to a toxic tripeptide which normally inhibits 
growth of this strain, suggesting uptake of the inhibitor by an alternative tripeptide 
transporter, now strongly hypothesised to be dtpA. They demonstrated that Thr-Thr-Thr 
can support the growth of a threonine auxotroph even in an opp mutant background, 
which can be antagonised by Leu-Leu-Leu and Met-Met-Met, suggesting that these three 
tripeptides are substrates for DtpA. Similarly, other L-Met-containing tripeptides were 
shown to support methionine auxotrophy in an opp mutant background (Naider & Becker, 
1975). There is also indirect evidence that modified tripeptide antimicrobials are 
transported by DtpA, as an opp mutant is resistant to the toxic tripeptide analogue Ala-
Ala-NH-Ala which contains a modified peptide linkage (Morley et al., 1983). The dipeptide 
analogue alafosfalin is also transported by DtpA (Smith & Payne, 1990). Of all four E. coli 
PTR family transporters, DtpA shares the strongest sequence similarity (24%) with the 
human PTR protein PepT1, suggesting partial functional similarity. PepT1 is found at the 
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brush border membrane of intestinal tissue and has an extremely broad ranging substrate 
specificity, which has been empirically validated and collated by Biegel et al. (2006) and 
plays an important role in general peptide uptake from the diet. The substrate specificity of 
DtpA has since been characterised in detail using an E. coli strain overexpressing the 
transporter. Using radiolabelled glycylsarcosine as a reporter substrate, Harder et al. 
(2008) observed strong specificity for the peptides Ala-Ala (99%), Ala-Ala-Ala (99%), D-
Ala-L-Ala (95%), Lys-Gly (98%), Gly-Asp (74%) along with the peptide-based 
antimicrobials Cephradine (71%), Cefalexin (65%) and Cefadroxil (81%). Weak uptake of 
alanine and Ala-Ala-Ala-Ala was observed, confirming that DtpA preferentially transports 
di- and tripeptides. Weitz et al. (2007) argue that DtpA shows a preference towards N-
terminally positively charged peptides such as Lys-Gly and Lys-Ala rather than C-
terminally positively charged peptides such as Gly-Lys. Overall, the substrate range of 
DtpA is relatively diverse, with simple di- and tripeptides being transported along with 
certain D-isoform peptides, some peptidomimetic compounds and other structural peptide 
analogues.  
DtpB of E. coli (previously named YhiP) is the least characterised member of the PTR 
family of peptide transporters, with the only single in-depth study carried out by Harder et 
al. (2008). Using an identical method to that used to characterise the substrate specificity 
of DtpA, radiolabelled glycylsarcosine was used as a reporter molecule to assess the 
substrate specificity of DtpB. Strong affinity was observed for Ala-Ala (83%), Ala-Ala-Ala 
(83%), Gly-Asp (83%) and Lys-Gly (43%), but weaker affinity was observed for the 
majority of other L- and D-isoform peptides, peptide analogues and peptidomimetic 
compounds, suggesting that DtpB has a more limited substrate range than DtpA. From 
the study it was concluded that DtpB has a C-terminal negative charge preference.  
DtpC (previously named YjdL) was first characterised by Ernst et al. (2009) who cloned 
and overexpressed the dtpC gene and used a fluorescent reporter molecule to assess 
substrate specificity of the transporter in a whole cell-based system. It was observed that 
DtpC could transport Ala-Ala but not Ala-Ala-Ala or Ala-Ala-Ala-Ala even at 500-fold 
excess. This was later supported by Prabhala et al. (2013). A similar phenomenon was 
seen with other tripeptides leading to the conclusion that DtpC has a preference for 
transporting dipeptides. Uptake of D-Ala containing dipeptides, the negatively charged 
dipeptides Ala-Asp and Asp-Ala and a dipeptide with a positively charged N-terminus, 
Lys-Ala, was not observed, but Ala-Lys, with a positively charged C-terminus, was 
transported. A general consensus has been reached which suggests that dipeptides 
possessing a positively charged C- terminus are excellent substrates for DtpC whereas 
negatively charged dipeptides are not transported. 
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A similar series of experiments have been carried out to understand the biochemical basis 
for peptide transport by DtpD (previously named YbgH), although a full analysis of the 
substrate specificity of this transport has yet to be carried out. Casagrande et al. (2009) 
concluded that DtpD has a definite preference for C-terminally charged dipeptides such as 
Ala-Lys and if the charge is reversed, for example in Lys-Ala then the dipeptide will not be 
transported by this protein. Jensen et al. (2012) argued that, like DtpC, DtpD has a 
preference for dipeptides rather than tripeptides. Jensen also used site-directed 
mutagenesis to demonstrate that Glu388, an invariant residue in all PTR transporters, is 
essential to facilitate peptide binding to DtpD, as the E388Q form of the protein could no 
longer bind Ala-Lys. A summary of the proposed properties of DtpA, DtpB, DtpC and DtpD 
is provided in Table 1.5. 
An additional secondary peptide transporter is encoded in the genome of E. coli, the 
carbon starvation gene, cstA. cstA encodes a peptide transporter which is part of the CsrA 
regulon and expressed under carbon-limited conditions (Dubey et al., 2003). When grown 
in peptide-containing media, cstA oppABCDF double mutants were shown to have a 
slower growth rate than wild-type or either single mutant strain alone (Schultz & Matin, 
1991), suggesting a cumulative effect of mutating both the high affinity ABC oligopeptide 
transporter (oppABCDF) and cstA. This suggests that CstA and Opp have overlapping 
substrate specificities and that CstA, like Opp, is able to transport a diverse range of 
oligopeptides. Unlike the Dtp transporters of E. coli, CstA is not a member of the PTR 
family, but part of its own superfamily, the CstA superfamily, of which full characterisation 
has yet to be carried out. 
1.5.3  Cystathionine- β-lyases of E. coli 
As discussed earlier (see section 1.4.3.2), it has been proposed that C-S- β-lyase, and in 
particular cystathionine β-lyase activity is required to biotransform conjugated thioalcohol 
malodour precursors. Therefore, if E. coli is to be used as a model system to study this 
process, an understanding of the C-S- β-lyase proteins of this organism is required. E. coli 
possesses two annotated and well characterised C-S- β-lyase proteins, MalY and MetC. 
MalY is a bi-functional protein with PLP-dependent aminotransferase activity and the 
ability to act as a negative regulator of the maltose regulon (Clausen et al., 2000). MalY 
has also been shown to catalyse carbon-sulphur bond cleavage of cystathionine (Zdych et 
al., 1995). These two functionalities are independent of each other; C-S- β-lyase enzyme 
activity is not required for the protein to fulfil its regulatory role.     
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Table 1.5. Properties of PTR-family secondary peptide transporters of E. coli 
Transporter Peptide transport properties 
Strong 
substrates 
(empirically 
verified) 
References 
DtpA 
Preference towards peptide 
with an N-terminal positive 
charge such as Lys-Gly and 
Lys-Ala.  
 
Transports a diverse range of 
di- and tripeptides and also 
some D-isoform peptides, 
peptidomimetic compounds 
and other structural peptide 
analogues. 
 
Ala-Ala 
Ala-Ala-Ala 
D-Ala-L-Ala 
Lys-Ala 
Lys-Gly 
Gly-Asp 
Gly-Gln 
Cefadroxil 
Alafosfalin 
 
Weitz & 
Harder (2007) 
 
Harder et al. 
(2008) 
DtpB 
Preference towards 
dipeptides with a C-terminal 
negative charge. 
 
More limited substrate 
specificity compared to DtpA, 
no evidence for tripeptide 
transport.  
 
 
Ala-Ala 
Ala-Ala-Ala 
Gly-Asp 
Harder et al. 
(2008) 
DtpC 
Preference towards 
dipeptides possessing a 
positively charged C- 
terminus.  
 
Does not transport negatively 
charged dipeptides. 
 
No evidence for tripeptide 
transport. 
 
 
 
Ala-Lys 
Ala-Gln 
Tyr-Ala 
Lys-Ala 
 
 
Ernst et al. 
(2009) 
 
Prabhala et al. 
(2013) 
 
Jensen et al. 
(2012) 
 
DtpD 
Preference for C-terminally 
charged dipeptides  
 
Does not transport N-
terminally charged dipeptides 
 
No evidence for tripeptide 
transport 
 
 
Ala-Lys 
Lys-Lys 
Gly-Lys 
Gly-Arg 
Jensen et al. 
(2012) 
 
Casagrande et 
al. (2009) 
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The other annotated cystathionine β-lyase of E. coli is MetC, which is also a PLP-
dependent aminotransferase playing an important biological role in methionine 
biosynthesis but also catalysing carbon-sulphur bond cleavage of cystathionine via C-S- 
β-lyase activity (Awano et al., 2003). The MalY/MetC classification of C-S- β-lyases 
originated in E. coli and newly characterised C-S- β-lyases proteins are now usually 
assigned into either the MalY or MetC subgroup (James et al., 2013).  
1.6  Aims of this study 
The physiologically relevant bacteria (at both genus and species level) involved in 
biotransformation of the conjugated thioalcohol malodour precursor Cys-Gly-3M3SH will 
be characterised using a library of axillary isolated bacteria. This will aid in identifying the 
most active Cys-Gly-3M3SH biotransforming species and strains within the human axilla.  
Peptide transporter deficient and C-S- β-lyase deficient strains of E. coli will be created 
and fully characterised in order to assess the suitability of E. coli as a model organism to 
study thioalcohol precursor biotransformation.   
Putative malodour precursor transporters and catabolic enzymes will be identified in the 
relevant organisms via in silico analysis. These genes will then be cloned and expressed 
in a strain of E. coli redundant for thioalcohol malodour precursor biotransformation in 
order to identify the molecular and biochemical basis behind this process within axillary-
isolated bacteria. 
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2.1  Chemicals and strains 
2.1.1  Chemicals  
All chemicals were reagent grade unless otherwise specified and purchased from Sigma 
Aldrich (Sigma) unless otherwise stated. 
2.1.2  Antibiotics  
Antibiotics were either from Melford (ampicillin sodium salt) or Gibco (kanamycin sulfate). 
All stock concentrations of antibiotics were dissolved in distilled water (dH2O) at 1000 X 
concentration (ampicillin 100 mg/ml and kanamycin 50 mg/ml), filter sterilised using a 0.22 
µm syringe filter and stored at 4oC for no longer than 1 week (ampicillin) or 4 weeks 
(kanamycin). The working concentrations were 100 µg/ml for ampicillin and 50 µg/ml for 
kanamycin. 
2.1.3  Malodour precursor substrate molecules 
2.67 mM stock solutions of the model malodour precursor molecules S-Benzyl-L-cysteine 
(Sigma) and S-Benzyl-L-cysteinylglycine (Bachem, Switzerland) were prepared in either 1 
X M9 salt buffer or Minimal Recovery Medium (MRM), depending on the particular assay. 
The physiological malodour precursor molecule Cys-Gly-3M3SH was chemically 
synthesised by Peakdale Molecular and routinely prepared at a stock concentration of 
2.67 mM in 1 X M9 salt buffer.  All malodour precursor molecules were filter sterilised 
using a 0.22 µm syringe filter and stored at 4oC until use. 
2.1.4  Bacterial strains and plasmids 
All species and strains of bacteria used in this work are listed in Tables 2.1, 2.2 and 2.3. 
Table 2.4 details all plasmids used in this work. 
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Strain Genotype Source or Reference 
 
      Escherichia coli 
 
BW25113 F-, ∆(araD-araB)567, ∆lacZ4787(::rrnB-3), lambda-, rph-1, ∆(rhaD-rhaB)568, hsdR514 Baba et al. (2006) 
JW1237 BW25113 oppC::Kan Baba et al. (2006)
JW3511 BW25113 dppC::Kan Baba et al. (2006)
JW1626 BW25113 dtpA::Kan Baba et al. (2006)
JW3463 BW25113 dtpB::Kan Baba et al. (2006)
JW4091 BW25113 dtpC::Kan Baba et al. (2006)
JW0699 BW25113 dtpD::Kan Baba et al. (2006)
JW3686 BW25113 tnaA::Kan Baba et al. (2006)
JW2975 BW25113 metC::Kan Baba et al. (2006)
JW1614 BW25113 malY::Kan Baba et al. (2006)
JW1285 BW25113 sapC::Kan Baba et al. (2006)
JW0590 BW25113 cstA::Kan Baba et al. (2006)
∆oppC BW25113 ∆oppC This work 
∆dppC BW25113 ∆dppC This work 
∆dtpA BW25113 ∆dtpA This work 
∆dtpB BW25113 ∆dtpB This work 
∆dtpC BW25113 ∆dtpC This work 
∆dtpD BW25113 ∆dtpD This work 
∆tnaA BW25113 ∆tnaA This work 
∆DB1 BW25113 ∆oppC ∆dppC This work 
∆DB5 BW25113 ∆dtpA ∆dtpB ∆dtpC ∆dtpD This work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1. Strains of E. coli used in this work 
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Strain Genotype Source or Reference 
 
                 Corynebacterium spp. 
 
Corynebacterium sp. Ax20 Wild-type Natsch et al. (2003) 
C. afermentans G434 Wild-type Unilever library 
C. afermentans G441 Wild-type Unilever library 
C. amycolatum G500 Wild-type Unilever library 
C. amycolatum G501 Wild-type Unilever library 
C. amycolatum G502 Wild-type Unilever library 
C. amycolatum G503 Wild-type Unilever library 
C. amycolatum G511 Wild-type Unilever library 
C. amycolatum G515 Wild-type Unilever library 
C. amycolatum G516 Wild-type Unilever library 
C. amycolatum G517 Wild-type Unilever library 
C. appendicis G465 Wild-type Unilever library 
C. glutamicum NCIMB 10025 Wild-type Kalinowski et al. (2003) 
C. jeikeium K411 Wild-type Tauch et al. (2005) 
C. mucifaciens G435 Wild-type Unilever library 
C. mucifaciens G462 Wild-type Unilever library 
C. mucifaciens G463 Wild-type Unilever library 
C. pseudogenitalium ATCC 33035 Wild-type Furness et al. (1979) 
C. pseudotuberculosis NCTC 3450 Wild-type Cummins (1962) 
C. striatum NCTC 764 Wild-type Pitcher (1983) 
C. suicordis G460 Wild-type Unilever library 
C. tuberculostearicum ATCC 35692 Wild-type Feurer et al. (2004) 
C. tuberculostearicum G438 Wild-type Unilever library 
C. tuberculostearicum G439 Wild-type Unilever library 
C. tuberculostearicum G440 Wild-type Unilever library 
C. tuberculostearicum G459 Wild-type Unilever library 
C. tuberculostearicum G464 Wild-type Unilever library 
C. tuberculostearicum G484 Wild-type Unilever library 
C. tuberculostearicum G485 Wild-type Unilever library 
C. tuberculostearicum A06 Wild-type Unilever library 
C. ulcerans NCTC 7910 Wild-type Riegel et al. (1995) 
Table 2.2. Strains of corynebacteria used in this work 
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Strain Genotype Source or Reference 
 
        Staphylococcus spp. 
 
S. capitis/caprae C07 Wild-type Unilever library 
S. capitis/caprae C15 Wild-type Unilever library 
S. cohnii A01 Wild-type Unilever library 
S. cohnii W17 Wild-type Unilever library 
S. epidermidis B01 Wild-type Unilever library 
S. epidermidis G427 Wild-type Unilever library 
S. epidermidis G428 Wild-type Unilever library 
S. epidermidis G429 Wild-type Unilever library 
S. epidermidis G430 Wild-type Unilever library 
S. epidermidis G467 Wild-type Unilever library 
S. epidermidis G468 Wild-type Unilever library 
S. epidermidis G469 Wild-type Unilever library 
S. epidermidis G470 Wild-type Unilever library 
S. epidermidis G471 Wild-type Unilever library 
S. epidermidis G473 Wild-type Unilever library 
S. epidermidis G474 Wild-type Unilever library 
S. epidermidis G475 Wild-type Unilever library 
S. epidermidis G476 Wild-type Unilever library 
S. haemolyticus G431 Wild-type Unilever library 
S. haemolyticus W19 Wild-type Unilever library 
S. epidermidis G467 Wild-type Unilever library 
S. hominis B10 Wild-type Kelly (2013) 
S. hominis G20 Wild-type Unilever library 
S. hominis I4 Wild-type Kelly (2013)
S. hominis J6 Wild-type Kelly (2013)
S. hominis J11 Wild-type Kelly (2013)
S. hominis J23 Wild-type Kelly (2013)
S. hominis J27 Wild-type Kelly (2013)
S. lugdunensis G310 Wild-type Unilever library 
S. saprophyticus B13 Wild-type Unilever library 
S. saprophyticus C06C Wild-type Unilever library 
S. saprophyticus W14 Wild-type Unilever library 
Table 2.3. Strains of staphylococci used in this work 
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Plasmid 
 
Plasmid 
backbone Size (Kb) 
Antibiotic 
resistance Source or reference 
pCP20 N/A 9.40 Amp/Cam Cherepanov & Wackernagel (1995) 
pKD46 N/A 6.33 Amp Datsenko & Wanner (2000) 
pBADcLIC2005 N/A 4.14 Amp Geertsma & Poolman (2007) 
pDtpA pBADcLIC2005 5.64 Amp This work 
pDtpB pBADcLIC2005 5.61 Amp This work 
pDtpC pBADcLIC2005 5.60 Amp This work 
pDtpD pBADcLIC2005 5.62 Amp This work 
pSH0415 pBADcLIC2005 5.33 Amp This work 
pSH1446 pBADcLIC2005 5.65 Amp This work 
pSH2140 pBADcLIC2005 5.32 Amp This work 
Table 2.4. Plasmids used in this work 
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2.1.5  Oligonucleotide primers 
All oligonucleotide primers used in this study are listed in Table 2.5. All primers were 
supplied by either Eurofins MWG Operon or Sigma. The supplied material was 
reconstituted in sterile dH2O to a stock concentration of 10 µM and stored at -20oC. 
 
Primer name Sequence (5’ – 3’) 
dppC F TGCTAATCGACACCGC 
dppC R TGGCGATCATCACGCG 
oppC F GCTGGCGTTATTGCCG 
oppC R CGCATCGAGCATCCGC 
dtpA F GACCTACAAAACATTACACTGGC 
dtpA R TAACGGCAAAGTAATCGTCACCG 
dtpB F AGCGTAAACACCTTATCTGGC 
TGATATCTATGCAGGTACGCC dtpB R 
dtpC F GTGTGAAATCGGCGCTCACTATCCG 
TAGCGTAGATAAAGAGACAGATCGG dtpC R 
dtpD F CTCGCCAGTTCGTCGATAGCC 
GCGTGAACGCCTTATCCAGCC dtpD R 
tnaA F TTACTTGTTTTAGTAAATGATGG 
TCAGCTTGATCAGTGATGATGCC  tnaA R 
dtpA pBADcLIC-F ATGGGTGGTGGATTTGCTGTGTCCACTGCAAACC 
dtpA pBADcLIC-R TTGGAAGTATAAATTTTCCGCTACGGCTGCTTTC 
dtpB pBADcLIC-F ATGGGTGGTGGATTTGCTATGAATACAACAACACCCATGGGG 
dtpB pBADcLIC-R TTGGAAGTATAAATTTTCATGGCTTTCCGGCGTCG 
dtpC pBADcLIC-F ATGGGTGGTGGATTTGCTATGAAAACACCCTCACAGCC 
dtpC pBADcLIC-R TTGGAAGTATAAATTTTCATCGTTGCTCTCCTGTATC 
dtpD pBADcLIC-F ATGGGTGGTGGATTTGCTATGAATAAACACGCATCACAGCCG 
dtpD pBADcLIC-R TTGGAAGTATAAATTTTCAGACTCCAGCGCCAGC 
0415 pBADcLIC-F ATGGGTGGTGGATTTGCTATGAAGAAGCACAGTAAAGATTAC 
0415 pBADcLIC-R TTGGAAGTATAAATTTTCATTTTTAATTGCTGTTTTAAAATATAAACC 
1446 pBADcLIC-F ATGGGTGGTGGATTTGCTATGGCAACAAATAACTCCCAT 
1446 pBADcLIC-R TTGGAAGTATAAATTTTCGTGAATACCTTTCATAGCTTTCGT 
2140 pBADcLIC-F ATGGGTGGTGGATTTGCTATGAGCTTATCTAAAGAAAC 
2140 pBADcLIC-R TTGGAAGTATAAATTTTCGCTACTAAAACGTTGTTCTTC 
 
 
 
 
Table 2.5. Oligonucleotide primers used in this work 
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2.1.6  Bacterial growth media and reaction buffers 
Liquid and solid media were prepared by dissolving appropriate quantities of powdered 
constituents in dH2O and autoclaving at 121oC, 15 Psi for 15 min. For agar plates, 
approximately 20 ml of molten agar-containing medium was poured into each Petri dish 
and allowed to solidify at room temperature. Plates were subsequently dried in a class II 
microbiology safety cabinet and stored at 4oC until use.  
Luria-Bertani (LB) medium contained (per litre dH2O): 10 g tryptone (Melford), 5 g yeast 
extract (ForMedium) and 10 g NaCl (Fisher Scientific). For LB agar plates, agar technical 
number 3 (Oxoid) was added to a final concentration of 1.5%. The pH was adjusted to 7.0 
by the addition of NaOH. 
Super Optimal Broth with Catabolite Repression (SOC) medium contained (per litre 
dH2O): 20 g tryptone, 5 g yeast extract, 0.584 g NaCl, 0.186 g KCl (Fisher Scientific) and 
0.024 g MgSO4 (Fisher Scientific). The pH was adjusted to 7.5 by the addition of NaOH. 
D-glucose (Fisher Scientific) was dissolved in dH2O to a stock concentration of 20%, filter 
sterilised through a 0.22 µm syringe filter and stored at room temperature. D-glucose was 
supplemented to the autoclaved SOC medium at a concentration of 20 mM. 
Tryptone Broth contained (per litre dH2O): 10 g tryptone and 10 g NaCl. The pH was 
adjusted to 7.0 by the addition of NaOH. 
Yeast Extract Broth contained (per litre dH2O): 10 g yeast extract and 10 g NaCl. The pH 
was adjusted to 7.0 by the addition of NaOH. 
Tryptone Soy Broth with Tween (TSBT) contained (per litre dH2O): 30 g tryptone soy 
broth (Fluka), 10 g yeast extract and 1 g Tween 80 (Fisher Scientific). The pH was 
adjusted to 7.0 by the addition of NaOH. For TSBT agar plates (TSAT), agar technical 
number 3 (Oxoid) was added to a final concentration of 1.5%. 
M9 glucose minimal medium contained (per litre dH2O): 6 g Na2HPO4, 3 g KH2PO4 
(Fisher Scientific), 1 g NH4Cl (Fisher Scientific) and 0.5 g NaCl. Filter-sterilised D-glucose 
was supplemented at 20 mM following autoclaving of the basal M9 medium. The pH was 
adjusted to 7.0 by the addition of NaOH. 
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Where peptides or amino acids served as the sole source of nitrogen, NH4Cl was omitted 
from the basal medium and filter-sterilised amino acids or peptides were supplemented to 
the autoclaved basal M9 medium at the appropriate concentration. 
Minimal recovery medium contained (per litre dH2O): 3.95 g Na2HPO4, 1.35 g KH2PO4, 
0.5 g casamino acids (MP Biomedicals) and 0.5 g MgSO4. The pH was adjusted to 7.2 by 
the addition of NaOH. 
1 X M9 minimal salt buffer contained (per litre dH2O): 6 g Na2HPO4, 3 g KH2PO4 and 0.5 
g NaCl. The pH was adjusted to 7.0 by the addition of NaOH. 
2.2  Molecular and biochemical techniques 
2.2.1  Polymerase Chain Reaction (PCR) with E. coli 
PCR was performed as described by (Mullins et al., 1986). Oligonucleotide primers were 
prepared as described in section 2.1.5. Template DNA consisted of a single, freshly 
streaked colony of the appropriate bacterial strain. A dNTP stock solution was prepared to 
a final concentration of 10 mM in dH2O (2.5 mM each dATP, dCTP, dGTP and dTCP). For 
analytical PCR, Taq DNA Polymerase (NEB) was used. In this instance, a 50 µl PCR 
reaction mixture was prepared by adding the following to a 0.5 ml Eppendorf tube, on ice: 
32.5 µl dH2O, 5 µl 10x ThermoPol Buffer (NEB), 4 µl 10 mM dNTPs (final concentration 
0.2 mM), 5 µl each forward and reverse primers (final concentration 1 µM each), 1 µl Taq 
DNA Polymerase and a single bacterial colony as template DNA. The reaction was mixed 
by pipetting. 
Where high-fidelity PCR was required, KOD Hot Start DNA Polymerase (Novagen) was 
used. For KOD Hot Start Polymerase PCR, a 50 µl reaction mixture was prepared by 
adding the following to a 0.5 ml Eppendorf, on ice: 32 µl dH2O, 5 µl 10x KOD Buffer 
(Novagen), 5 µl 2 mM dNTPs (Novagen) (final conc. 0.2 mM), 4 µl 25 mM MgSO4 
(Novagen) (final conc. 2 mM) 1.5 µl each forward and reverse primers (final conc. 0.3 µM 
each), 1 µl KOD Hot Start DNA Polymerase and a single bacterial colony as template 
DNA.  
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All PCRs were performed using a Techne Techgene thermocycler. For Taq DNA 
Polymerase PCRs, the following cycling parameters were used:  
 
Initial 
denaturation 95
oC 5' 
Denaturation 95oC 45'’ 
 
Annealing 45oC - 60oC 45’' 
Extension 72oC 1' 20’’ 
Final Extension 72oC 5' 
Hold 4oC HOLD 
 
For KOD DNA Polymerase PCRs, the following cycling parameters were used:  
 
 
Initial 
denaturation 95
oC 5' 
Denaturation 95oC 20'’ 
 
Annealing 45oC - 60oC 30’' 
Extension 70oC 30’’ 
Final Extension 70oC 5' 
Hold 4oC HOLD 
 
2.2.2 PCR with S. hominis B10 
To amplify the desired genes from S. hominis B10, degenerate primers were manually 
designed based on the nucleotide sequence of the orthologous genes in S. hominis 
SK119. PCR was performed using high fidelity MyFi DNA Polymerase (Bioline). A crude 
sample of S. hominis B10 DNA to be used as a DNA template was prepared by a 
preceding DNA extraction thermocycle reaction (Table 2.8) using a single freshly streaked 
bacterial colony resuspended in 20 µl dH2O. A 50 µl PCR reaction mixture was prepared 
by adding the following to a 0.5 ml Eppendorf: 35 µl dH2O, 10 µl 5x MyFi Buffer 
(containing 2 mM dNTPs), 2 µl each 10 µM forward and reverse primers (final 
concentration 0.3 µM each) and 1 µl MyFi DNA Polymerase. The PCR reaction 
parameters used are shown in Table 2.9. 
X 30 cycles 
Table 2.6. Thermocycling parameters used 
for standard Taq DNA polymerase PCR 
X 32 cycles 
Table 2.7. Thermocycling parameters used 
for standard KOD DNA polymerase PCR 
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65oC 30" 
8oC 30" 
65oC 90" 
97oC 180" 
8oC 60" 
65oC 180" 
97oC 60" 
65oC 60" 
4oC HOLD 
 
  
 
Initial 
denaturation 95
oC 2' 
Denaturation 95oC 15'’ 
 
Annealing 45oC - 55oC 15’' 
Extension 72oC 45’’ 
Final Extension 72oC 5' 
Hold 4oC HOLD 
 
2.2.3  Agarose gel electrophoresis 
1% (w/v) agarose gels were made by melting 0.5 g agarose (Melford, electrophoresis 
grade) in 50 ml 1X TBE buffer (10.8 g Tris HCl, 5.5 g Boric acid, 0.75 g EDTA, per litre 
dH2O). Following the addition of 5 µl of 10 mg/ml ethidium bromide, the molten agarose 
was poured into a pre-cast DNA electrophoresis gel tank. A comb was inserted to create 
appropriately sized wells and the gel was allowed to solidify at room temperature for 
approximately 30 min. For sample preparation, appropriate volumes of 5X DNA loading 
dye (containing 62.5 ml 30% glycerol, 31.25 ml dH2O, 6.25 ml 10% SDS, 0.125 g 
bromophenol blue and 0.125 g xylene cyanol, per 100 ml dH2O) were added to the PCR 
samples. The samples were loaded into the wells of the gel and then electrophoresed at 
70 V for 60 min. Gels were visualised under the transilluminator of a Syngene 
GeneGenius Gel BioImaging Unit using Syngene GeneSnap software.  
 
X 35 cycles 
Table 2.9. Thermocycling parameters used 
for standard MyFi DNA polymerase PCR 
Table 2.8. Thermocycling parameters used to 
extract crude S. hominis B10 template DNA 
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2.2.4  DNA extraction from agarose gel 
The agarose gel was visualised under low-intensity UV transilluminator and the 
appropriate band of DNA excised using a clean scalpel and placed inside a 1.5 ml 
Eppendorf tube. DNA extraction was performed using the Macherey-Nagel NucleoSpin 
Extract II kit following the manufacturers recommended protocol and eluted in 20-30 µl 
sterile dH2O. The quantity and quality of DNA in the sample was determined using a 
Nanodrop (ND-1000) spectrophotometer. DNA samples were stored at -20oC until use.  
2.2.5  Preparation of chemically competent E. coli cells 
A 5 ml overnight culture of the desired strain was grown overnight at 37°C in LB with the 
appropriate antibiotic selection. The following day, 100 µl of the culture was added to 10 
ml of LB (containing the appropriate antibiotic) and incubated aerobically at 37°C until the 
OD650 nm reached 0.3 – 0.4. The cells were pelleted by centrifugation at 3500 rpm for 8 
min at 4°C. The cells were resuspend in 1 ml of 0.1 M ice cold sterile CaCl2 and incubated 
on ice for 30 min. The cells were pelleted by centrifugation at 3500 rpm for 8 min at 4°C 
and resuspend in 300 µl of ice cold 0.1 M CaCl2.100 µl aliquots of cells were prepared and 
either used immediately or stored at -80°C until future use. 
2.2.6 Transformation of chemically competent E. coli with plasmid 
DNA 
100 µl aliquots of chemically competent cells were either made fresh or thawed on ice 
from -80°C stock. 100 ng of plasmid DNA was added to an aliquot of cells and incubated 
on ice for 30 min. The cells were heat-shocked at 42°C for 90 sec. 900 µl pre-warmed 
(42°C) SOC medium was immediately added and the cells were incubated at the 
appropriate recorvery temperature (30°C or 37°C) for 1 h. 200 µl of cells were spread onto 
LB agar plates supplemented with the appropriate antibiotic and incubated overnight at 
either 30°C or 37°C. A negative control with no added plasmid DNA added was always 
included. 
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2.2.7 Purification and restriction endonuclease digestion of plasmid 
DNA 
A 5 ml overnight culture of E. coli harbouring the desired plasmid was grown overnight in 
LB supplemented with the appropriate antibiotic. Plasmid DNA was extracted using either 
Macherey-Nagel NucleoSpin Plasmid miniprep kit or Wizard Plus SV Minipreps DNA 
Purification System (Promega) following the manufacturers recommended protocol. The 
amount of plasmid DNA extracted was quantified using a Nanodrop (ND-1000) 
spectrophotometer. To confirm extraction of the correct plasmid, or to confirm gene 
insertion in a particular plasmid, restriction enzyme digestion was carried out. In a 0.5 ml 
Eppendorf tube, the following components were combined: 2 µl 10 X restriction enzyme 
buffer (different depending on the restriction enzyme used), 300 ng plasmid DNA, 0.5 µl 
restriction enzyme (NEB or Promega) and sterile dH2O to adjust the volume to 20 µl. The 
reaction was incubated at the optimum temperature for the particular restriction enzyme 
for at least 1 h but no more than 2.5 h. The DNA was then separated on a 1% agarose 
gel, as detailed in section 2.6.3. 
2.2.8 pCP20-mediated removal of the kanamycin resistance cassette 
from Keio Collection strains 
Keio Collection strains (Baba et al., 2006)  were accessed from an in-house library. To 
remove the kanamycin resistance cassette from the desired strain in order to create a 
clean chromosomal deletion, the strain was transformed with pCP20 (Datsenko & 
Wanner, 2000) following the protocol detailed in section 2.2.6. Three independent 
colonies were then subcultured in 5 ml LB with no antibiotic supplement and incubated 
aerobically overnight at 43°C to cure pCP20. A loopful of each culture was plated on LB 
agar and 10 subsequent colonies from each plate subcultured onto three individual plates 
consisting of: 1) LB agar, 2) LB agar + 50 µg/ml kanamycin and 3) LB agar + 100 µg/ml 
ampicillin. Colonies which had lost kanamycin resistance were screened by PCR to 
confirm removal of the kanamycin resistance cassette. Sensitivity to ampicillin confirmed 
loss of pCP20. 
 
 
67 

2.2.9 pKD46-mediated replacement of wild-type genetic loci with the 
kanamycin resistance cassette 
A 5 ml overnight culture of the desired strain harbouring pKD46 (Datsenko & Wanner, 
2000) was incubated overnight in LB at 30°C with 100 µg/ml ampicillin. The following day, 
100 µl of the culture was added to 10 ml of LB supplemented with 100 µg/ml ampicillin 
and 20 mM L-arabinose and incubated aerobically at 30°C until the OD650 reached 0.3 – 
0.4. The cells were pelleted by centrifugation at 3500 rpm for 8 min at 4°C. The cells were 
washed three times in 2 ml ice-cold sterile 10% glycerol and finally resuspended in 200 µl 
ice-cold sterile 10% glycerol. 50 µl aliquots were prepared and added to pre-cooled 0.2 
cm gap sterile electroporation cuvettes (Bio-Rad). 200 – 400 ng purified kanamycin 
resistance cassette DNA (amplified by KOD polymerase PCR with appropriate flanking 
homology to the selected gene to be removed) was added to the cuvette. Electroporation 
was performed using a Bio-Rad Micropulser on the pre-programmed Ec2 setting (V = 2.50 
kV, time constant = 5.5 ms). Immediately following electroporation, 950 µl SOC medium, 
pre-warmed to 42°C and supplemented with 20 mM L-arabinose was added to the cuvette 
and mixed by pipetting. The mixture was transferred to a 1.5 ml Eppendorf and incubated 
horizontally at 30°C for 1 h. Cells were pelleted in a benchtop microfuge at 3500 rpm for 3 
min, resuspended in 200 µl LB and spread onto LB agar plates supplemented with 30 
µg/ml kanamycin and incubated overnight at 30°C. At least 5 resulting colonies were 
checked for integration of the kanamycin resistance cassette at the appropriate locus by 
Taq DNA polymerase PCR. pKD46 was subsequently cured from the strain by growing a 
single bacterial colony in 5 ml LB with no antibiotic selection, aerobically at 43°C, 
overnight. Loss of pKD46 from the strain was confirmed by sensitivity to ampicillin.   
2.2.10 Cloning 
2.2.10.1 Purification of cloning vector pBADcLIC2005 and preparation of 
‘LIC-ready’ plasmid 
pBADcLIC2005 (Geertsma & Poolman, 2007) was purified from E. coli MG1655 
harbouring the plasmid. To create LIC-ready pBADcLIC2005, 400 ng was digested with 
SwaI (NEB) for 2 h at 37oC. The plasmid was gel extracted and purified. The following 
components were then added to a 0.5 ml Eppendorf: 400 ng SwaI digested 
pBADcLIC2005, 1.5 µl 25 mM dCTP, 1.5 µl 10 X buffer, 1 µl T4 DNA polymerase and 
sterile dH2O to adjust the volume to 15 µl. The reaction was incubated for 30 min at 37oC 
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and the enzyme subsequently heat inactivated by incubating at 70oC for 20 min. LIC-
ready plasmid was stored at -20oC for up to 6 months. 
2.2.10.2 Purification and preparation of LIC-ready insert 
The E. coli or S. hominis B10 gene to be cloned into pBADcLIC2005 was amplified by 
PCR using KOD Hot Start DNA polymerase as detailed in Table 2.7 (for E. coli) or MyFi 
DNA polymerase as detailed in Table 2.9 (for S. hominis B10). The PCR products were 
then separated by electrophoresis on a 1% agarose gel. The DNA was then gel extracted 
and purified as detailed in section 2.2.7. To make the insert product LIC-ready, the 
following components were added to a 1.5 ml Eppendorf: 400 ng DNA, 1.5 µl 25 mM 
dGTP, 1.5 µl 10 X buffer, 1 µl T4 DNA polymerase and sterile dH2O to adjust the volume 
to 15 µl. The reaction was incubated for 30 min at 37oC and the enzyme subsequently 
heat inactivated by incubating at 70oC for 20 min. LIC-ready insert was stored at -20oC for 
up to 6 months. 
2.2.10.3 Ligation independent cloning of ‘LIC-ready’ plasmid and insert 
To ligate insert and plasmid, the following were added to a 0.5 ml Eppendorf: 50 ng LIC-
ready pBADcLIC2005, a 6 X or 10 X molar excess of LIC-ready insert DNA and sterile 
dH2O to adjust the volume to 10 µl. The reaction was incubated at room temperature for 8 
min. 3 µl was transformed in to Strategene SoloPack Gold Supercompetent E. coli cells 
(Agilent) using the manufacturers recommended protocol. The cells were plated on LB 
agar plates supplemented with 100 µg/ml ampicillin. A negative control was always 
included which consisted of 50 ng SwaI digested pBADcLIC2005 vector in the absence of 
insert DNA. 
2.2.10.4 Confirmation of gene insertion into pBADcLIC2005  
10 resulting colonies from cloning of individual genes into pBADcLIC2005 were grown 
overnight in LB supplemented with 100 µg/ml ampicillin. Plasmid DNA was extracted from 
each individual culture and digested using restriction endonuclease digestion as detailed 
in section 2.2.7 using a single restriction endonuclease that cuts at the same site in both 
pBADcLIC2005 and the gene insert. The digested DNA was then separted by agarose gel 
electrophoresis and the pattern of restriction compared to that of pBADcLIC2005 plasmid 
alone, digested with the same restriction enzyme. Correct gene insertion was confimed by 
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Sanger sequencing of putative correct constructs using the LIGHTrun service provided by 
GATC-biotech Ltd. 
2.2.11 Malodour precursor biotransformation assays 
2.2.11.1 S-Benzyl-L-cysteine and S-Benzyl-L-cysteinylglycine 
biotransformation assays using resting cells 
5 to 20 ml of the appropriate bacterial strain grown overnight in LB (E. coli) or TSBT 
(corynebacteria and staphylococci) was centrifuged at 3500 rpm for 10-15 min and 
resuspended in 2 ml sterile minimal recovery medium (corynebacteria and staphylococci) 
or 1 X M9 salts (E. coli). Where appropriate, E. coli strains harbouring inducible genes on 
the pBADcLIC2005 plasmid were pre-induced during overnight growth with 0.0001% L-
arabinose. To a sterile glass vial (8 ml volume capacity), the following were added: 2 mM 
substrate (S-Benzyl-L-cysteine or S-Benzyl-L-cysteinylglycine), cells to an OD650 of 5 (for 
E. coli) or an OD590 of 5 (for corynebacteria and staphylococci) and appropriate buffer to 
adjust the volume to 4 ml. All components of the reaction were dissolved or resuspended 
in either 1 X M9 salt buffer or MRM, depending on the particular assay. Where 
appropriate, carbonyl cyanide m-chlorophenyl hydrazone (CCCP) was added at a 
concentration of 50 µM. For reactions where competitive inhibitors were added, a 100 mM 
stock solution of competitor molecule was made in 1 X M9 salts, filter sterilised and 
supplemented to the reaction at a final concentration of 20 mM. Cell only (no added 
substrate) and substrate only (no added cells) reactions were also included in every 
individual experiment. The reactions were incubated at 37°C for up to 48 h with samples 
taken at appropriate time points. Subsequent isolation and quantification of released 
benzyl-mercaptan thioalcohol was carried out as detailed below. 
2.2.11.2 (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) (MTS) and phenazine methosulfate 
(PMS)-mediated chemical labelling of benzyl-mercaptan 
To isolate released benzyl-mercaptan thioalcohol, a 500 µl volume from each reaction 
(isolated as described in section 2.2.11.1) was taken at the appropriate time point and 
centrifuged at 13000 rpm for 2 min.  
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To chemically label benzyl-mercaptan, 50 µl of labelling reagent, consisting of MTS 4.09 
mM MTS (Promega) and 0.2 mM PMS (Sigma) (Goodwin et al., 1995), dissolved in dH2O, 
was aliquotted into either a 96 well microplate or 0.5 ml Eppendorf tubes.  
For reactions using a 96 well microplate, 200 µl reaction supernatant was added to the 
pre-aliquotted 50 µl MTS/PMS. The plate was sealed with a semi-permable film lid, 
incubated at room temperature for 50 min and the A492 was recorded on a Biotek 
PowerWave XS microplate spectrophotometer. The data was captured by KC junior and 
exported to Microsoft Excel. For reactions in Eppendorf tubes, 20 µl to 50 µl reaction 
supernatant was added to 50 µl MTS/PMS. The reaction was incubated at room 
temperature for 50 min. 20 µl was subsequently removed and diluted in 980 µl dH2O in a 
1.5 ml disposbale plastic cuvette. The A492 was recorded. 
2.2.11.3 Chemical labelling of known concentrations of benzyl-
mercaptan and 3-mercaptohexan-1-ol using MTS/PMS 
1 µM stock concentrations of benzyl-mercaptan (Sigma) and 3-mercaptohexan-1-ol 
(Sigma) were prepared in a final volume of 2 ml in a sterile, 8 ml capacity glass vial. 200 µl 
of thioalcohol (diluted to the appropriate concentration using MRM) was added to 50 µl 
MTS/PMS in a 96-well plate. Labelling of the thioalcohol proceeded as detailed in section 
2.2.11.2. 
2.2.11.4 Cys-Gly-3M3SH biotransformation assays using resting cells  
5 to 20 ml of the appropriate bacterial strain grown overnight in LB (E. coli) or TSBT 
(corynebacteria and staphylococci) was centrifuged at 3500 rpm for 10 - 15 min and 
resuspended in 2 ml sterile 1 X M9 minimal salts. Where appropriate, E. coli strains 
harbouring inducible genes on the pBADcLIC2005 plasmid were pre-induced during 
overnight growth with 0.0001% L-arabinose. To a sterile glass vial (8 ml volume capacity), 
the following were added: 2 mM Cys-Gly-3M3SH substrate (dissolved in 1 X M9 salts), 
cells to an OD650 of 5 (for E. coli) or to an OD590 of 5 (for corynebacteria and staphylococci) 
and 1 X M9 minimal salts to adjust the volume to 1 ml. Where appropriate, 100 µM CCCP 
or 20 mM sodium orthovanadate were added. For reactions where competitive inhibitors 
were added, a 100 mM stock solution of competitor molecule was made in 1 X M9 salts, 
filter sterilised and supplemented to the reaction at a final concentration of 20 mM. Cell 
only (no added substrate) and substrate only (no added cells) reactions were also 
included in every individual experiment but are not always shown in each individual figure. 
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The reactions were incubated at 37°C for up to 48 h with samples taken at appropriate 
time points. Subsequent isolation and quantification of released 3M3SH thioalcohol was 
carried out as detailed below. 
2.2.11.5 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB)-mediated chemical 
labelling of 3M3SH 
To quantify free 3M3SH, a 75 µl volume from each reaction (isolated as described in 
section 2.2.11.4) was taken at the appropriate time point and centrifuged at 13000 rpm for 
2 min.  
950 µl labelling solution, consisting of: 800 µl dH2O, 100 µl UltraPure Tris (pH 8.0) and 50 
µl DTNB (Ellman, 1958) stock solution (50 mM sodium acetate, 2 mM DTNB, dissolved in 
dH2O) was added to a 1.5 ml disposable cuvette. 50 µl reaction supernatant was added to 
the cuvette, mixed by pipetting and incubated at room temperature for 5 min. The A412 was 
recorded (Van Horn, 2003). 
2.2.11.6 Lysostaphin-mediated cell lysis of staphylococci 
50 ml overnight cultures of S. hominis B10 and S. epidermidis G428 were centrifuged at 
3500 rpm for 15 min at 4°C. The pellet was resuspended in 3 ml 1 X M9 minimal salts and 
the OD590 was recorded. 50 µg lysostaphin (dissolved in 50 µl 1 X M9 salts) was added to 
the bacterial suspension along with an appropriate volume of 1 X bacterial protease 
inhibitor cocktail (Sigma), where required. The culture was incubated at 37°C for up to 5 h 
until visible clearing of the culture was seen. Following incubation, crude cell lysate was 
obtained by centrifugation of the material at 13000 rpm for 20 min at 4°C. Crude cell 
lysate was divided into 300 µl aliquots and stored at -20°C until use.     
2.2.11.7 S-Benzyl-L-cysteine and Cys-Gly-3M3SH biotransformation by 
Staphylococcus spp. crude cell lysate 
The protocol for S-Benzyl-L-cysteine and Cys-Gly-3M3SH biotransformation assays by 
staphylococcal crude cell lysate was comparable to that described in section 2.2.11.1 and 
2.2.11.4, respectively. However, resting cells were substituted for crude cell lysate. The 
volume of crude cell lysate added to each reaction was calculated from the OD590 of the 
bacterial suspension prior to lysostaphin-mediated cell lysis (for which, 100% bacterial 
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lysis and protein recovery was assumed). Labelling of released benzyl-mercaptan and 
3M3SH was performed using MTS/PMS (section 2.2.11.2) and DTNB (section 2.2.11.5), 
respectively. 
2.2.11.8  Purified cystathionine β-lyase enzyme activity assays 
Purified recombinant cystathionine β-lyase from C. jeikeium K411 (James et al., 2013) 
was provided by Unilever. For S-Benzyl-L-cysteine, S-Benzyl-L-cysteinylglycine and Cys-
Gly-3M3SH biotransformation assays, a 1:2000 dilution from stock was prepared and 
substrate biotransformation assays performed as detailed in section 2.2.11.1 - 2.2.11.2 
(for benzyl-substrates) and 2.2.11.4 - 2.2.11.5 (for Cys-Gly-3M3SH). 
2.2.11.9  Thin layer chromatography (TLC) 
7.5 µl samples of reaction supernatant (as prepared in section 2.2.11.1) were loaded at 
1.5 cm intervals on a cellulose F thin layer chromatography glass plate (Merck Millipore) 
and allowed to dry at room temperature for 15 min. A 2.5 cm gap was left between the 
bottom edge of the plate and sample load position. The internal surfaces of a glass TLC 
tank were lined with technical/qualitative filter paper (Sartorius) and the running solvent 1-
butanol:dH2O:glacial acetic acid in a 4:1:1 ratio (Emter & Natsch, 2008) was poured to a 
depth of 1.5 cm at the bottom of the tank and allowed to saturate the filter paper for at 
least 1 h. The TLC plate was placed, samples at the bottom, into the tank at an angle of 
approximately 70o. The solvent front was allowed to proceed for a minimum of 7 h until it 
reached 2-3 cm from the top of the plate. The plate was then removed from the tank and 
the solvent was allowed to evaporate in a chemical fume hood for 15 min. The plate was 
then stained by applying a liberal amount of aerosolised 2% ninhydrin (dissolved in 1-
butanol:glacial acetic acid in a 97:3 ratio) to the surface of the TLC plate. The plate was 
subsequently heated to 55°C for at least 30 min. The plate was incubated overnight at 
room temperature and then visualised under upper white light in a Syngene GeneGenius 
Gel BioImaging Unit using Syngene GeneSnap software.  
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2.3  Microbiological techniques 
2.3.1 Speciation of unidentified axillary isolates using MicroSeq 500 
An individual colony of each strain was diluted in 100 µl PrepMan Ultra sample 
preparation buffer (Applied Biosystems) and heated to 100°C for 10 min to crudely extract 
genomic DNA. 8 µl of this preparation was diluted in 395 µl sterile, nuclease free dH2O 
and stored at 4°C until use.The MicroSeq 500 16S rDNA bacterial identification PCR kit 
(PN 4348229) (Applied Biosystems) contains a PCR master mix required to amplify the 
first 500 base pairs of the 16S rDNA region of any bacterial chromosome. The 
manufacturers recommended protocol and reaction set up was followed and PCR was 
carried out using aGeneAmp PCR System 2700 using the previously isolated DNA as a 
template. Resulting PCR products were stored at -20°C until use. Forward and reverse 
cycle sequencing reactions were prepared by adding 3 µl volumes of each purified PCR 
product, 4 µl of dH20 (supplied in the kit) and 13 µl aliquots of either the forward or reverse 
sequencing mixes into appropriate PCR tubes. PCR reactions were again performed on a 
GeneAmp PCR System 2700 and amplicons were purified and dried in a vacuum 
centrifuge for 15 min. Electrophoretic sequencing was carried out using an Applied 
Biosystems 3100X Genetic Analyzer instrument. Treatment of the samples was as 
recommended by Applied Biosystems for the BigDye Terminator Version 2 chemistry. The 
sequencing data was analysed using MicroSeq ID Analysis Software and confirmed by 
taking the raw sequence data and searching using the Ribosomal Database Project 
(http://rdp.cme.msu.edu/) for the closest DNA match. 
2.3.2  Growth phenotype experiments in shake flasks 
Shake flask growth experiments were typically conducted in 100 ml shake flasks using 20 
ml growth medium. Cells were routinely pre-grown overnight in M9 glucose medium and 
directly inoculated into fresh medium the following day to a starting OD650 nm of 0.1. The 
cultures were incubated aerobically at 37°C at 180 rpm for the duration of the experiment. 
Where supplements were made during bacterial growth, they were aseptically added at 
the appropriate time point. For sampling, a 1 ml sample (or appropriate dilution thereof) 
was taken from each shake flask on an hourly basis and the OD650 recorded using a 
Jenway 6305 spectrophotometer. 
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2.3.3  Growth phenotype experiments in 96-well microplates 
Growth experiments in a 96-well microplate were performed on a Tecan Infinite M200 Pro 
microplate reader. For pre-growth of bacterial cultures, strains were inoculated from a 
single colony into 2.5 ml M9 glucose medium and incubated aerobically overnight at 37oC.  
For tryptone broth, LB and yeast extract broth growth assays, 150 µl medium was 
aliquotted into the internal wells of a 96-well microplate (Corning Costar 3595). The 
perimeter wells of the microplate were filled with 150 µl of sterile dH2O to prevent 
evaporation from the internal wells. For minimal medium assays, 150 µl of filter sterilised 
M9 glucose medium with the appropriate concentration of dipeptide or amino acid as the 
sole source of nitrogen was aliquotted into the internal wells of the microplate. 
To inoculate the medium, the OD650 of each overnight culture was measured and adjusted 
to 1.0 by addition of 1X M9 salts. 1.5 µl of this bacterial cell suspension was added to the 
appropriate well and mixed by pipetting to give a starting OD650 of 0.01. The Tecan Infinite 
M200 Pro was set to monitor OD650 every 30 min for 24 to 48 h and maintain a constant 
temperature of 37oC. Data was exported to Magellan data analysis software for analysis. 
For data analysis, the average of three uninoculated growth medium only control wells 
was taken at every 30 min time point and the experimental data was normalised by 
subtracting this value from the OD650 reading for all cultures at the respective time point to 
eliminate background OD values. 
2.3.4  Agar plate toxic tripeptide inhibition assays 
M9 agar plates were made by pre-warming 2X concentrated sterile M9 minimal salts to 
50oC and adding this to an equivolume of sterile 2% agar, melted and cooled to 50oC. 
0.4% (v/v) D-glucose, 18.7 mM NH4Cl and 1 mM MgSO4 were then supplemented. Plates 
were poured, allowed to set and dried in a class II microbiology safety cabinet and stored 
at 4oC until use.  
For the toxic tripeptide inhibition assays, 400 µl of a saturated culture of the appropriate 
strain of E. coli, grown in M9 glucose, was spread onto the surface of an M9 agar plate 
and allowed to dry for at least 20 min. Sterile 5 mm filter paper discs were aseptically 
placed onto the surface of the dried bacterial culture and saturated with equimolar 
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concentrations of L-valine, L-valylglycylglycine (Val-Gly-Gly) or sterile dH2O. Specifically, 
in a final volume of 10 µl, 5.45 µl of 5 µg/µl L-valine, 5.65 µl of 10 µg/µl Val-Gly-Gly or 10 
µl sterile dH2O were used. The solutions were allowed to saturate the filter paper discs 
and dry. Plates were incubated overnight at 37°C. Zones of inhibition were calculated as 
the distance of bacterial clearance from the centre of the filter paper disc.  
2.3.5  Growth of E. coli in spent tryptone broth medium 
Spent tryptone broth was prepared from a saturated culture of the appropriate E. coli 
strain following 24 h growth in tryptone broth. The bacterial cultures were centrifuged at 
13000 rpm for 20 min. The medium was then filter sterilised twice through a 0.22 µm filter 
and stored at room temperature. 5 ml aliquots were prepared and bacteria, grown 
overnight in M9 glucose medium, was added to a starting OD650 of 0.1. The cultures were 
incubated overnight at 37oC and the final growth yield (OD650 following 24 h incubation) 
was recorded. 
2.3.6  End point final growth yield measurement 
Final yield growth experiments were conducted in 5 ml growth medium. Bacteria were pre-
grown overnight in M9 glucose medium and added to the fresh medium the following day 
to a starting OD650 of 0.1. The cultures were incubated overnight at 37oC and the final 
growth yield (OD650 following 24 h incubation) was recorded. 
2.3.7 Preparation of crude cell lysate from E. coli  
4 X 50 ml saturated overnight cultures of E. coli K-12 were centrifuged at 3500 rpm for 20 
min at 4°C. Each pellet was resuspended in 5 ml 1X M9 minimal salts and the cells pooled 
in to a single 50 ml Falcon tube. 10 ml 1 X M9 salts was added to adjust the total volume 
to 35 ml. The OD650 was recorded. To obtain cell lysate, the cells were disrupted using a 
Misonix Sonicator 3000 Ultrasonic Cell Disruptor. The sample was placed (lid off) inside a 
500ml plastic beaker filled with ice. The probe was inserted into the sample and the cells 
were sonicated for a total of 60 pulses of 3 sec, with 7 sec intervals between pulses. 
Following sonication, cell debris was removed by centrifuging of the sample at 13000 rpm 
for 20 min at 4°C. Crude cell lysate was divided into 600 µl aliquots and stored at -20°C 
until use.     
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2.4 Bioinformatics 
2.4.1 Construction of Dtp protein phylogenetic tree 
The amino acid sequence of each Dtp protein of E. coli K-12 was taken from the E. coli 
genetic database EcoCyc (http://www.ecocyc.org). Each protein was used as a BLAST 
query to search for orthologous proteins in other organisms. Orthologues of each Dtp 
protein were identified based on sequence homology with DtpA, DtpB, DtpC or DtpD. 
Each independently identified Dtp orthologue was subsequently used as a reciprocal 
BLAST query against all four E. coli Dtp proteins to confirm true orthology to the original 
protein. The amino acid sequences were compiled in FASTA format using unique 
identifiers and a multiple sequence alignment was performed using ClustalX2. A 
phylogenetic tree was constructed in ClustalX2 using the neighbour joining method, 
employing 1000 bootstrap trials. The phylogenetic tree was viewed and annotated using 
FigTree v1.4.0 (http://www. http://tree.bio.ed.ac.uk/software/figtree/).  
2.4.2 Construction of staphylococcal C-S- lyase protein phylogenetic 
tree 
The amino acid sequence of the characterised C-S- β-lyase from C. jeikeium K411 (NCBI 
ref: YP_250369.1) was used as a BLAST query to search for homologous proteins in 
staphylococci. Each independently identified homologue was subsequently used as a 
reciprocal BLAST query against YP_250369.1 to confirm true homology to the original 
protein. The amino acid sequences were compiled in FASTA format using unique 
identifiers and a multiple sequence alignment was performed using ClustalX2. A 
phylogenetic tree was constructed in ClustalX2 using the neighbour joining method, 
employing 1000 bootstrap trials. The phylogenetic tree was viewed and annotated using 
FigTree v1.4.0.  
2.4.3 Identification of molecular symporters in S. hominis SK119 
The genome of S. hominis SK119 was analysed through the BioCyc Database Collection 
(http://biocyc.org/organism-summary?object=SHOM629742-HMP). The search query 
terms ‘transporter’ and ‘permease’ were used to search the genome of S. hominis SK119 
for proteins with annotated transport function. Any transporter that was clearly part of a 
multi-gene ABC transporter operon was excluded from the analysis. The unique 
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identification references from both BioCyc and NCBI were collated for each protein and 
compiled into a table.  
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Introduction and aims 
A strong qualitative link between malodour intensity and a high population density of 
corynebacteria within the axilla has been demonstrated (Taylor et al., 2003). It has also 
been demonstrated that corynebacteria, particularly the model organism C. jeikeium K411 
and type strain C. tuberculostearicum SK141, were strong biotransformers of the model 
malodour precursor substrate S-Benzyl-L-cysteine (Fig. 1.2B) (James et al., 2013). These 
assertions have formed a long-standing hypothesis that Corynebacterium is the dominant 
malodour forming bacterial genus residing within the human axilla. In order to test this 
hypothesis, a library of skin-isolated staphylococci and corynebacteria will be screened for 
malodour precursor biotransformation using both model and physiologically-relevant 
precursor substrates. The most active malodour producing bacteria will be identified and 
malodour precursor uptake in these organisms will be rigorously characterised.  
Specific aims 
• To assess the biotransformation ability of culture collection and skin-isolated 
corynebacteria and staphylococci using both the model (S-Benzyl-L-
cysteinylglycine) and physiological (Cys-Gly-3M3SH) malodour precursor 
substrates 
 
• To assess the range of malodour precursor substrate concentration and 
concentration of bacterial cells required to generate malodour 
 
• To speciate unspeciated isolates used in the substrate biotransformation assays 
 
• To assess the energetic requirements of Cys-Gly-3M3SH uptake in the relevant 
bacteria 
 
• To assess a range of Cys-Gly-3M3SH mimetic substrates for inhibition of 
malodour production 
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3.1  Uptake and biotransformation of S-Benzyl-L-cysteinylglycine by 
corynebacteria and staphylococci 
S-Benzyl-L-cysteine has been used routinely by Unilever in thioalcohol production assays 
for several years. It is broken down intracellularly by C-S- β-lyase to the thioalcohol 
benzyl-mercaptan, pyruvate and ammonia. By directly measuring benzyl-mercaptan 
release in a whole-cell assay, the relative malodour precursor biotransformation ability of 
individual bacterial isolates can be assessed. To determine the malodour precursor 
biotransformation ability of corynebacteria and staphylococci, a screen of several isolates 
was carried out using the model dipeptide-conjugated malodour precursor substrate S-
Benzyl-L-cysteinylglycine (Fig. 1.2C), a molecule sharing greater structural similarity to the 
physiological malodour precursor molecule Cys-Gly-3M3SH than S-Benzyl-L-cysteine. 
The thioalcohol production assay developed by Unilever and applied here is detailed in 
section 2.2.11.1. Briefly, substrate (final concentration 2 mM) and resting bacterial cells 
(final OD590 of 5) were mixed in a sterile glass vial and the final volume was adjusted to 4 
ml with reaction buffer. The vials were incubated with shaking at 37oC for 24 h. A sample 
of cell suspension was taken following 24 h incubation, centrifuged, and 200 µl 
supernatant was combined with the thioalcohol labelling reagent MTS/PMS in order to 
quantify benzyl-mercaptan yield. 
High thioalcohol yield (A492 > 3) was observed in Corynebacterium sp. Ax20, C. 
tuberculostearicum G459 and C. striatum (Fig. 3.1) Moderate thioalcohol yield (A492 1.5 - 
3) was observed in C. glutamicum, C. tuberculostearicum G438, C. jeikeium K411 and S. 
haemolyticus G431. Low thioalcohol yield (A492 < 1.5) was observed for all other 
Corynebacterium and Staphylococcus isolates. High, moderate and low yield 
classifications are a relative assignment based on the yield of any given isolate relative to 
the strongest thioalcohol producer, C. tuberculostearicum G459. The data suggest that, in 
general, corynebacteria are strong biotransformers of S-Benzyl-L-cysteinylglycine. This 
correlates with previous reports suggesting a qualitative link between corynebacteria and 
malodour intensity (Taylor et al., 2003).  
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Figure 3.1. Biotransformation of S-Benzyl-L-cysteinylglycine by corynebacteria and 
staphylococci. Thioalcohol yield (A492) was quantified for each isolate using MTS/PMS after 24 
h incubation. ‘Substrate only’ and ‘cells only (C. tuberculostearicum G459)’ refer to reactions 
incubated in the absence of S-Benzyl-L-cysteinylglycine or bacterial cells respectively. Error 
bars represent standard deviation of two biological replicates. Corynebacteria are coloured red, 
staphylococci are blue and controls are black.  
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3.2  Development of a thioalcohol labelling assay to detect 
physiologically relevant malodour molecules 
To gain insight into the dynamics of malodour production in the human axilla, there is a 
clear need to move away from model malodour precursor substrates and assess bacterial 
biotransformation of the physiologically relevant malodour precursor, Cys-Gly-3M3SH 
(Fig. 1.2A). As described in chapter 1, Cys-Gly-3M3SH represents one of the most 
abundant malodour precursor molecules in apocrine gland secretions. It is proposed to be 
broken down intracellularly by either a single step (Starkenmann et al., 2005) or dual 
catabolic process (Emter & Natsch, 2008) into glycine, pyruvate, ammonia and the highly 
odorous thioalcohol 3M3SH. By directly measuring 3M3SH release, the relative ability of 
individual bacterial isolates to biotransform Cys-Gly-3M3SH can be assessed. 
To quantify 3M3SH release, an alternative thioalcohol labelling assay was developed. 
This was necessary as the pre-existing MTS/PMS labelling reagent showed poor chemical 
labelling of 3-mercaptohexan-1-ol (Fig. 3.2A), a thioalcohol structurally related to 3M3SH. 
It was envisaged that MTS/PMS-mediated labelling of 3M3SH would be equally poor. 
An alternative approach was sought and the sulfhydryl group labelling molecule, 5,5'-
dithiobis-(2-nitrobenzoic acid) (Ellman’s reagent or DTNB) was integrated into the pre-
existing assay. The mechanism of action of DTNB is summarised in Fig. 3.2B. Essentially, 
a sulfhydryl group-containing molecule, for example, 3M3SH, forms a disulfide with DTNB, 
displacing 2-nitro-5-thiobenzoate (NTB-). In water, at neutral or alkaline pH, NTB- ionises 
to NTB2- with 1:1 stoichemistry (Dal Prá et al., 2013). NTB2- is bright yellow in solution and 
has an absorbance maximum at 412 nm (Ellman, 1958). The amount of released 3M3SH 
(or other thioalcohol product) is thus directly quantifiable. 
This assay allows direct quantification of physiologically relevant malodorants and 
represents a novel method to screening bacteria for malodour precursor biotransformation 
using physiological substrates. 



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Figure 3.2. (A) Biochemical labelling of benzyl-mercaptan (filled green circles) and 3-
mercaptohexan-1-ol (filled blue circles) with MTS/PMS. For absorbance readings >0.7, 
samples were diluted appropriately prior to measurement. (B) Mechanism of sulfhydryl 
group labelling by DTNB. 
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3.3  DTNB labelling assay assessment - uptake and 
biotransformation of Cys-Gly-3M3SH by corynebacteria and 
staphylococci 
To assess how efficiently the DTNB labelling method works with 3M3SH, substrate 
biotransformation assays were repeated as in section 3.1 using the physiologically 
relevant malodour precursor molecule, Cys-Gly-3M3SH as the substrate. The 3M3SH 
labelling method is detailed in 2.2.11.5.  
Following 24 h incubation, high 3M3SH yield (A412 > 0.2) was observed in only one 
bacterial isolate, S. haemolyticus G431 (Fig. 3.3). Moderate 3M3SH yield (A412 0.07 - 0.2) 
was observed for Corynebacterium sp. Ax20. All other corynebacteria and staphylococci 
displayed low or negligible 3M3SH yield (A412 < 0.07). With the exception of C. 
tuberculostearicum G438 and C. tuberculostearicum G459, all Corynebacterium isolates 
used here were type or culture collection strains. All three Staphylococcus isolates were 
obtained from Unilever’s library of skin-isolated bacteria. 
There is a surprising discordance between the ability of a bacterial isolate to biotransform 
Cys-Gly-3M3SH (Fig. 3.3) and the ability to biotransform the model malodour precursor S-
Benzyl-L-cysteinylglycine (Fig. 3.1). In a physiological setting, biotransformation of Cys-
Gly-3M3SH is clearly more relevant and important. This data questions the relative 
contribution of corynebacteria and staphylococci to thioalcohol generation, as all of the 
Corynebacterium isolates tested show weak 3M3SH generation, whereas S. haemolyticus 
G431 is clearly an efficient biotransformer of this substrate. A more detailed assessment 
of corynebacterial and staphylococcal (particularly S. haemolyticus G431) Cys-Gly-
3M3SH biotransformation is evidently required in order to define the most efficient 
thioalcohol generating bacterial genus (and species) within the axilla. 
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Figure 3.3. Biotransformation of Cys-Gly-3M3SH by corynebacteria and staphylococci 
isolates. Thioalcohol yield (A412) was quantified for each isolate using DTNB after 24 h 
incubation. ‘Substrate only’ and ‘cells only (S. haemolyticus G431)’ refer to reactions 
incubated in the absence of Cys-Gly-3M3SH or bacterial cells respectively. Error bars 
represent standard deviation of three biological replicates. Corynebacteria are coloured red, 
staphylococci are blue and controls are black.  
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3.4  Cys-Gly-3M3SH biotransformation by S. haemolyticus G431 
S. haemolyticus G431 was identified as a strong 3M3SH generating isolate. For that 
reason, a detailed analysis of Cys-Gly-3M3SH biotransformation by S. haemolyticus G431 
was undertaken. To determine how quickly Cys-Gly-3M3SH is biotransformed by S. 
haemolyticus G431, a time course of 3M3SH generation was performed. Maximum 
3M3SH yield was achieved following only 3 h incubation with Cys-Gly-3M3SH (Fig. 3.4.1). 
The concentration of 3M3SH in the reaction remained constant over 24 h, suggesting that 
there is no loss of thioalcohol signal during the course of the assay. The data suggest that 
Cys-Gly-3M3SH biotransformation by S. haemolyticus G431 is relatively efficient and 
requires no supplemented enzymatic co-factor. 
In order to determine whether 3M3SH yield correlates with the starting concentration of 
bacterial cells and substrate, Cys-Gly-3M3SH biotransformation assays were performed 
with decreasing concentrations of bacterial cells (S. haemolyticus G431) and Cys-Gly-
3M3SH, respectively. 
Standard Cys-Gly-3M3SH biotransformation assays use a high concentration of bacterial 
cells (OD590 = 5.0). It was observed that decreasing the cell density to OD590 = 2.5 had no 
effect on final 3M3SH yield (Fig. 3.4.2A). However, step-wise decreases in cell density 
(OD590 = 1.25 and OD590 = 0.625), led to step-wise reductions in 3M3SH yield after 24 h. 
This suggests that the minimum cell density required to efficiently biotransform 2 mM Cys-
Gly-3M3SH is an OD590 of between 1.25 and 2.5. An increase in cell density above OD590 
= 2.5 does not correlate with an increase in thioalcohol yield, suggesting that at these cell 
densities, either all substrate has been biotransformed after 24 h or 3M3SH is inhibitory 
when produced at relatively high concentrations. 
A similar pattern of 3M3SH generation was observed when the starting concentration of 
Cys-Gly-3M3SH was reduced in a step-wise manner. Standard Cys-Gly-3M3SH 
biotransformation assays use 2 mM substrate. Interestingly, no increase in thioalcohol 
yield was observed when the concentration of Cys-Gly-3M3SH was doubled from 2 mM to 
4 mM (Fig. 3.4.2B). This suggests that at substrate concentrations above 2 mM, either the 
substrate or product is inhibitory to further Cys-Gly-3M3SH biotransformation. It was 
observed, as expected, that single-fold serial reductions in Cys-Gly-3M3SH concentration 
(from 2 mM down to 0.1 mM) lead to a step-wise decrease in 3M3SH yield. At 0.1 mM 
Cys-Gly-3M3SH it becomes unfeasible to distinguish between signal (3M3SH yield) and 
background noise. This suggests that at Cys-Gly-3M3SH concentrations below 2 mM, the 
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majority of substrate is biotransformed as there is a progressive reduction in thioalcohol 
yield as initial substrate concentration decreases. An alternative explanation is that the 
Cys-Gly-3M3SH transporter is relatively low affinity and transport of Cys-Gly-3M3SH is 
inefficient at concentrations below 2 mM. 
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Figure 3.4.1. Time-dependent biotransformation of Cys-Gly-3M3SH by S. haemolyticus 
G431. At each time point, thioalcohol yield (A412) was quantified using DTNB. Isolated data 
point represents thioalcohol yield following 24 h incubation. Error bars represent standard 
deviation of three biological replicates. 
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Figure 3.4.2. Biotransformation of Cys-Gly-3M3SH by S. haemolyticus G431 with 
decreasing concentrations of (A) bacterial cells (substrate concentration = 2 mM) and (B) 
Cys-Gly-3M3SH (cell OD590 = 5.0). Thioalcohol yield (A412) was quantified using DTNB after 
24 h incubation period. Error bars represent standard deviation of three biological replicates. 
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3.5 Speciation of unknown axillary isolates by riboprofiling at 
Unilever Discover, Colworth 
A large library of axillary isolated bacteria has been collected and partially speciated at 
Unilever Discover, Colworth. Some unspeciated isolates were to be included in 
subsequent screening assays and it was therefore necessary to speciate these 
unidentified isolates. Accordingly, 16S rDNA amplification followed by DNA sequence 
analysis was performed. 
A detailed protocol can be found in section 2.3.1. Briefly, DNA was extracted from a single 
bacterial colony and used as a template to amplify a section of the 16S rDNA. The purified 
products were sequenced using an Applied Biosystems 3100X Genetic Analyzer. The 
read length of good quality sequencing data varied per sample from 400 to 500 
nucleotides. A continuous read of at least 300 nucleotides of good quality sequence data 
(defined by a strong, defined peak) was used as a BLAST query against the pre-existing 
rDNA database. The highest matching BLAST hit for each individual bacterial isolate is 
displayed in Table 3.1. All top BLAST hits were unambiguous, meaning that the 16S rDNA 
nucleotide sequence matched the identified species more closely than any other species. 
All unspeciated corynebacteria (G501, G503, G511, G515, G516 and G517) were 
identified as Corynebacterium amycolatum. This correlates with the physical morphology 
of other C. amycolatum strains, which, when suspended in liquid, exhibit a non-
homogenous clumping phenotype. This clumping phenotype appears to be unique to the 
C. amycolatum species of Corynebacterium, as all other species tested suspend 
homogenously in liquid medium. 
Single species of S. cohnii (A01), S. haemolyticus (G431) and S. hominis (G323) were 
also identified. 
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Isolate 
Consensus 
sequence length (nt) Top  NCBI hit % identity 
G501 465 
Corynebacterium amycolatum 
CIP103452 
100 
G503 465 
Corynebacterium amycolatum 
CIP103452 
100 
G511 466 
Corynebacterium amycolatum 
CIP103452 
100 
G515 465 
Corynebacterium amycolatum 
CIP103452 
100 
G516 426 
Corynebacterium amycolatum 
CIP103452 
100 
G517 402 
Corynebacterium amycolatum 
CIP103452 
100 
A01 480 
Staphylococcus cohnii subsp. 
urealyticus CK27 
100 
G323 445 
Staphylococcus hominis subsp. 
hominis DM122 
99 
G431 476 
Staphylococcus haemolyticus 
JCSC1435 
99 
 
 
 






 
Table 3.1. Speciation of axillary isolated corynebacteria and staphylococci identified via 
16S rDNA sequence analysis. All top NCBI hits were unambiguous.  
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3.6  Uptake and biotransformation of Cys-Gly-3M3SH by skin-
isolated corynebacteria and staphylococci 
Biotransformation of Cys-Gly-3M3SH by skin-isolated bacteria has never been 
investigated in detail, with the majority of studies using this substrate being limited to a 
handful of bacterial isolates (Starkenmann et al., 2005, Emter & Natsch, 2008). With the 
relative contribution of corynebacteria and staphylococci to 3M3SH-based malodour under 
question (section 3.3), a comprehensive screen of multiple skin isolated bacteria is 
required to reveal active and non-active Cys-Gly-3M3SH biotransforming species. 
Accordingly, the Unilever-based library of skin-isolated bacteria was screened for Cys-
Gly-3M3SH biotransformation ability, in a species-dependant manner. 
Fig. 3.6.1A illustrates Cys-Gly-3M3SH biotransformation ability of multiple axilla-isolated 
Corynebacterium species. All individual species that were assessed are shown, and 
where multiple isolates of the same species were screened, a representative isolate of 
that species is displayed. Negligible 3M3SH generation (A412 < 0.075) was observed for all 
Corynebacterium species with the exception of C. amycolatum G502, which displayed 
moderate 3M3SH yield (A412 = 0.1-0.2). In total, negligible 3M3SH generation (A412 < 
0.075) was observed for 8 out of 8 isolates of C. tuberculostearicum (G438, G439, G440, 
G459, G464, G484, G485 and A06), 3 out of 3 isolates of C. mucifaciens (G435, G462 
and G463), 2 out of 2 isolates of C. afermentans (G434 and G441), 1 out of 1 isolate of C. 
appendicis (G465) and 1 out of 1 isolate of C. suicordis (G460), following 24 h incubation 
(data not shown). Moderate 3M3SH yield (A412 = 0.1-0.2) was observed for 7 out of 8 
strains of C. amycolatum (G500, G501, G502, G503, G515, G516 and G517) and low 
3M3SH yield was observed for C. amycolatum G511, following 24 h incubation. 
Fig. 3.6.1B illustrates Cys-Gly-3M3SH biotransformation ability of multiple skin-isolated 
Staphylococcus species. All individual species that were assessed are shown, and where 
multiple isolates of the same species were screened, a representative isolate is displayed. 
In total, high 3M3SH generation (A412 > 0.2) was observed for 9 out of 10 isolates of S. 
hominis (B10, G20, I4, J6, J11, J23, J27, J31 and W12), all of which are volar forearm 
isolates (Kelly, 2013), 2 out of 2 isolates of S. haemolyticus (G431 and W19) and 1 out of 
1 isolates of S. lugdunensis (G310) following 24 h incubation. In most cases, high 3M3SH 
yield was observed following only 5 h incubation, suggesting efficient substrate 
biotransformation in these strains. 
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Moderate 3M3SH yield was observed for S. cohnii A01, whereas S. cohnii W17 displayed 
negligible 3M3SH yield. Similarly, negligible 3M3SH yield was observed for 13 out of 13 
isolates of S. epidermidis (B01, G427, G428, G429, G430, G467, G468, G469, G470, 
G473, G474, G475 and G476), 3 out of 3 isolates of S. saprophyticus (B13, C06C and 
W14), and 2 out of 2 isolates of S. capitis/S. caprae (C07 and C15) (species 
discrimination not possible by previous riboprofiling analysis) following 24 h incubation.  
In order to determine the kinetics of 3M3SH generation, a time-course of 3M3SH 
generation was performed with S. hominis B10. This isolate was chosen as it displays 
efficient Cys-Gly-3M3SH biotransformation. S. hominis B10 reaches maximum 3M3SH 
yield after approximately 4.5 h incubation (Fig. 3.6.2). 
To confirm that the number of cells added to each reaction is not significantly different 
between corynebacteria and staphylococci, CFU counts were performed using bacteria at 
a starting OD590 of 1.0. Average CFU counts for S. hominis B10 were 9.03 x 107 CFU ml-1 
and for C. jeikeium K411 were 6.44 x 107 CFU ml-1. This confirms that an OD590 of 5 
(added at the start of each reaction) represented approximately 25% more staphylococcal 
cells than corynebacteria. Although this slightly skews direct inter-genus comparison of 
thioalcohol yield, the all-or-nothing phenotype observed for the majority of strains would 
remain unaffected by this small difference in absolute number of cells in the assay.  
At this point, analysis of staphylococci was switched from S. haemolyticus G431 to S. 
hominis B10. This was because, unlike S. haemolyticus, S. hominis represents a relatively 
prevalent species of Staphylococcus in the human axilla (Callewaert et al., 2013). 
Characterisation of malodour production in S. hominis is therefore more closely 
associated to a physiological situation and subsequently collected data is more 
informative of the in vivo state. 
Taken together, these data suggest that S. hominis, S. haemolyticus, and S. lugdunensis 
are the most efficient biotransformers of Cys-Gly-3M3SH, as they reach high 3M3SH yield 
after only 5 h incubation. Although C. amycolatum is able to partially biotransform Cys-
Gly-3M3SH, it takes over 5 h to reach even a moderate yield, suggesting it is inefficient 
and likely insignificant in thioalcohol-based malodour relative to certain Staphylococcus 
species. The efficient Cys-Gly-3M3SH biotransformation ability and relatively high 
abundance of S. hominis in the human axilla (Callewaert et al., 2013) makes it an 
appealing target for further biochemical characterisation of thioalcohol generation.    
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Figure 3.6.1. Biotransformation of Cys-Gly-3M3SH by representative isolates of (A) skin-
isolated Corynebacterium spp. and (B) skin-isolated Staphylococcus spp. Thioalcohol yield 
(A412) was quantified for each isolate using DTNB after 5 h (blue bars) and 24 h (green bars) 
incubation periods. Error bars represent standard deviation of three biological replicates. 
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Figure 3.6.2. Time-dependent biotransformation of Cys-Gly-3M3SH by S. 
hominis B10. At each time point, thioalcohol yield (A412) was quantified using 
DTNB. Error bars represent standard deviation of three biological replicates. 
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3.7  Energetics of Cys-Gly-3M3SH uptake by S. hominis and             
S. haemolyticus 
In order to characterise Cys-Gly-3M3SH uptake by S. hominis more comprehensively, an 
assessment of the energetic requirements of substrate uptake was performed. Based on 
the size of the molecule, it was hypothesised that Cys-Gly-3M3SH would be transported 
through a dedicated transport system, rather than passively diffuse across the bacterial 
cell membrane. To determine whether uptake of Cys-Gly-3M3SH is energy-dependent, 
the ability of several S. hominis isolates to biotransform the substrate in an energy-
independent manner was assessed. Firstly, Cys-Gly-3M3SH biotransformation assays 
were carried out in the presence of the protonophore, carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP). CCCP disrupts the proton motive force, effectively preventing symport 
of molecules across the membrane (Kaback et al., 1974). In the presence of 100 µM 
CCCP, 3M3SH generation was inhibited in all 9 S. hominis isolates along with S. 
haemolyticus isolate G431 (Fig. 3.7A). This suggests that Cys-Gly-3M3SH is transported 
through a secondary transport system, requiring the co-transport of a proton to facilitate 
substrate translocation into the cell. 
Secondly, Cys-Gly-3M3SH biotransformation assays were repeated for several isolates in 
the presence of the ATPase inhibitor, sodium orthovanadate (Na3VO4). Na3VO4 was able 
to inhibit 3M3SH generation in 3 out of 3 S. hominis isolates along with S. haemolyticus 
G431 (Fig. 3.7B). Initially, this result contradicted the work carried out using CCCP and 
suggested that Cys-Gly-3M3SH may be taken up via an ABC transporter, which relies on 
ATP hydrolysis to drive substrate translocation across the membrane (Higgins, 2001). 
However, Na3VO4 is also a strong inhibitor of pyridoxal phosphate (PLP)-dependent 
enzymes and may therefore act to inhibit intracellular catabolism of Cys-Gly-3M3SH via 
the proposed carbon-sulphur-lyase route. It is also possible that Na3VO4 acted 
pleiotropically to disrupt other ATPase-dependent cellular processes, ultimately leading to 
inhibition of substrate biotransformation. A combination of these factors could explain why 
both CCCP and Na3VO4 prevent 3M3SH generation in all strains tested.  

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3.8 Preparation and characterisation of staphylococcal whole cell 
lysate for malodour precursor biotransformation assays  
To determine whether non-Cys-Gly-3M3SH biotransforming bacteria have the enzyme(s) 
required to biotransform Cys-Gly-3M3SH, whole cell bacterial lysate was prepared from 
two isolates. It was hypothesised that within the crude cell extract, the enzymes required 
to biotransform Cys-Gly-3M3SH would be present. If crude cell extract from non-3M3SH 
generating bacteria was able to biotransform Cys-Gly-3M3SH then the defect in substrate 
biotransformation ability of these strains must be at the level of substrate uptake. 
Accordingly, soluble crude cell extract was generated from S. hominis B10 and S. 
epidermidis G428 using lysostaphin-mediated cell lysis (for protocol see section 2.2.11.6). 
Lysostaphin is a glycyl-glycyl metalloendopeptidase capable of cleaving glycine-crosslinks 
in the cell wall of staphylococci (Schroeder et al., 2009) and has been routinely used to 
generate staphylococcal crude cell lysate for DNA and RNA extraction.  
Cys-Gly-3M3SH and S-Benzyl-L-cysteine biotransformation assays were performed using 
either whole bacterial cells (final concentration OD590 = 5.0) or crude cell extract 
(normalised to an equivalent of whole cell OD590 = 5.0). S-Benzyl-L-cysteine 
biotransformation assays were carried out as it has been demonstrated that purified C-S- 
β-lyase (a soluble cytoplasmic protein) from C. jeikeium K411 is sufficient to biotransform 
S-Benzyl-L-cysteine into its cognate thioalcohol, benzyl-mercaptan (James et al., 2013). 
S-Benzyl-L-cysteine biotransformation assays were therefore expected to act as a positive 
control for cell lysate activity.  
Soluble cell extract from both S. hominis B10 and S. epidermidis G428 was unable to 
biotransform S-Benzyl-L-cysteine (Fig. 3.8A). Similarly, no activity against Cys-Gly-
3M3SH was observed (Fig. 3.8B). The addition of protease inhibitors during cell lysate 
preparation had no impact on substrate biotransformation activity (data not shown).  
Taken together, these data demonstrate that there is no intrinsic activity of soluble cell 
extract from S. hominis B10 or S. epidermidis G428 against S-Benzyl-L-cysteine or Cys-
Gly-3M3SH. By lysing the cells, the ability to intracellularly concentrate the substrate is 
removed, which could be an important factor that prevents substrate biotransformation. 
Alternatively, the concentration of enzyme(s) within the cell extract required to 
biotransform these substrates may be insufficient due to normalisation of lysate volume 
against a cellular optical density rather than against total protein concentration.   
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3.9  Competitive inhibition of Cys-Gly-3M3SH biotransformation in 
S. hominis B10 
Active transport of Cys-Gly-3M3SH was demonstrated in section 3.7 and it was 
hypothesised that Cys-Gly-3M3SH would be transported in S. hominis (and other Cys-
Gly-3M3SH biotransforming bacteria) by a peptide transporter. Additionally, the 
intracellular catabolic enzyme(s) would also likely recognise the peptide backbone of the 
substrate. Small di- and tripeptides could therefore potentially inhibit Cys-Gly-3M3SH 
biotransformation, either by blocking substrate uptake or by preventing intracellular 
substrate catabolism. 
Accordingly, several small peptide-based molecules and their respective single amino 
acid building blocks were screened for ability to prevent 3M3SH generation in S. hominis 
B10. All competitor molecules were added at 20 mM, representing a 10-fold excess of 
competitor to substrate. 
Several dipeptides including Phe-Ala, Ala-Phe, Ala-Tyr-Tyr-Ala, Leu-Ala, Ala-Leu, Gly-Phe 
and Ala-Ala were able to completely inhibit 3M3SH generation in S. hominis B10 (Fig. 
3.9.1A). Gly-Gly and Gly-His also inhibited 3M3SH generation by 62 % ± 3 % and 76 % ± 
2 % respectively, following 5 h incubation. Gly-Ser slightly increased 3M3SH yield. The 
single amino acid constituents of these dipeptides, L-Phe, L-Ala, L-Leu and Gly had little 
observable effect on 3M3SH generation (Fig. 3.9.1B). L-Met inhibited 3M3SH generation 
by 77% ± 2 %. L-Tyr and L-His could not be included due to solubility issues. 
Several L-Lys-containing tripeptides were also strong inhibitors of 3M3SH generation in S. 
hominis following 5 h incubation. The most effective tripeptide, Lys-Lys-Met completely 
inhibited 3M3SH generation (Fig. 3.9.2A). Strong inhibition was also observed for Lys-
Phe-Lys (76 % ± 2 %), Lys-Lys-Tyr (61 % ± 2 %), Lys-Lys-Ala (60 % ± 7 %) and Gly-Gly-
Gly (57% ± 3 %). Moderate inhibition was observed for Lys-Pro-Lys (39 % ± 6 %). No 
significant inhibition was observed for Lys-Arg-Lys. 
Other compounds tested for inhibition of Cys-Gly-3M3SH biotransformation that had no 
observable effect on 3M3SH generation following 5 h incubation included D-glucose, S-
methylglutathione, S-methyl-L-cysteine and biotin (Fig. 3.9.2B). As expected, N-
lauroylsarcosine, an ionic surfactant, completely inhibited 3M3SH generation. 
Interestingly, 4-aminomethylbenzonoic acid (AMBA), a known inhibitor of peptide 
symporters (Meredith et al., 1998), reduced 3M3SH generation by (47 % ± 3 %) following 
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5 h incubation. This data supports the notion that in staphylococci, uptake of Cys-Gly-
3M3SH may be mediated by a general peptide symporter. 
For the majority of molecular inhibitors, the level of inhibition remained constant over the 
24 h time period. This suggests that either the inhibitor compound is not metabolised by 
the bacteria, or, more likely, given the diverse range of effective small peptide inhibitors, 
that the concentration of inhibitor compound in the reaction remains sufficiently high 
regardless of continuous turnover by bacterial metabolism. 
It is a realistic assumption that small peptides could inhibit either the putative Cys-Gly-
3M3SH transporter or the intracellular enzymatic machinery required for biotransformation 
of the substrate but unfortunately it is not possible to distinguish the precise inhibitory 
targets of these molecules using this assay. 
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Figure 3.9.1. Biotransformation of Cys-Gly-3M3SH by S. hominis B10 isolate in 
the presence of 20 mM (10-fold excess) (A) dipeptides and (B) amino acids. 
Unless stated, all amino acids and peptides used were the L- isoform. Thioalcohol 
yield (A412) was quantified using DTNB after 5 h and 24 h incubation. Error bars 
represent standard deviation of three biological replicates. 
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Figure 3.9.2. Biotransformation of Cys-Gly-3M3SH by S. hominis B10 isolate in 
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3.10  Discussion 
In this chapter, the C-S- β-lyase activity of several bacterial species was confirmed using 
a pre-existing Unilever assay to measure released benzyl-mercaptan from the model 
dipeptide malodour precursor substrate S-Benzyl-L-cysteinylglycine. The analysis 
revealed that the majority of corynebacteria (both axillary-isolated and type/culture 
collection strains) were able to biotransform S-Benzyl-L-cysteinylglycine relatively 
efficiently. This is in general agreement with previous studies that assessed 
biotransformation of a similar model malodour precursor substrate, S-Benzyl-L-cysteine. 
For example, it was demonstrated by Natsch et al. (2004), that biotransformation of S-
Benzyl-L-cysteine is carried out by multiple Corynebacterium isolates and release of 
benzyl-mercaptan is attributable to cystathionine β-lyase in this genus. Purified C-S- β-
lyase from Corynebacterium isolate Ax20 was shown to cleave S-Benzyl-L-cysteine even 
more efficiently than its natural substrate cystathionine, demonstrating the important role 
of this enzyme in thioalcohol generation from model malodour precursor substrates. This 
observation was corroborated by James et al. (2013), who demonstrated that of 28 
individual Corynebacterium isolates, 67% were C-S- β-lyase positive, whereas only 3 out 
of 17 Staphylococcus strains (17%) isolated from the same environmental niche, 
displayed the same activity. These collective observations strongly implicated 
corynebacteria in thioalcohol-based malodour until, in this study, a biochemical assay was 
developed to detect 3M3SH, the thioalcohol product of the physiological malodour 
precursor molecule, Cys-Gly-3M3SH. Using this assay, Unilever’s library of axillary 
isolates was screened for Cys-Gly-3M3SH biotransformation activity. The expectation was 
that strong Cys-Gly-3M3SH biotransformation by axillary isolated bacteria would be 
attributable to Corynebacterium spp., based on the general association of this genus with 
malodour. This assumption proved to be inaccurate, as, generally speaking, all 
Corynebacterium isolates tested displayed weak to moderate Cys-Gly-3M3SH 
biotransformation. This raises important considerations regarding the use of model 
substrates in analysis of biochemical processes, as the pattern of biotransformation of 
model (S-Benzyl-L-cysteine and S-Benzyl-L-cysteinylglycine) versus physiological (Cys-
Gly-3M3SH) malodour precursor substrates was completely different in this instance.  
Although this was the first example of a large-scale screen of Cys-Gly-3M3SH 
biotransformation by bacteria, weak Cys-Gly-3M3SH biotransformation by corynebacteria 
is not completely unprecedented. It was demonstrated by Emter & Natsch (2008) that 
crude cell lysate prepared from three discrete axillary-isolated strains of C. jeikeium and a 
single C. bovis isolate was unable to biotransform Cys-Gly-3M3SH to a significant yield. In 
contrast, however, the same report illustrated that crude cell lysate of Corynebacterium 
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isolate Ax20 was able to generate >60% 3M3SH yield from biotransformation of Cys-Gly-
3M3SH, suggesting that Ax20 is involved in Cys-Gly-3M3SH biotransformation in the 
human axilla. Despite this observation, in the whole cell Cys-Gly-3M3SH 
biotransformation assay presented here (Fig. 3.3), Ax20 produced <30% 3M3SH yield 
compared to an efficient Cys-Gly-3M3SH biotransformer, S. hominis B10. Interestingly, 
however, whole cell lysate from S. hominis B10 was completely unable to biotransform 
Cys-Gly-3M3SH (Fig. 3.8B). These collective observations imply two things. Firstly, that S. 
hominis and Corynebacterium sp. Ax20 may employ different enzymes to catabolise this 
substrate. This hypothesis is based on the observation that the intracellular enzyme(s) 
utilised by S. hominis to biotransform Cys-Gly-3M3SH were not recovered during cell 
lysate preparation, or were inactive during the assay, whereas the necessary enzymes 
from Ax20 were clearly recovered by Emter & Natsch (2008) using a similar cell lysate 
recovery procedure. No attempt was made here to recapitulate the results of Emter and 
Natsch by preparing whole cell extract from Ax20 due to the general difficulty in working 
with this strain in vivo, along with the consideration that Ax20 does not represent a highly 
prevalent axillary isolate. Secondly, given that whole cell lysate but not whole cells of 
Ax20 is able to biotransform Cys-Gly-3M3SH, it is likely that Ax20 is unable to transport 
Cys-Gly-3M3SH into the cytoplasm, a process which is clearly not required in the crude 
cell lysate assay but which is necessary in vivo and also in the physiological environment 
of the bacterium. Therefore, despite the report by Emter & Natsch that Corynebacterium 
isolate Ax20 possesses a set of enzymes necessary to biotransform Cys-Gly-3M3SH, in a 
physiological setting, Ax20 is unlikely to be a significant contributor to 3M3SH generation. 
The general inability of corynebacteria to biotransform Cys-Gly-3M3SH is surprising, given 
the overall prevalence of this genus in the human axilla. It was reported by Taylor et al. 
(2003) that aerobic coryneforms were present in the axilla of >90% of individuals (n=61) 
and were the dominant bacterial genus in 35% of these axillae. Taylor also proposed that 
unlike staphylococci, corynebacteria have a high general association with malodour 
intensity, particularly at high population densities, as determined by an axillary malodour 
scoring system. As discussed in chapter 1, the biochemical basis for this remains 
undetermined. 
The species-wide analysis of Cys-Gly-3M3SH biotransformation presented here revealed 
three species of bacteria which were able to actively transport and efficiently biotransform 
this substrate: S. haemolyticus, S. hominis and S. lugdunensis. Starkenmann et al. (2005) 
previously reported that an axillary-isolated strain of S. haemolyticus was able to 
efficiently biotransform synthetic Cys-Gly-3M3SH with a final 3M3SH yield of 75%. This is 
in agreement with the high Cys-Gly-3M3SH biotransformation activity of S. haemolyticus 
106 

G431 observed in this study. The ability of S. lugdunensis to biotransform Cys-Gly-3M3SH 
has not been previously reported, nor has the prevalence of this species on human skin. 
Interestingly, S. lugdunensis was not described as a taxon until 1988. The most 
phenotypically related species to S. lugdunensis is S. hominis, suggesting that in bacterial 
identification studies prior to 1988, S. lugdunensis may have been grouped with S. 
hominis. This could explain why there are no early reports of S. lugdunensis as an axillary 
commensal or as an active malodour producer. In contrast, S. hominis has been known as 
a major skin commensal since the mid-1970’s (Kloos and Schleifer, 1975). A report by 
Kloos & Musselwhite (1975) that assessed the relative distribution of bacteria on human 
skin concluded that of all species of staphylococci present in the axilla, generally 
speaking, the population density of S. hominis is second only to that of S. epidermidis. 
Reports of malodour precursor biotransformation by S. hominis are not widespread in the 
literature, with the only notable report by Egert et al. (2013) identifying a putative S. 
hominis isolate as the most efficient staphylococcal biotransformer of the model malodour 
precursor substrate, S-Benzyl-L-cysteine. Given that 90% of S. hominis strains tested 
here were strong biotransformers of Cys-Gly-3M3SH (Fig. 3.7A), coupled with their high 
population density in the human axilla, it is reasonable to suggest that S. hominis 
represents an important microbial species in terms of thioalcohol-based malodour. 
It was interesting to note that of the two isolates of S. cohnii assessed, isolate A01 was a 
strong biotransformer of Cys-Gly-3M3SH whereas isolate W17 was weak. Little is known 
about the axillary malodour potential of S. cohnii, as this organism has not been routinely 
studied. It is weakly associated with a common foot malodour pathway, converting small 
amounts (16.2% mol:mol) of L-leucine to isovaleric acid (James et al., 2012) but not as 
strongly as other staphylococci such as S. capitis, which displayed an 80% mol:mol yield 
under the same conditions. The discordance of Cys-Gly-3M3SH biotransformation 
between S. cohnii A01 and W17 and the all-or-nothing phenotype suggests that A01 
possesses a gene which is essential for Cys-Gly-3M3SH biotransformation and which is 
absent from isolate W17. In order to characterise Cys-Gly-3M3SH biotransformation in S. 
cohnii in more detail, both strains could be genome sequenced and compared for the 
presence or absence of putative Cys-Gly-3M3SH biotransformation genes, or single 
nucleotide polymorphisms (SNPs). However, given that S. cohnii appears to be a minor 
axillary commensal species (Kloos and Musselwhite, 1975) it is unlikely to be a major 
contributory organism to thioalcohol-based malodour in the axilla. 
All strains of S. epidermidis tested here (13 out of 13) were negative for Cys-Gly-3M3SH 
biotransformation. This observation does not support the report by Starkenmann et al. 
(2005) which demonstrated that an axillary isolated S. epidermidis was able to 
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biotransform Cys-Gly-3M3SH to a final yield of 17%. Although 3M3SH yield was relatively 
low, a final yield of 17% would still be recognised as biotransformation activity in this 
study. This discordance likely results from isolation of non-clonal S. epidermidis isolates 
by Starkenmann and Unilever, respectively, but the negligible Cys-Gly-3M3SH 
biotransformation by multiple S. epidermidis isolates assessed here suggests that even 
moderate Cys-Gly-3M3SH biotransforming S. epidermidis are the exception rather than 
the rule. This conclusion is also supported by Emter & Natsch (2008) who demonstrated 
that whole cell extracts from various staphylococci, including that of an axillary isolated 
strain of S. epidermidis were unable to biotransform Cys-Gly-3M3SH. This phenotype is 
notable given the domineering prevalence of S. epidermidis over other Staphylococcus 
species in the human axilla (Kloos & Musselwhite, 1975). The high microbial density of S. 
epidermidis over other staphylococci in the axilla, coupled with the evident inability of this 
species to biotransform Cys-Gly-3M3SH is an attractive basis for a unique area of 
research; deodorant probiotics. This area has received little to no attention in the 
literature, perhaps due to the arrival of a United States patent by Banwoski et al. (2007). 
Banowski proposed a method for promoting growth of non-malodorous bacterial species 
in the axilla using a variety of naturally occurring compounds extracted from a variety of 
plants including grapes (Vitis viticola), white tea (Camellia sinensis) and myrrh 
(Commiphora myrrh). The group claim that such compounds promote the growth or 
physiological activity of non-odour producing bacteria while at the same time reducing or 
at least not promoting the growth of odour-producing bacteria. The fundamental basis of 
this innovation is to allow non-odour producing bacteria to thrive and ultimately out-
compete their odour-forming counterparts. Despite the novelty and originality of the 
proposal, to this date, no mainstream probiotic deodorants have entered the market.  
Overall, it seems that S. haemolyticus, S. hominis and S. lugdunensis have specifically 
evolved the Cys-Gly-3M3SH biotransformation trait, rather than it being a biological side 
effect of another, more important biochemical process common to all staphylococci. This 
conclusion is based on the evidence provided here that this functionality is only present in 
a small group of phylogenetically related staphylococci and is not widespread within the 
genus as a whole, although the entire staphylococcal species diversity was not screened 
in this study. The most parsimonious explanation for a bacterium to evolve Cys-Gly-
3M3SH biotransformation ability is that it allows the organism to utilise the molecule as a 
nutrient supplement by providing a unique carbon and nitrogen source. The ability to 
transport and biotransform Cys-Gly-3M3SH is likely to present the bacterium with a fitness 
advantage by providing an exclusive substrate for growth within the human axilla.  
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Further studies on the representative S. hominis isolate B10 revealed that 3M3SH 
production could be prevented by a range of di- and tripeptides (Fig. 3.9.1 & 3.9.2). As it is 
known that a transport step and at least one intracellular catabolism step is required to 
liberate 3M3SH from Cys-Gly-3M3SH the exact site of action of the peptide inhibitors is 
unknown. Gram-negative bacteria such as E. coli encode a plethora of peptidases which 
are able to cleave cysteinylglycine (Suzuki et al., 2001) along with a diverse range of other 
peptide substrates (Miller and Schwartz, 1978). Therefore, peptide competitor molecules 
could feasibly prevent 3M3SH production by inhibiting broad substrate specificity 
staphylococcal peptidases or other enzymes involved in intracellular Cys-Gly-3M3SH 
biotransformation. However, there is also indirect evidence that peptide transporter(s) of 
S. aureus have broad substrate specificity. This conclusion was drawn when it was noted 
that uptake of the peptide antibiotic bacilysin is inhibited by a wide range of di- and 
tripeptide competitor molecules (Perry & Abraham, 1979). It is therefore attractive to 
hypothesise that peptide competitor molecules, rather than inhibit intracellular substrate 
catabolism, directly interact with the binding site of the specific Cys-Gly-3M3SH 
transporter, preventing uptake of the malodour precursor molecule into the cell. Given that 
transport occurs before intracellular substrate catabolism, competitive inhibition of Cys-
Gly-3M3SH uptake by blocking access to the transport protein is the preferred postulate. 
It was also interesting to note that L-methionine inhibited Cys-Gly-3M3SH 
biotransformation in S. hominis B10 by 75% (Fig. 3.9.1B). Since all staphylococcal 
cystathionine β-lyases belong to the MetC sub-group (James et al., 2013), this 
observation indirectly suggests a role for this C-S- β-lyase in malodour precursor 
biotransformation in S. hominis. This hypothesis is supported by the fact that MetC is 
involved in cellular methionine biosynthesis (Awano et al., 2003) and expression of metC 
(in E. coli) is repressed by L-methionine (Rowbury & Woods, 1964). The strong inhibition 
of Cys-Gly-3M3SH biotransformation by L-methionine observed here therefore provides 
indirect evidence that MetC of S. hominis B10, or a similar enzyme whose expression is 
also repressed by L-methionine, is involved in malodour precursor biotransformation.   
The discovery of S. hominis as a strong thioalcohol producer means that this organism 
now becomes the focus for identification of the staphylococcal Cys-Gly-3M3SH 
transporter. Unfortunately, there are few biological tools available for genetic manipulation 
in S. hominis and more importantly no easily accessible gene deletion protocol. Since 
Cys-Gly-3M3SH is likely transported by a peptide transporter owing to the dipeptide 
backbone of the molecule, understanding the biological basis of peptide transport in the 
model organism E. coli K-12 is an appropriate starting point to gain insight into 
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fundamental peptide (and subsequently Cys-Gly-3M3SH) transport in the relevant 
bacteria. 
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Introduction and aims 
The direct application of E. coli as a model organism to study malodour production, 
specifically the molecular mechanism behind dipeptide-malodour precursor uptake and 
biotransformation, has not been attempted before. As uptake is likely to occur via a 
specific peptide transporter with the ability to transport dipeptide analogues, it is important 
to firstly understand fundamental peptide transport in this organism. E. coli expresses both 
ABC peptide transporters (Dpp and Opp) and several peptide symporters including DtpA, 
DtpB, DtpC and DtpD (section 1.5.2). Accordingly, individual and multiple peptide 
transporter-specific genes will be deleted, including the ABC transporters opp and dpp, 
along with the aforementioned Dtp peptide symporters. These peptide transporter-
deficient (TD-Pep) strains of E. coli K-12 will then be characterised in terms of their ability 
to transport specific peptide molecules. This will aid in providing a comprehensive 
overview of peptide transporter biology in this well-studied bacterium, particularly for the 
less well-characterised Dtp transporters.  
Specific aims 
• To assess the phylogenetic relationship between E. coli Dtp peptide symporters 
and PTR-family homologues in both prokaryotes and eukaryotes.  
 
• To create individual chromosomal deletions in the following genes of E. coli K-12: 
oppC, dppC, dtpA, dtpB, dtpC and dtpD.  
 
• To create multiple chromosomal deletions in the ABC- and peptide symporter 
systems of E. coli K-12, specifically a double mutant ∆oppC ∆dppC and a 
quadruple mutant ∆dtpA ∆dtpB ∆dtpC ∆dtpD. 
 
• To characterise these mutants in terms of their ability to grow in minimal medium 
supplemented with specific dipeptides as a sole nutrient source. 
 
• To characterise these mutants in terms of their ability to grow in a complex media 
consisting of mixed di- and oligopeptides as the sole nutrient source. 
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4.1  Genome-wide phylogenetic analysis of Dtp-like proteins across 
the bacterial kingdom 
Although high affinity peptide transport via the Opp and Dpp peptide transport systems in 
E. coli has been investigated in detail (see section 1.5.2.1), only a limited number of 
studies have examined the role of the MFS superfamily peptide transporters in this 
organism. E. coli possesses multiple MFS peptide transporters, of which four, DtpA, DtpB, 
DtpC and DtpD, are members of the PTR family (see section 1.5.2.2). The phylogenetic 
relationship between Dtp proteins from E. coli and other selected bacteria was assessed. 
Each E. coli Dtp protein was used as a Basic Local Alignment Search Tool (BLAST) query 
to identify the closest homologues in other bacteria. The inclusion of an individual 
organism in the final analysis was dependent upon that bacterium having at least one 
orthologue of an E. coli K-12 Dtp protein. An orthologue was defined as a protein 
identified in the original BLAST search that corresponded to the original query (DtpA, 
DtpB, DtpC or DtpD) when a reciprocal BLAST search was performed. Although 
Gammaproteobacteria represented the principal bacterial class in this analysis, 
representative organisms from diverse classes and phyla were also included, along with 
representatives with known structure such as the peptide transporter PepTSO from 
Shewanella oneidensis (Newstead et al., 2011) and the human intestinal peptide 
transporter hPEPT1, which, when sequence aligned with bacterial Dtp proteins, shows the 
strongest identity to DtpA (24% identity at the amino acid level). 
Fig. 4.1 shows the phylogenetic relationship between bacterial Dtp transport proteins. 
Where an organism is present in one clade but absent from another, there is no clear 
orthologue of that respective Dtp protein in that bacterium. The majority of 
Gammaproteobacteria have at least one orthologue of a Dtp transport protein, but the 
precise number of Dtp proteins varies between 1 (for example Vibrio cholera HE-09 and 
Yersinia pestis strain Angola) to 5 (for example Klebsiella oxytoca KCTC 1686 and 
Klebsiella pneumoniae KCTC2242). Each Dtp protein falls into a specific clade, with DtpA 
and DtpB forming a sub-clade and DtpC and DtpD likewise. DtpC and DtpD are clearly a 
more recent duplication than DtpA and DtpB. The presence of multiple Dtp proteins is 
almost exclusive to Gammaproteobacteria, with only a single example of a Dtp protein in 
representative Epsilonproteobacteria (Campylobacter jejuni jejuni PT14 and Helicobacter 
mustelae 12198), Alphaproteobacteria (Acetobacter tropicalis NBRC 101654), 
Betaproteobacteria (Burkholderia terrae BS001 and Chromobacterium violaceum ATCC 
12472) and Deltaproteobacteria (Desulfovibrio salexigens DSM 2638 and Lawsonia 
intracellularis MN1-00). Of the non-Gammaproteobacteria, only C. violaceum has an 
orthologue of DtpA. All representative Proteobacteria with the exception of the 
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Epsilonproteobacteria have an orthologue of DtpB. The DtpC and DtpD expansion 
appears to be unique to the Gammaproteobacteria, although not all 
Gammaproteobacteria have a DtpC protein, S. boydii is a notable example. 
The DtpE clade appears to be a further expansion of the Dtp proteins in the 
Gammaproteobacteria, particularly the Enterobacteriaceae, but there is a notable absence 
of a DtpE-like protein in E. coli K-12. Within the Gammaproteobacteria, E. coli K-12 and 
Salmonella enterica subsp. enterica serovar Typhimurium strain LT2 (abbreviated as S. 
Typhimurium LT2) share the same repertoire of Dtp proteins (DtpA, DtpB, DtpC and 
DtpD), which would be expected given the genetic relatedness of these bacteria. Within 
Yersinia, Y. pestis strain Angola has only a single Dtp protein, DtpA, whereas Y. 
kristensenii ATCC 33638 has both a DtpA and a DtpE orthologue. Both DtpA and DtpE 
are present in the majority of Yersinia spp. but notably absent in all Y. pestis and Y. 
pseudotuberculosis strains. 
It is interesting that Dtp proteins are present in both prokaryotes and eukaryotes, with 
clear examples in humans (Homo sapiens PepT1 and PepT2) and yeast (Saccharomyces 
cerevisiae 2S288c), suggesting that the role of the Dtp proteins is important enough for 
the ancestral genes to have been maintained across all domains of life. A sequence 
comparison of Dtp and Dtp-like proteins is provided in Fig. 4.9. 
While there is a clear expansion of Dtp proteins in Gammaproteobacteria, the reasons 
behind this remain undetermined and the relative role of ABC- versus Dtp-peptide 
transporters in E. coli has not been established. For this reason, functional 
characterisation of peptide transport in E. coli was undertaken.  
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Figure 4.1. Rooted phylogenetic tree displaying the relationship between PTR family Dtp 
proteins. Colour coding is based on each Dtp protein family within the Gammaproteobacteria: 
DtpA – Red, DtpB – Blue, DtpC – Green, DtpD – Orange, DtpE – Pink. Multiple sequence 
alignment and phylogenetic tree building was carried out using ClustalX2.  

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4.2  Creation of peptide transporter deficient (TD-Pep) strains of E. 
coli K-12 
To create the strains required to characterise the relative role of ABC- and Dtp-mediated 
peptide transport in E. coli K-12, clean genetic deletions of peptide transporters were 
constructed using Keio Collection strains. The original Keio Collection strains were 
constructed by the Mori group (Baba et al., 2006) following the gene replacement method 
developed by Datsenko & Wanner (2000). Following constrcution, each respective strain 
was checked via colony PCR to confirm pCP20-mediated gene deletion at the respective 
locus. Oligonucleotide primers were designed to amplify from within the chromosomal 
regions immediately upstream and downstream of the deleted gene which resulted in 
different sized amplicons at individual loci. Where multiple genes were deleted in the 
same strain, pKD46-mediated homologous recombination (section 2.2.9) followed by 
pCP20-mediated gene deletion (section 2.2.8) was used to sequentially remove the 
chosen genes.  
The ABC-peptide transporters Dpp and Opp are each encoded by a five gene operon. To 
delete dpp and opp, a deletion of a single transmembrane subunit gene of each 
transporter was created. These strains were designated ∆dppC and ∆oppC, respectively. 
Agarose gel images of colony PCR (using primers detailed in Table 2.5) to confirm 
construction of ∆dppC, ∆oppC and the double mutant ∆dppC ∆oppC (∆DB1) are shown in 
Fig. 4.2. The amplicon size of the kanamycin gene replacement Keio collection strain is 
larger than wild-type (WT) in both cases. Successful deletion mutants resulted in a clean 
deletion of the kanamycin resistance gene in the respective strain. The amplicons for the 
strains harbouring deleted genes relate to the upstream and downstream regions of the 
chromosome that are amplified by the respective primers, and are consistently smaller 
than the respective wild-type gene and the kanamycin gene replaced Keio collection 
strain.  
The dtpA, dtpB, dtpC and dtpD genes encode single gene peptide transporters as detailed 
in section 4.1. Strains ∆dtpA, ∆dtpB, ∆dtpC and ∆dtpD were created to represent deletion 
mutants of the PTR family peptide transporters of E. coli. The quadruple deletion mutant 
∆dtpA ∆dtpB ∆dtpC ∆dtpD (∆DB5) was also created. Agarose gel images to confirm the 
creation of ∆DB5 are shown in Fig. 4.2. A decision was taken at this point not to make all 
possible double and triple deletion combinations of the Dtp transporters in order to allow a 
consistent collection of strains to be used for phenotypic characterisation. 
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Figure 4.2. Agarose gel (1%) stained with ethidium bromide showing colony PCR amplification 
products from single gene deletions at dppC and oppC loci (top left panel), the double gene deletion 
strain ∆DB1 (∆dppC ∆oppC) (top right panel) and the quadruple gene deletion strain ∆DB5 (∆dtpA 
∆dtpB ∆dtpC ∆dtpD) (bottom panel). Lane ‘M’ denotes DNA size marker. All other lanes are labelled 
accordingly. WT – wild type gene amplified from BW25113, Kan – kanamycin gene replacement 
amplified from respective Keio collection strain, ∆ – clean genetic deletion at respective locus. 
Expected amplicons sizes (bp): dppC WT: 1885 Kan: 2239 ∆: 1052 oppC WT: 1969 Kan: 2317 ∆: 
1130 dtpA WT: 2098 Kan: 1852 ∆: 689 dtpB WT: 1786 Kan: 1573 ∆: 810 dtpC WT: 1835 Kan: 1634 
∆: 447 dtpD WT: 1815 Kan: 1981 ∆: 804 
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4.3  Growth of E. coli TD-Pep strains in L-Alanine-L-Alanine-
containing minimal medium 
In order to characterise the effect of deleting peptide transporters in E. coli, a series of 
growth-based assays were performed using peptides as the sole nitrogen source. Firstly, 
TD-Pep strains were grown in M9 minimal glucose medium containing L-Alanine-L-
Alanine (Ala-Ala) as the sole source of nitrogen. Ala-Ala was chosen as it represents a 
simple dipeptide. The high affinity dipeptide ABC-transporter mutant ∆dppC showed no 
growth phenotype relative to wild-type (Fig. 4.3A). There was no clear growth defect for 
the oligopeptide ABC-transporter mutant ∆oppC or the double deletion mutant, ∆dppC 
∆oppC (∆DB1). This suggests that neither Dpp nor Opp are significantly involved in Ala-
Ala uptake in E. coli. Similarly, there was no growth defect for any single symporter 
deletion mutant ∆dtpA, ∆dtpB, ∆dtpC or ∆dtpD. In contrast, a strong growth defect was 
observed for the multiple peptide symporter deletion mutant, ∆DB5, which failed to grow 
following 24 h incubation. This suggests that there is redundancy between these 
transporters and that multiple Dtp proteins can transport Ala-Ala. As a control, growth of 
wild-type, ∆DB1 and ∆DB5 was assessed on M9 minimal glucose medium containing L-
Alanine as the sole source of nitrogen. Both mutant strains grew comparatively well 
compared to wild-type (Fig. 4.3B), confirming that the observed phenotype relates 
specifically to using the dipeptide Ala-Ala as the sole source of nitrogen.  
Overall, the significant growth defect of ∆DB5 compared to any other strain suggests that 
the primary route for Ala-Ala uptake in E. coli is via a combination of Dtp peptide 
transporters and not high affinity ABC-peptide transport systems. 
 
118 

 
A 
Time (hours)
0 2 4 6 8 10 12 14 16 18 20 22 24
OD
65
0 
n
m
0.0
0.1
0.2
0.3
0.4
WT
∆DB1
∆DB5
B 
Figure 4.3. Growth curves of TD-Pep strains of E. coli K-12 grown in M9 glucose 
minimal medium containing, as the sole source of nitrogen; (A) 20 mM L-Alanine-L-
Alanine or (B) 20 mM L-Alanine. Cultures were grown under aerobic conditions at 
37oC. Error bars represent standard deviation of four (part A) or three (part B) 
biological replicates. 
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4.4  Growth of E. coli TD-Pep strains in aromatic residue-containing 
dipeptide minimal medium 
To assess the impact of bulky aromatic residues on dipeptide uptake in E. coli, TD-Pep 
strains were grown in M9 minimal glucose medium containing L-Alanine-L-Phenylalanine 
(Ala-Phe), L-Phenylalanine-L-Alanine (Phe-Ala), or L-Tyrosine-L-Alanine (Tyr-Ala) as the 
sole source of nitrogen. These dipeptides were chosen as representative N-terminal 
small, C-terminal bulky/aromatic dipeptides (Ala-Phe) and N-terminal bulky/aromatic, C-
terminal small dipeptides (Phe-Ala and Tyr-Ala).  
When grown on Phe-Ala as the sole source of nitrogen, there was no growth phenotype 
for ∆dtpB, ∆dtpC or ∆dtpD (Fig. 4.4.1A) and little observable growth phenotypes for 
∆dppC, ∆oppC, ∆DB1 and ∆dtpA. However, the multiple peptide symporter deletion 
mutant ∆DB5 displayed a strong growth defect, which is similar but not as severe as the 
phenotype observed when grown on Ala-Ala (Fig. 4.3A). Overall, this data suggest that 
the peptide symporters have a greater role in Phe-Ala uptake than Dpp or Opp. When TD-
Pep strains were grown in minimal medium containing Tyr-Ala as the sole source of 
nitrogen, small growth defects were observed for strains ∆DB1 and ∆DB5  (Fig. 4.4.1B). 
Both ∆DB1 and ∆DB5 appear to grow at a slower rate than wild-type but reached similar 
final growth yields. This suggests that Tyr-Ala uptake in E. coli can be mediated by a 
multiplicity of peptide transporters and cannot be attributed to a single peptide transport 
system. 
Growth of TD-Pep strains was then assessed in M9 minimal glucose medium containing 
Ala-Phe as the sole source of nitrogen. In this medium, the most impaired growth was 
observed for ∆DB1, but clear growth defects were also seen for ∆dppC and ∆oppC (Fig. 
4.4.2). There was no apparent phenotype for any single peptide symporter deletion and a 
negligible growth defect was observed for ∆DB5. This suggests that Dpp and Opp are 
predominantly responsible for Ala-Phe uptake in E. coli.  
Overall, it appears that ABC peptide transporters are the primary means of transporting 
Ala-Phe, whereas N-terminal bulky/aromatic, C-terminal small dipeptide uptake (Phe-Ala 
and Tyr-Ala) appears to be mediated either peptide symporters or ABC peptide 
transporters. Across the limited substrate range assessed, there appears to be an additive 
effect of deleting multiple peptide transporters in terms of ability to grow on peptides, with 
∆DB1 and ∆DB5 consistently displaying stronger growth defects than individual deletion 
mutants.  
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Figure 4.4.1. Growth curves of TD-Pep strains of E. coli K-12 grown in M9 glucose 
minimal medium containing, as the sole source of nitrogen; (A) 20 mM L-
Phenylalanine-L-Alanine or (B) 20 mM L-Tyrosine-L-Alanine. Cultures were grown 
under aerobic conditions at 37oC. Error bars represent standard deviation of three 
biological replicates. 
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Figure 4.4.2. Growth curves of TD-Pep strains of E. coli K-12 grown in M9 glucose 
minimal medium containing 20 mM L-Alanine-L-Phenylalanine as the sole source of 
nitrogen. Cultures were grown under aerobic conditions at 37oC. Error bars represent 
standard deviation of three biological replicates. 
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4.5  Inhibition of growth of E. coli TD-Pep strains by L-leucine-
containing dipeptides  
The growth inhibitory effects of L-leucine (Leu)-containing dipeptides on E. coli K-12 is 
thought to arise from a direct interaction between a Leu-containing dipeptide and 
threonine deaminase (IlvA), which is responsible for the first step in L-isoleucine (Ile) 
biosynthesis. The dipeptide is thought to directly bind to the Ile binding site on IlvA, 
leading to Ile limitation in the absence of an exogenous source of Ile (Vonder Haar & 
Umbarger, 1972). As Leu-containing dipeptide is catabolised by the cell, the inhibitory 
effects subside and the growth rate increases. This phenomenon can be exploited to 
assess the route of Leu-containing peptide uptake in E. coli. 
If Leu-containing peptides are taken up at inhibitory concentrations by E. coli, growth will 
be inhibited. However, if Leu-containing peptide transport is disrupted, a lower (non-
inhibitory) concentration of intracellular Leu-dipeptide will be maintained, allowing for 
stronger growth. To define the transport system(s) used to take up Leu-containing 
dipeptides, TD-Pep strains of E. coli were grown in M9 minimal glucose medium 
supplemented with either L-Alanine-L-Leucine (Ala-Leu) or L-Leucine-L-Alanine (Leu-Ala) 
as the sole nitrogen source.  
When grown in minimal medium containing either 20 mM Ala-Leu (Fig. 4.5A) or 20 mM 
Leu-Ala (Fig. 4.5B) as the sole nitrogen source, negligible growth phenotypes were 
observed for all mutants assessed with the exception of ∆DB5, although the final optical 
density reached in these experiments were approximately 2-fold lower using Ala-Leu or 
Leu-Ala compared to other, non-inhibitory Ala-containing dipeptides. Although a modest 
phenotype, these data suggest that deletion of multiple Dtp peptide transporters leads to 
slower uptake of Ala-Leu or Leu-Ala, conceivably allowing this strain to overcome the toxic 
effects of the dipeptide by maintaining sub-inhibitory intracellular concentrations of Leu, 
ultimately enabling slow but sustained growth. This implies Ala-Leu and Leu-Ala are 
substrates for Dtp- rather than ABC peptide transporters. 
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Figure 4.5. Growth curves of TD-Pep strains of E. coli K-12 grown in M9 glucose 
minimal medium containing, as the sole source of nitrogen; (A) 20 mM L-Alanine-L-
Leucine or (B) 20 mM L-Leucine-L-Alanine. Cultures were grown under aerobic 
conditions at 37oC. Error bars represent standard deviation of three biological 
replicates. 
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4.6  Inhibition of growth of E. coli TD-Pep strains by L-valine-
containing tripeptides  
In E. coli, branched-chain amino acid biosynthesis begins with any one of three isozymes 
of acetohydroxy acid synthase (AHAS). Expression of AHAS I (encoded by ilvB and ilvN) 
and AHAS III (encoded by ilvH and ilvI), which are both involved in L-isoleucine (Ile) and 
L-valine (Val) biosynthesis is repressed when Val is in excess (Leavitt and Umbarger, 
1962) However, if not exogenously supplied, the bacterium still requires de novo synthesis 
of Ile, which normally proceeds via AHAS II (encoded by ivlG and ilvM). E. coli K-12 has a 
frameshift mutation in ilvG meaning that AHAS II is non-functional. Consequently, when 
AHAS I and III are repressed by Val in E. coli K-12, Ile biosynthesis is completely turned 
off. Fundamentally, when Val is added to a culture of E. coli K-12 at millimolar 
concentrations, the cells become starved for L-isoleucine and growth is inhibited. This 
phenomenon can be exploited to assess the route of Val-containing peptide uptake. If Val-
containing peptides are taken up by E. coli, they will be intracellularly metabolised to free 
Val and accumulate to inhibitory concentrations, leading to inhibition of growth. However, 
if Val-containing peptide transport is disrupted, a non-inhibitory concentration of 
intracellular Val will be maintained, allowing the cells to grow. 
To establish the transport route of L-valine-L-glycine-L-glycine (Val-Gly-Gly) in E. coli K-
12, an agar plate growth inhibition assay was performed. A lawn of each TD-Pep strain 
was spread onto the surface of an M9 minimal glucose agar plate and allowed to dry. 
Filter paper discs were placed onto the surface of the plate and saturated with equimolar 
concentrations of Val or Val-Gly-Gly and, as a control, H20. Zones of inhibition around the 
toxic substrates for each strain were measured following overnight incubation. The 
average zones of inhibition for all strains are shown in Table 4.6 and a representative 
image of growth inhibition of each strain is shown in Fig. 4.6. Small zones of inhibition 
signify a weak inhibitory effect of Val-Gly-Gly, meaning that the peptide transporter 
mutation in that given strain prevents Val-Gly-Gly uptake. ∆dtpA and ∆DB5 both displayed 
a small average zone of inhibition (5.3 mm ± 0.67 and 4.7 mm ± 0.33, respectively). The 
phenotype of ∆DB5 was almost exclusively attributable to the dtpA mutation in this strain, 
as neither ∆dtpB, ∆dtpC nor ∆dtpD were able to overcome the toxic effects of Val-Gly-Gly. 
∆DB1 displayed a zone of inhibition of 8.7 mm ± 0.33, which was primarily the result of the 
oppC deletion; ∆oppC alone had an average zone of inhibition of 9.7 mm ± 0.33. All 
strains displayed similar growth inhibition when Val was supplemented, confirming that the 
difference in inhibitory effect of Val-Gly-Gly is attributable to differences in peptide uptake 
between strains. It was concluded that Val-Gly-Gly uptake in E. coli is primarily carried out 
by DtpA. 
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Strain 
Average zone of inhibition (mm) SEM 
Val-Gly-Gly Val 
Wild-type 11 ± 0.0 13.7 ± 0.33 
∆dppC 12 ± 0.57 13.3 ± 0.33 
∆oppC 9.7 ± 0.33 14 ± 0.0 
∆DB1 8.7 ± 0.33 13.3 ± 0.33 
∆dtpA 5.3 ± 0.67 13.3 ± 0.88 
∆dtpB 13.3 ± 0.88 13.3 ± 1.2 
∆dtpC 12.7 ± 0.88 14 ± 0.0 
∆dtpD 11 ± 0.57 14 ± 0.58 
∆DB5 4.7 ± 0.33 13.3 ± 0.33 
Table 4.6. Average zone of inhibition (three biological replicates) 
of TD-Pep strains grown on M9 minimal glucose agar plates 
containing discs saturated with equimolar concentrations of Val-
Gly-Gly or Val. Zones of inhibition were measured from the centre 
of the disc. 
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Figure 4.6. Representative images of TD-Pep strains grown on M9 minimal glucose 
agar plates with toxic peptide supplementation. A lawn of bacteria was spread onto 
each plate, allowed to dry and filter paper discs added and saturated with the given 
compound. Top panel shows layout of filter discs on each plate. Discs were saturated 
with equimolar concentrations of Val-Gly-Gly, L-Valine or H20.  
Wild-type ∆dppC ∆oppC 
∆DB1 ∆dtpA ∆dtpB 
∆dtpC ∆dtpD ∆DB5 
Val-Gly-Gly 
Val 
H20 
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4.7  Growth of E. coli TD-Pep strains on tryptone broth 
The TD-Pep strains were assessed for their ability to grow in medium consisting of 1% 
tryptone and 1% NaCl (tryptone broth). Tryptone is a trypsin-digest of the milk protein 
casein and while the exact composition of commercially available tryptone has not been 
characterised, the bulk of the material is likely comprised of a complex mixture of amino 
acids and small peptides. This experiment was carried out to assess the relative 
involvement of each peptide transporter when a complex peptide mixture is supplied as 
the sole source of both carbon and nitrogen.  
When the peptide symporter deletion mutants were grown in tryptone broth, it was 
observed that both ∆dtpB and ∆dtpC grew at the same rate and reached similar growth 
yields compared to wild-type (Fig. 4.7.1). However, growth of ∆dtpD began to visibly slow 
following 5 h incubation. A similar phenotype was observed for ∆dtpA which displayed a 
slower growth rate than wild-type and reached a lower final growth yield.  
Given that a growth defect is observed for ∆dtpA and ∆dtpD, we can conclude that these 
two peptide symporters play a role in peptide uptake in E. coli and likely participate in 
general peptide uptake. As no growth defect was observed for ∆dtpB or ∆dtpC, this 
suggests that the substrate specificity of these transporters may be more defined.  
When the ABC-peptide transporter deletion mutants were grown in tryptone broth, it was 
observed that ∆dppC, ∆oppC and ∆DB1 grew at a similar rate to wild-type during the 
initial 3 h of growth (Fig. 4.7.2A), suggesting that during this time, E. coli is using a non-
peptide based nutrient source for growth, specifically, amino acids. Following 4 h 
incubation, a strong and immediate cessation of growth was observed for ∆oppC and 
∆DB1. ∆dppC continued to grow at a similar rate to wild-type until approximately 5 h, 
when the growth rate began to decrease. ∆oppC and ∆DB1 reached a final growth yield of 
approximately 40% compared to wild-type. In contrast, while ∆dppC continued to grow at 
a slower rate than wild-type, it reached a comparable final yield following 24 h incubation. 
This pattern of growth was strongly reproducible when the strains were grown under the 
same conditions in 100 ml shake flasks (Fig. 4.7.2B). 
The point at which growth halts in ∆oppC and ∆DB1 implies that all utilisable growth 
substrates, assumed to be amino acids and dipeptides, had been exhausted. Without a 
functional Opp transport system, these strains were unable to access the large pool of 
oligopeptides that remained in the medium. The similarity in growth rate and yield 
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between wild-type and ∆dppC suggests that the Dpp peptide transport system is not 
involved in general peptide uptake in tryptone broth. Equally, given that a strong growth 
defect is observed for ∆oppC and ∆DB1 but not ∆dppC, these data suggest that the major 
component nutrient source in tryptone is oligopeptides. Further support for this hypothesis 
is observed when wild-type and ∆DB1 strains were grown on tryptone broth medium taken 
from an overnight culture of ∆DB1. Within this ‘spent’ medium, there were predicted to be 
a pool of oligopeptides that ∆DB1 failed to utilise for growth. Bacteria from the spent 
medium were removed by centrifugation and the medium was filter sterilised. Wild-type 
and ∆DB1 were inoculated into the spent medium and grown for 24 h. Wild-type grew to a 
final yield 5-fold higher than ∆DB1 (Fig. 4.7.3), suggesting that wild-type is able to access 
the pool of peptides in the spent medium that ∆DB1 cannot. Both wild-type and ∆DB1 
grew to similar final growth yields when D-glucose was supplemented, confirming that the 
inability of ∆DB1 to grow on spent medium was not due to cell death. 
Taken together, it can be concluded that Opp, DtpA and DtpD participate in general 
oligopeptide uptake in E. coli, with Dpp playing a minor role. It appears that under normal 
growth on a mixed amino acid and peptide medium (tryptone broth), E. coli preferentially 
transports and utilises the non-peptide-based nutrient source (presumably amino acids) 
as a growth substrate. 
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Figure 4.7.1. Growth curves of peptide symporter deficient strains of E. coli K-12 
in 96-well plate format grown in 1% tryptone broth medium. Cultures were grown 
under aerobic conditions at 37oC. Error bars represent standard deviation of 
three biological replicates. 
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Figure 4.7.2. Growth curves of ABC TD-Pep strains of E. coli K-12 in tryptone broth 
medium. (A) 96-well plate format and (B) 100 ml shake flasks. Inset (in panel B) 
shows final growth yield of all cultures following 24 h incubation. For OD650 
measurements over 0.8, appropriate dilutions were made. Cultures were grown 
under aerobic conditions at 37oC. Error bars represent standard deviation of four 
(96-well plate) or three (shake flasks) biological replicates. 
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Figure 4.7.3. Final growth yield (OD650 nm) of WT and ∆DB1 E. coli K-12 
grown in filter-sterilised, spent tryptone broth growth medium of ∆DB1. As a 
control, 20 mM D-glucose (Glc) was supplemented where appropriate. Error 
bars represent standard deviation of six biological replicates. 
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4.8  Late-stage exponential growth of E. coli on tryptone broth is 
limited by carbon starvation 
The immediate cessation of exponential growth of ∆DB1 following 5 h incubation in 
tryptone broth was predicted to be caused by either carbon or nitrogen starvation. To 
assess this, 20 mM D-glucose or 18.7 mM ammonium chloride were added to cultures of 
wild-type and ∆DB1 cultures of E. coli following 5 h growth in tryptone broth. 
It was observed that following addition of D-glucose, both strains re-established 
exponential growth for at least 1 h (Fig. 4.8.1A). In contrast, the growth rate of both strains 
was unaltered following addition of ammonium chloride (Fig. 4.8.1B). This suggests that at 
late-stage exponential growth in tryptone broth, E. coli is carbon, not nitrogen starved. 
Similarly, supplementation of 1% yeast extract also led to a re-establishment of 
exponential growth in both strains, which lasted longer in wild-type than ∆DB1 (Fig. 
4.8.2A). This suggests that the composition of commercially available yeast extract has 
some peptide content which wild-type E. coli is able to use as a carbon source, but ∆DB1 
cannot. This conclusion was refuted however when wild-type and ∆DB1 were grown in 1% 
yeast extract broth. No visible growth rate or final yield defect was observed for ∆DB1 
compared to wild-type (Fig. 4.8.2B), suggesting that peptides do not make up a significant 
proportion of the utilisable nutrient source in commercially available yeast extract. 
Similarly, no growth defect was observed during early to mid-exponential growth when 
both strains were grown in LB medium (Fig. 4.8.3A). There was however a small growth 
defect for ∆DB1 during late exponential growth, suggesting that peptides may be utilised 
during this time. No significant differences were observed in the final yield of ∆DB5 
compared to wild-type when grown on tryptone broth, yeast extract broth or LB (Fig. 
4.8.3B), suggesting that peptide symporters are not preferentially used over ABC-peptide 
transporters to transport undefined mixed peptides. 
Overall, it was concluded that, during growth on amino acid- and peptide-based medium, 
E. coli is exhausted for carbon before nitrogen. Given that neither ∆DB1 nor ∆DB5 show 
significant growth defects when grown on LB or components thereof, it may be that both 
ABC-peptide transporters and peptide symporters can compensate for each other and 
play a dual role in peptide uptake on undefined media. In order to see a significant growth 
defect, a ∆DB1/∆DB5 combination strain may be required.

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Figure 4.8.1. Growth curves of wild-type (WT) and ∆DB1 E. coli K-12 in 1% tryptone 
broth medium with carbon or nitrogen supplementation. Black arrow designates 
addition of (A) 20 mM D-glucose or (B) 18.7 mM ammonium chloride (NH4Cl). Inset 
shows final growth yield of all cultures following 24 h incubation. Cultures were 
grown under aerobic conditions at 37oC. Error bars represent standard deviation of 
three biological replicates. 
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Figure 4.8.2. (A) Growth curves of wild-type (WT) and ∆DB1 E. coli K-12 in 1% 
tryptone broth medium with yeast extract supplementation (+YE). Black arrow 
designates addition of 1% yeast extract. Inset shows final growth yield of all cultures 
following 24 h incubation. (B) Growth curves of wild-type (WT) and ∆DB1 E. coli K-12 
in 1% yeast extract broth medium. All cultures were grown under aerobic conditions at 
37oC. Error bars represent standard deviation of three biological replicates. 
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Figure 4.8.3. (A) Growth curves of wild-type (WT) and ∆DB1 E. coli K-12 
in LB medium. (B) Final growth yield (OD650 nm) of wild-type (WT) and 
∆DB5 E. coli K-12 grown in LB, 1% yeast extract broth and 1% tryptone 
broth. All cultures were grown under aerobic conditions at 37oC. Error bars 
represent standard deviation of three biological replicates. 
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4.9  Discussion 
The presence or absence of Dtp transport proteins across the bacterial kingdom has been 
characterised, with particular attention paid to the Proteobacteria, where there is a clear 
expansion of Dtp transporters within the Gammaproteobacteria, particularly the 
Enterobacteriaceae. Although the reasons for this expansion remain unclear, it could be 
suggested that the environmental niche of enteric Gammaproteobacteria that have a 
disproportionately large number of Dtp transporters such as K. oxytoca, K. pneumoniae, 
E. aerogenes and C. freundii (a total of 5 Dtp proteins each) necessitates an increased 
requirement for peptide transport due to high availability of peptides within the human 
intestinal tract (Adibi, 1971), particularly after their host has consumed a protein-rich meal. 
The presence of an array of Dtp transporters, all with differing substrate specificities may 
serve to increase the probability that any given peptide will be transported, maximising the 
variety and total number of di- and oligopeptides that are taken up by the bacterium to be 
used as a nutrient source. It could be envisaged that a fitness advantage may be gained 
from being able to uptake peptides that other bacteria within the environmental niche are 
unable access. Generally speaking, non-enteric bacteria may have a reduced requirement 
for peptide transport due to lower environmental peptide availability; it may be 
energetically unfavourable and disadvantageous to overall fitness to encode and express 
multiple peptide transporters if peptides do not make up a significant portion of available 
growth substrates. This would be reflected in the limited number of Dtp transporters 
typically found in the genome of non-Enterobacteriaceae as described in section 4.1, 
although a comprehensive analysis of the peptide transporter repertoire of non-enteric 
bacteria was not carried out in this study.  
While the exact substrate specificity of individual prokaryotic PTR2 family transporters 
differs (as discussed later), they clearly share a general related functionality in terms of 
ability to transport peptides. This is substantiated by the observation that the majority of 
residues deemed to be important for catalytic activity and substrate positioning within the 
binding pocket of PTR2 family proteins are conserved between structurally characterised 
members and E. coli Dtp proteins, although there are some notable exceptions, as 
discussed below. A multiple sequence alignment of all E. coli Dtp proteins, DtpE from K. 
pneumoniae, along with examples of structurally characterised prokaryotic homologues, 
PepTSo (Newstead et al., 2011), PepTSo2 (Guettou et al., 2013), PepTSt (Solcan et al., 
2012) and GkPOT (Doki et al., 2013), is shown in Fig. 4.9. 
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Figure 4.9. Multiple sequence alignment of E. coli Dtp proteins and selected 
prokaryotic homologues. Alignment was carried out in Clustal X2. ESPript 3.0 
(http://espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi) multiple sequence alignment 
graphic software was used to visualise the alignment. 
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Histidine residue 57 (His57) of H. sapiens PTR2 family peptide transporter, PepT1, which 
is essential for catalytic function (Fei et al., 1997) and was later reported to be the 
possible proton binding site of the transporter (Uchiyama et al., 2003) is conserved only in 
PepT1 (not shown) and PepTSo, demonstrating that the equivalent His57 residue in E. coli 
is not essential for catalytic function. In a similar vein, all PTR2 family proteins have been 
reported to contain a conserved sequence motif in transmembrane helix 1, ExxERFxYY 
(Newstead, 2014, in press). Interestingly, this motif does not show absolute conservation 
across all E. coli Dtp transporters with differences arising in DtpC and DtpD, where the 
first Glu residue in the motif, Glu21 in PepTSo, has been replaced with Gln. More notably, 
just upstream of this motif, a conserved Arg residue (at position 32 in PepTSo) has been 
replaced with a Gln in DtpA, (Gln41), DtpB (Gln34) and, as previously reported by 
Newstead, PepTSo2 (Gln32). In structurally characterised PTR2 proteins, Arg32 is 
proposed to form a salt bridge with the C-terminus of a peptide substrate, aiding in its 
coordination within the binding pocket (Newstead, 2014, in press). The Arg32Gln 
substitution observed in DtpA, DtpB and PepTSo2 means that the peptide substrate is now 
coordinated slightly differently within the binding pocket, as it has to now form a salt bridge 
with an alternative arginine residue, Arg25 in PepTSo2. This may imply that PTR2 family 
members with Arg32Gln substitutions exhibit different substrate specificity to their more 
ancestral counterparts, allowing bacteria with examples of both protein types to transport 
a wider range of peptide substrates. Arg25 itself is relatively well conserved among PTR2 
family proteins, with a mutation of this residue to His in human PepT2 completely 
inactivating transport (Terada et al., 2004). This raises questions relating to the role of this 
non-conservative mutation in DtpC and DtpD, again, suggesting that these transporters 
are able to recognise different peptide-based substrates to DtpA and DtpB.  
Furthermore, the FYxxINxG sequence motif, attributed to show absolute conservation 
between PTR2 peptide transporters from bacteria to mammals (Daniel et al., 2006) is not 
conserved among E. coli Dtp transporters, or in PepTSt. This suggests that PTR2 family 
proteins are not as well conserved as historically suggested and residue substitutions 
within these regions are likely important for the overall function of the protein. 
The H. sapiens PTR2 family member and DtpA homologue, PepT1, is found at the brush 
border membrane of intestinal tissue and has an extremely broad ranging substrate 
specificity, which has been empirically validated (Biegel et al., 2006), indicating an 
important role in general peptide uptake from diet. PepT1 shares homology of between 
17% to 24% with individual E. coli K-12 Dtp proteins, suggesting a partial functional 
similarity. The fact that the range of enteric bacteria analysed here generally encode 
multiple dtp homologues in their genome supports the notion that in the human intestine, 
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these transporters play a role in scavenging nutrients from the human diet. It could be 
hypothesised that because out of all four Dtp proteins of E. coli, H. sapiens PepT1 shares 
the most sequence identity with DtpA (24%), that DtpA and PepT1 have some level of 
parallel substrate specificity; both could be broad-specificity, general transporters of di- 
and tripeptides. This notion is supported by the observation that a ∆dtpA strain of E. coli 
K-12 exhibited a significant growth phenotype when required to uptake 5 out of the 7 
individual di- or tripeptides assessed in this work (Phe-Ala, Tyr-Ala, Val-Gly-Gly, Leu-Ala 
and Ala-Leu), along with the complex peptide mixture, tryptone. This observation largely 
supports the conclusions drawn in other studies of E. coli DtpA which together 
demonstrate that purified DtpA is able to transport a wide range of structurally unrelated 
peptides containing both L- and D- amino acid isoforms, along with a plethora of 
peptidomimetic drugs (Harder et al., 2008, Weitz et al., 2007, Prabhala et al., 2014).  
While it is clear that DtpA has broad substrate specificity, the same is not true for the other 
three E. coli Dtp transporters, DtpB, DtpC and DtpD. During this work, no significant 
phenotype was observed for individual mutants of either dtpB or dtpC when required to 
uptake any of the 7 individual di- or tripeptides, or the complex peptide mixture, tryptone. 
Very little published work has been carried out on the substrate specificity of DtpB. The 
single in-depth study concluded that DtpB has a strong C-terminal negative charge 
preference (Harder et al., 2008), which may explain why DtpB is not implicated in 
transport of any peptide substrate assessed here. Conversely, DtpC has been shown to 
transport C-terminal positively charged peptides (Ernst et al., 2009), but, again, due to 
limited availability of certain peptides, none of the dipeptides assessed here have those 
chemical properties, possibly explaining why no growth phenotype was observed for 
∆dtpC. A limited number of previous attempts to functionally characterise DtpD revealed 
that the transporter has a preference for L-lysine containing dipeptides (Jensen et al., 
2012), a strong C-terminal charge preference and no affinity for N-terminally charged 
peptides (Casagrande et al., 2009). Based on the toxic dipeptide growth assays, DtpD 
also appears to transport amino acids with a hydrophobic residue at either the N- or C-
terminus (Leu-Ala or Ala-Leu, respectively) and may also play a role in general peptide 
uptake, suggested by the growth rate and final yield defect exhibited by ∆dtpD when 
grown in tryptone broth. It is difficult to distinguish why DtpA and DtpD would share 
common peptide transport features when phylogenetically, bacterial DtpA proteins cluster 
more closely to DtpB than DtpD. It may be that the nature of the peptide binding site of 
DtpA and DtpD is naturally more promiscuous, being able to accept a wider range of 
peptide substrates, meaning that the effect of deleting these transporters has a more 
pronounced effect than deleting either DtpB and DtpC, which may have a more 
specialised substrate specificity. 
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Although unique phenotypes have been observed for at least two Dtp transporter mutants 
of E. coli, it is pertinent to assume that these transporters have a degree of overlapping 
substrate specificity, given that they all belong to the same family. This proposal is 
strengthened by the observation that when E. coli is required to uptake Ala-Ala as the sole 
source of nitrogen, growth is almost completely abolished only when multiple Dtp 
transporters are mutated, meaning that at least two transporters play a role in Ala-Ala 
uptake. The capacity to transport Ala-Ala has been demonstrated for DtpA (Weitz et al., 
2007), DtpB (Harder et al., 2008) and DtpC (Ernst et al., 2009), all of which supports the 
observation that single dtp deletions have little effect on Ala-Ala uptake. It was surprising 
to note that the high affinity ABC peptide transporters of E. coli (Dpp and Opp) appear not 
to transport Ala-Ala in vivo, given that previously published work suggests that Ala-Ala is a 
good substrate for the substrate binding protein of Dpp, DppA (Smith et al., 1999). While 
this work does not directly contradict the observation of Smith, it brings into question the 
relative role of Dpp in relation to Ala-Ala transport in vivo and proposes that in a biological 
system, Ala-Ala is preferentially transported by a combination of Dtp transporters and not 
by Dpp. It is not unprecedented that a substrate of Dpp is also a substrate for other 
peptide transporters, such as Opp or DtpA (Smith and Payne, 1990), which partly explains 
why no growth phenotype is observed for ∆dppC or ∆DB1 when Ala-Ala is supplied as the 
sole source of nitrogen.  
It is clear from the work described above that E. coli does not rely exclusively on Dpp and 
Opp for uptake of every individual di- or tripeptide. However, it was concluded that these 
high affinity peptide transporters play a role in general peptide uptake in undefined 
peptide-based medium. This conclusion was based on the observation that a ∆dppC 
∆oppC double mutant (∆DB1) displayed strong growth rate and final yield phenotypic 
defects compared to wild type when grown in tryptone broth, which was almost solely 
attributable to the mutation in oppC. It should also be noted that ∆dtpA also displayed a 
growth rate and yield defect when grown in tryptone broth, although the phenotype was 
not as severe as observed for ∆DB1 or ∆oppC. This suggested that during late 
exponential and stationary phase growth, strains with a functional oppC were able to 
access a pool of oligopeptides within the growth medium that ∆DB1 (∆oppC) could not, 
confirming that Opp is primarily responsible for uptake of the major nutrient peptide source 
in tryptone broth, oligopeptides. This conclusion largely supports previous literature that 
suggests E. coli has at least two oligopeptide transporters (later identified as Opp and 
DtpA) that have a combination of diverse and overlapping substrate specificities (Naider & 
Becker, 1975, Barak & Gilbarg, 1975). 
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While E. coli undoubtedly uses peptides as a growth substrate during the latter stages of 
growth, all TD-Pep strains exhibited almost identical growth rates during lag and early 
exponential phase when grown in tryptone broth and the differential growth rate and final 
yield phenotype between wild-type E. coli and ∆DB1 was almost completely abolished 
when strains were grown in LB. This suggests that during early growth in tryptone broth 
and until late exponential/early stationary phase growth in LB, E. coli preferentially utilises 
non-peptide based growth substrates before switching to peptide metabolism. These 
observations are in agreement with relative expression of the dpp and opp operons in E. 
coli, which are maximally expressed during late exponential and stationary phase during 
growth in LB medium (Baev et al., 2006a) suggesting a reliance on peptides as a nutrient 
source only during later phases of growth. This also contradicts anecdotal claims that 
when growing in LB, E. coli is growing solely on peptides. It is likely that during non-
peptide metabolising growth in tryptone broth and LB, E. coli utilises either amino acids or 
sugars as the primary growth substrate. However, the relative amount of these nutrients 
present in commercially available tryptone has not been disclosed nor empirically verified. 
Baev et al. (2006b) demonstrated that the relative expression of genes involved in 
catabolism of D-maltose, D-galactose, L-fuculose, D-mannose and D-mannitol fluctuate 
according to the specific growth rate of E. coli when grown in LB and further stated that, 
according to the Difco manual (a commercial supplier of tryptone), the carbohydrate 
content of tryptone is 7.7% and in yeast extract is 17.5%. Extrapolating this to calculate 
the total carbohydrate concentration of typical LB medium, which contains twice as much 
tryptone as yeast extract, a value of 0.16% is obtained ((7.7*2)+17.5)/2). This is equivalent 
to an approximate mixed carbohydrate concentration of 8 mM, if normalised based on the 
molecular weight of D-glucose. If accurate, this concentration of sugar would be sufficient 
to support initial bacterial growth for several hours, with the saccharide component of the 
medium preferentially used over the peptide component. However, the sugar content of 
commercially available yeast extract is extremely inconsistent, with a notable report by 
Zhang et al., (2003), demonstrating that the trehalose content of yeast extract can range 
from <2 to >17% between individual lots, emphasising the significant variation in the total 
amount of individual growth substrates present in separate batches undefined, complex 
bacterial growth media. If sugars are used as the primary growth substrate in 1% tryptone 
broth, the approximate sugar concentration is 3.85 mM, based on a 7.7% carbohydrate 
content of Difco branded tryptone, as suggested by Baev. This would be sufficient to 
support bacterial growth for several hours before becoming limiting, forcing the bacteria to 
switch metabolism to the only remaining nutrient source, peptides. However, this would 
likely be observed during bacterial growth in the form of a diauxic shift from sugar-based 
to peptide-based metabolism, which was not apparent. Thus, the initial growth substrate 
used by E. coli in tryptone broth is unlikely to be sugar-based. 
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A conflicting report by Sezonov et al. (2007) indirectly calculated the sugar content of LB 
as less than 100 µM, based on absence of growth of an E. coli strain that required 
fermentable sugars to support growth. Sezenov also calculated the total amino acid 
concentration of LB by hydrolysing all peptide bonds to release the entire pool of free 
amino acids. The total amino acid concentration was calculated to be in the range of 80 
mM – 100 mM, an ample amount to support bacterial growth in the absence of any sugar 
component within the medium. Therefore, in the absence of a diauxic growth shift, the 
almost identical growth rate of all TD-Pep strains during early exponential phase in 
tryptone broth supports the claims of Sezonov, where E. coli grows sequentially on free 
amino acids and then peptides. This pattern of growth is unlikely to be diauxic as the 
bacteria will already be expressing a plethora of peptidases (Miller & Schwartz, 1978), the 
necessary amino acid-catabolising enzymes and a basal level of dpp and opp (Baev et al., 
2006a) required to make a seamless transition from amino acid to peptide uptake and 
catabolism (note that the relative expression levels of dtpA and dtpD during growth of E. 
coli in any media are unknown). 
The pattern of growth observed for TD-Pep E. coli in tryptone broth with no diauxie (Fig. 
4.7.1 and 4.7.2) supports the hypothesis that the sugar content of tryptone is relatively 
low. This implies that lag and early exponential phase bacterial growth is sustained by 
amino acid catabolism. However, this conclusion cannot be drawn when E. coli is grown in 
LB, as the molecular composition of the added yeast extract component, while extremely 
inconsistent, is reported to contain non-amino acid based growth substrates including 
sugars which were observed to drastically reduce the differential phenotype between wild-
type E. coli and ∆DB1. This confirms that when grown in LB, the requirement of E. coli to 
catabolise peptides is reduced. Overall, this highlights the requirement for a 
comprehensive, direct analysis of commercially available tryptone and yeast extract to 
reach a consensus regarding the composition of nutrients available to bacteria during 
growth in tryptone broth and LB.  
Data presented here also suggested that when grown in tryptone broth, E. coli becomes 
starved for carbon before nitrogen, as the addition of either D-glucose or 1% yeast extract 
following entry into stationary phase allowed E. coli to re-establish exponential growth. 
This phenotype was not observed following addition of the nitrogen source ammonium 
chloride. This phenomenon has been reported previously by Sezenov et al. (2007), who 
observed that addition of a carbon source (D-glucose) to exhausted LB medium allowed 
E. coli to re-establish growth to a final yield proportional to the amount of D-glucose 
added. This brings into question the importance of the nitrogen starvation response (the 
Ntr regulon), in relation to peptide transporter expression when E. coli is growing in LB 
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and challenges previous reports which have demonstrated that both dpp and opp are part 
of the Ntr regulon and expression is upregulated during nitrogen starvation (Zimmer et al., 
2000). The observation that E. coli is not nitrogen limited during stationary phase coupled 
with the report that expression of dpp and opp increase during exponential growth LB 
(Baev et al., 2006a) suggests that opp and dpp are also upregulated by carbon limitation. 
This is a realistic hypothesis as it has been reported that expression of dpp and opp is 
also regulated by several other factors including the amino acids L-leucine and L-alanine 
(Andrews et al., 1986), a small untranslated RNA, GcvB (Urbanowski et al., 2000) and 
phosphate limitation (Smith and Payne, 1992). Therefore, under the conditions tested, 
expression of dpp and opp is likely to be controlled by factors other than nitrogen 
limitation. 
In summary, Opp, DtpA, DtpD and to a certain extent Dpp, appear to be involved in 
general, high flux peptide transport. This likely masks the true substrate specificity of 
DtpB, DtpC and DtpD, as individual mutants of these strains still retain DtpA, Dpp and 
Opp. If a more detailed analysis of the substrate specificities of these transporters is 
sought, an E. coli K-12 strain with the genotype ∆dppC, ∆oppC ∆dtpA should be used as 
the parental strain, in which, sequential individual mutations of dtpB, dtpC and dtpD 
should be made in order to assess the relative involvement of these more poorly 
characterised transporters in peptide uptake. Generally speaking, the observation that the 
Dtp peptide transporters are crucial for growth of E. coli in certain peptide-containing 
media brings into question the reliance on the ABC peptide transporters Dpp and Opp for 
primary peptide uptake in this organism. Under physiological conditions it would be 
prudent to suggest that both ABC and peptide symporters work in tandem to facilitate 
peptide transport into the cell. 
A summary of the growth-associated phenotypes of all TD-Pep strains is displayed in 
table 4.9. 
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Introduction and aims 
Following characterisation of E. coli TD-Pep strains detailed in chapter 4, analysis of 
malodour precursor uptake in these strains can be investigated. There is an absence of 
knowledge regarding malodour precursor uptake and biotransformation in E. coli as this 
bacterium has never been used as a model organism for this purpose. It is envisaged that 
understanding malodour precursor uptake and biotransformation in E. coli will provide 
insight into malodour precursor uptake and biotransformation in the relevant axillary 
bacteria.  
Uptake of dipeptide-conjugated malodour precursor molecules is likely to occur via a 
specific peptide transporter with the ability to transport dipeptide analogues. If E. coli is to 
be used as a model organism to study this process, it is essential that the specific peptide 
transporter(s) that transports malodour precursors is identified. Additionally, it is important 
to understand the biochemical and molecular mechanisms that lead to intracellular 
catabolism of malodour precursor substrates. This will subsequently allow putative Cys-
Gly-3M3SH transporters and intracellular catabolic enzymes from S. hominis to be cloned 
and expressed in the relevant mutant strains of E. coli. 
Specific aims 
• To assess the ability of E. coli K-12 to metabolise dipeptide-conjugated malodour 
precursor substrates using substrate depletion and thioalcohol labelling assays. 
 
• To identify the genes involved in both transport and intracellular catabolism of the 
substrate using TD-Pep mutants generated and characterised in chapter 4. 
 
• To clone and express these genes in E. coli in order to functionally complement 
TD-Pep mutants for malodour precursor biotransformation activity. 
 
• To assess the effect of dipeptide competitor molecules on malodour precursor 
biotransformation in E. coli.  
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5.1  Uptake and biotransformation of S-Benzyl-L-cysteinylglycine by 
E. coli K-12 
Firstly, it was shown that E. coli is able to metabolise S-Benzyl-L-cysteinylglycine in a 
time-dependant manner by following a time-course of benzyl-mercaptan production. In a 
standard S-Benzyl-L-cysteinylglycine biotransformation assay, benzyl-mercaptan 
production increased linearly until approximately 4.5 h, at which point, production levelled 
off (Fig. 5.1A). The benzyl-mercaptan yield for E. coli K-12 wild-type (A492 = 6.82 ± 0.11 at 
t = 6.5 h) was 3-fold higher than the high thioalcohol producer S. haemolyticus G431 (2.24 
± 0.03), confirming that E. coli is an efficient S-Benzyl-L-cysteinylglycine biotransformer. 
Biotransformation of S-Benzyl-L-cysteinylglycine was inhibited by carbonyl cyanide m-
chlorophenyl hydrazone (CCCP) (Fig. 5.1A, inset). CCCP is a protonophore, which 
disrupts the proton-motive force across the bacterial cell membrane. Uptake processes 
that are inhibited by CCCP generally use protons to drive substrate translocation across 
the membrane. This suggests that S-Benzyl-L-cysteinylglycine may be transported by E. 
coliusing a molecular symporter, rather than an ABC transporter. 
S-Benzyl-L-cysteinylglycine depletion by resting E. coli cells was also followed semi-
quantitatively using a Thin-Layer Chromatography (TLC) assay. The TLC protocol is 
detailed in section 2.2.11.9. Substrate (S-Benzyl-L-cysteinylglycine) could be visualised by 
staining with the amine-specific stain, ninhydrin (Santiago et al., 2006). Removal of 
substrate from the buffer by resting cells was followed over time and almost complete 
removal was observed following 3 h incubation (Fig. 5.1B). When S-Benzyl-L-
cysteinylglycine was incubated in the absence of cells, it could still be detected following 5 
h incubation, confirming that bacterial cells are required to remove the substrate from the 
buffer. 
Together, these data demonstrate that E. coli actively transports and metabolises the 
model malodour precursor substrate S-Benzyl-L-cysteinylglycine in an efficient and time-
dependent manner. 
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S-Benzyl-L-
cysteinylglycine 
Figure 5.1. Uptake and biotransformation of S-Benzyl-L-cysteinylglycine by E. coli K-12. (A) 
Time dependant biotransformation of S-Benzyl-L-cysteinylglycine. Inset shows thioalcohol yield 
of S-Benzyl-L-cysteinylglycine biotransformation by E. coli K-12 in the absence and presence 
of 50 µM CCCP. Thioalcohol yield (A492) was quantified for using MTS/PMS at the respective 
time point. Error bars represent standard deviation of three biological replicates. (B) TLC 
analysis of S-Benzyl-L-cysteinylglycine uptake by E. coli K-12. Lanes are labelled accordingly. 
Time points refer to incubation time. ‘Unincubated’ and ‘incubated’ substrate refers to S-Benzyl-
L-cysteinylglycine incubated in the absence of bacterial cells at 37oC and room temperature, 
respectively. Substrate only samples were taken following 5 h incubation. ‘Cells only’ refers to 
bacterial cells incubated in the absence of substrate. 
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5.2  The role of C-S- β-lyase enzymes in biotransformation of 
malodour precursor substrates 
Previous work within Unilever had ascertained that model malodour precursor 
biotransformation (S-Benzyl-L-cysteine) was dependent on the cytoplasmic enzyme 
cystathionine β-lyase in the model organism C. jeikeium K411 (James et al., 2013). This 
work was corroborated here in malodour precursor biotransformation assays using a 
purified recombinant preparation of this C-S- β-lyase (NCBI accession: YP_250369.1) 
from C. jeikeium K411 (supplied by Unilever). It was observed that S-Benzyl-L-cysteine 
was efficiently biotransformed by K411 C-S- β-lyase and maximum benzyl-mercaptan 
yield was reached following 3 h incubation (Fig. 5.2A). In contrast, K411 C-S- β-lyase was 
unable to generate benzyl-mercaptan from the model dipeptide malodour precursor 
substrate, S-Benzyl-L-cysteinylglycine, or biotransform the physiological malodour 
precursor dipeptide substrate Cys-Gly-3M3SH. This strongly suggests that a dipeptidase-
like enzyme is required to liberate L-cysteine-malodour precursors from their respective 
dipeptide counterparts, which would then be biotransformed into thioalcohol by 
cystathionine β-lyase. Alternatively however, malodour precursor substrate 
biotransforming bacteria may possess a novel enzyme which is able to convert dipeptide 
malodour precursor substrate into its constituent thioalcohol in a single-step process. This 
may be particularly true of physiological substrates, as there is no direct empirical 
evidence for the involvement of cystathionine β-lyase in Cys-Gly-3M3SH 
biotransformation.  
To assess which enzyme(s) is/are involved in intracellular S-Benzyl-L-cysteinylglycine 
catabolism in E. coli, substrate biotransformation assays were performed using Keio 
Collection strains mutated in genes with known C-S- β-lyase activity. E. coli possesses 
two known C-S- β-lyase encoding genes, malY and metC, as discussed in section 1.5.3.  
Mutants of both malY and metC showed no significant decrease in benzyl-mercaptan 
production compared to wild-type in an S-Benzyl-L-cysteinylglycine biotransformation 
assay (Fig. 5.2B). This implies that neither MalY or MetC alone are essential for S-Benzyl-
L-cysteinylglycine biotransformation. This surprising result led to further examination of 
relevant literature to identify other E. coli genes with characterised C-S- β-lyase activity, 
which revealed tnaA as a possible candidate. In E. coli, TnaA has a biological role in 
tryptophan catabolism, enabling the bacterium to utilise L-tryptophan as a carbon or 
nitrogen source (Phillips et al., 2003). TnaA has also been shown to possess C-S- β-lyase 
activity against S-Benzyl-L-cysteine (Awano et al., 2003, Awano et al., 2005). A tnaA 
150 

mutant, ∆tnaA, was completely incapable of biotransforming S-Benzyl-L-cysteinylglycine, 
demonstrating that TnaA is an essential protein for S-Benzyl-L-cysteinylglycine catabolism 
in E. coli, although the requirement for an initial dipeptidase step in the biotransformation 
reaction remains to be determined.  
In summary, it has been established that C. jeikeium cystathionine β-lyase is able to 
biotransform the model malodour precursor substrate S-Benzyl-L-cysteine but not S-
Benzyl-L-cysteinylglycine or the physiological malodour precursor substrate Cys-Gly-
3M3SH. In E. coli, S-Benzyl-L-cysteinylglycine catabolism is dependent upon TnaA and 
not the commonly recognised C-S- β-lyase proteins MalY or MetC. Given the relative 
similarities in structure between L-tryptophan and S-Benzyl-L-cysteine, with both 
containing a bulky aromatic ring, the fact that TnaA is able to catabolise both molecules is 
unsurprising, although given the abundance of proteins with C-S- β-lyase activity that E. 
coli possesses, it is remarkable that TnaA is the only protein involved in S-Benzyl-L-
cysteine catabolism. 
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Figure 5.2. (A) Biotransformation of S-Benzyl-L-cysteine and S-Benzyl-L-
cysteinylglycine by purified C-S- β-lyase from C. jeikeium K411. Thioalcohol yield (A412) 
was quantified using DTNB. ‘Enzyme only’ refers to purified C-S- β-lyase incubated in 
the absence of substrate. Error bars represent standard deviation of two technical 
replicates. (B) Biotransformation of S-Benzyl-L-cysteinylglycine by E. coli C-S- β-lyase 
mutants. Thioalcohol yield (A492) was quantified using MTS/PMS following 4 h 
incubation. Error bars represent standard deviation of three biological replicates. 
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5.3  Transport and biotransformation of S-Benzyl-L-cysteinylglycine 
by TD-Pep E. coli 
Following the discovery that TnaA is an essential enzyme in malodour precursor 
biotransformation, analysis of putative malodour precursor transporters in E. coli was 
undertaken. Given that the backbone structure of the S-Benzyl-L-cysteinylglycine is 
dipeptide-based, it was predicted that it would be transported by a peptide transporter. To 
identify which transport system(s) E. coli uses to transport malodour precursors, the TD-
Pep strains were screened for S-Benzyl-L-cysteinylglycine biotransformation ability.  
A reduction in benzyl-mercaptan yield of approximately 70% was observed for ∆DB5 (Fig. 
5.3). This was almost exclusively attributable to the mutation in dtpB, as ∆dtpB exhibited 
approximately 60% reduction in benzyl-mercaptan yield. No significant decrease in 
benzyl-mercaptan yield relative to wild-type was observed for ∆DB1 (∆dppC ∆oppC), 
∆dtpA, ∆dtpC or ∆dtpD, demonstrating that these transporters are not involved in S-
Benzyl-L-cysteinylglycine uptake. Two other strains that were assessed in the screen 
were Keio Collection strains cstA::kan and sapC::kan. sapC encodes a transport system 
for antimicrobial peptides whereas cstA is a peptide symporter expressed during carbon 
starvation (see section 1.5.2). Neither sapC::kan nor cstA::kan showed any reduction in 
benzyl-mercaptan yield and are therefore not involved in S-Benzyl-L-cysteinylglycine 
uptake. 
It was concluded that DtpB is the principal S-Benzyl-L-cysteinylglycine transporter, which 
represents a novel phenotype for this Dtp transporter in E. coli. The absence of a 
significant cumulative effect of mutating multiple Dtp transporters (∆DB5) on S-Benzyl-L-
cysteinylglycine biotransformation suggests that DtpB may be more specialised in terms 
of substrate specificity than other Dtp transporters. 
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Figure 5.3. Biotransformation of S-Benzyl-L-cysteinylglycine by TD-Pep E. coli. 
Thioalcohol yield (A492) was quantified for each strain using MTS/PMS following 4 h 
incubation. ‘Substrate only’ and ‘cells only’ refer to reactions incubated in the absence 
of S-Benzyl-L-cysteinylglycine or bacterial cells respectively. Error bars represent 
standard deviation of three biological replicates. 
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5.4  Cloning, overexpression and functional complementation of 
dtpA, dtpB, dtpC and dtpD 
To confirm the role of DtpB in malodour precursor transport and to verify that this role is 
unique to DtpB and no other Dtp transporter, dtpA, dtpB, dtpC and dtpD from E. coli were 
cloned into a high copy number inducible expression vector pBADcLIC2005 (Fig. 5.4.1A) 
(Geertsma & Poolman, 2007). pBADcLIC2005 is a ligation-independent cloning (LIC) 
vector and is routinely used for protein overexpression in E. coli. It contains an araBAD 
arabinose-inducible promoter and generates proteins with a C-terminal decahistidine tag. 
This vector was chosen as it was anticipated that Dtp transporter overexpression would 
give a stronger overall signal in malodour precursor biotransformation assays than using a 
low copy number complementation vector, assuming that homologous protein 
overexpression was not toxic to the bacterium. There was also the added benefit that 
pBADcLIC2005 produces His-tagged proteins which would be useful for downstream 
purification analysis, if required. All four dtp genes were cloned into pBADcLIC2005 by 
ligation independent cloning (see section 2.2.10.3). Resulting constructs were checked by 
Sanger sequencing and named pDtpA, pDtpB, pDtpC and pDtpD respectively. The 
isogenic background strain, E. coli K-12 BW25113 was transformed with each plasmid to 
create strains WT pDtpA, WT pDtpB, WT pDtpC and WT pDtpD.  
To confirm that DtpB is responsible for S-Benzyl-L-cysteinylglycine transport in E. coli 
substrate biotransformation assays were carried out using WT pDtpA, WT pDtpB, WT 
pDtpC and WT pDtpD. Cultures containing plasmid were induced overnight to ensure that 
high levels of Dtp protein were present at the beginning of the assay. High benzyl-
mercaptan yield was observed for WT pDtpB, following 10 min incubation (Fig. 5.4.1B). 
No significant differences in benzyl-mercaptan yield were observed for strains 
overexpressing DtpA, DtpC or DtpD, relative to wild-type. This confirms that DtpB is solely 
responsible for uptake of S-Benzyl-L-cysteinylglycine in E. coli. Given the high benzyl-
mercaptan yield following only 10 min incubation (wild-type takes > 1 h to reach a similar 
benzyl-mercaptan yield; see Fig. 5.1A), it can be suggested that native dtpB expression in 
E. coli is low.  
The benzyl-mercaptan yield from S-Benzyl-L-cysteinylglycine biotransformation by WT 
pDtpB increased as the araBAD promoter was titrated with increasing concentrations of L-
arabinose (Fig. 5.4.2A). Maximum benzyl-mercaptan yield was achieved using an 
overnight induction L-arabinose concentration of 0.1%. This was however coupled with a 
decrease in total cell yield (data not shown), suggesting that excessive overexpression of 
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DtpB is toxic to the bacterium. For this reason, all subsequent experiments used an 
overnight L-arabinose induction concentration of 0.0001%, which correlated with high 
benzyl-mercaptan yield (Fig. 5.4.2A) and high cell yield (data not shown).     
To further characterise S-Benzyl-L-cysteinylglycine biotransformation in E. coli, analysis of 
additional mutant strains was carried out. It was observed that S-Benzyl-L-cysteinylglycine 
biotransformation in ∆tnaA cannot be rescued by overexpression of DtpB (Fig. 5.4.2B), 
confirming that substrate uptake and biotransformation are independent processes. It was 
also shown that CCCP was able to inhibit S-Benzyl-L-cysteinylglycine biotransformation in 
WT pDtpB, confirming that a proton gradient is required to transport the substrate into the 
cytoplasm of E. coli. 
Whole cell lysate was prepared from WT pDtpB and used in S-Benzyl-L-cysteinylglycine 
biotransformation assays in parallel with WT pDtpB whole cells to assess the effect of 
peptide competitor molecules on substrate biotransformation. It was predicted that the 
peptide competitors would prevent either transport or intracellular catabolism of S-Benzyl-
L-cysteinylglycine and this assay would discriminate between these two possibilities. 
Almost identical yields of benzyl-mercaptan were produced in whole cells and whole cell 
lysate in the absence of any competitor molecule (Fig. 5.4.3). This confirmed that 
enzymes required to biotransform S-Benzyl-L-cysteinylglycine were captured in the cell 
lysate preparation and remained functional throughout the assay. When dipeptide 
competitor molecules were added, Ala-Tyr failed to inhibit benzyl-mercaptan production in 
whole cells, but inhibited production by whole cell lysate by approximately 72%. This 
suggests that Ala-Tyr inhibits the enzymatic catabolism of S-Benzyl-L-cysteinylglycine but 
does not affect uptake via DtpB. In contrast, both Ala-Ala and Tyr-Ala strongly inhibited 
benzyl-mercaptan production in both whole cell and whole cell lysate assays, suggesting 
that these dipeptides are substrates for the S-Benzyl-L-cysteinylglycine catabolic 
enzyme(s) and potentially DtpB. No significant effect on S-Benzyl-L-cysteinylglycine 
biotransformation was observed following addition of either Gly-Gly or Gly-Gly-Gly, 
confirming that DtpB and the S-Benzyl-L-cysteinylglycine catabolic enzymes are not 
completely promiscuous in terms of substrate specificity.  
In summary, following cloning and overexpression of all four E. coli Dtp peptide 
symporters, it has been demonstrated that S-Benzyl-L-cysteinylglycine is transported 
solely by DtpB, which represents a novel substrate for this transporter. Overexpression of 
DtpB allows for rapid and efficient uptake and biotransformation of S-Benzyl-L-
cysteinylglycine, suggesting that dtpB is expressed at low intrinsic levels in E. coli and the 
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rate of substrate biotransformation is limited at the level of transport. As expected, S-
Benzyl-L-cysteinylglycine uptake via overexpressed DtpB can be blocked by CCCP but 
also Ala-Ala and Tyr-Ala, suggesting that these two dipeptides are also DtpB substrates. 
Some dipeptides, including Ala-Ala, Ala-Tyr and Tyr-Ala, also block the catabolic enzymes 
required to biotransform S-Benzyl-L-cysteinylglycine, providing a cautionary note that not 
all inhibitors of this process act to prevent substrate biotransformation at the level of 
transport.  
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Figure 5.4.1. (A) Plasmid map of pBADcLIC2005. Decahistidine tag (10xHis), origin of 
replication (ori) and LIC insertion site (SwaI) are marked. Plasmid map was created 
using SnapGene Viewer 2.2.2. (B) Biotransformation of S-Benzyl-L-cysteinylglycine by 
Dtp protein-overexpressing E. coli. Cultures containing strains harbouring plasmids 
were pre-induced with 0.0001% L-arabinose overnight. ‘WT empty vector’ refers to 
wild-type E. coli expressing pBADcLIC2005 with no gene insertion. Thioalcohol yield 
(A492) was quantified using MTS/PMS after 10 min incubation. Error bars represent 
standard deviation of three biological replicates. 
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Figure 5.4.2. (A) Biotransformation of S-Benzyl-L-cysteinylglycine by E. coli WT pDtpB 
with decreasing levels of overnight L-arabinose induction. (B) Biotransformation of S-
Benzyl-L-cysteinylglycine by E. coli WT, WT pDtpB, WT pDtpB, ∆tnaA and ∆tnaA 
pDtpB in the presence of 100 µM CCCP. Thioalcohol yield (A492) was quantified using 
MTS/PMS after 30 min incubation (part A) or 10 min incubation (part B). Error bars 
represent standard deviation of three biological replicates. 
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Figure 5.4.3. Biotransformation of S-Benzyl-L-cysteinylglycine by E. coli WT pDtpB 
and whole cell lysate prepared from WT pDtpB in the presence of 20 mM (10-fold 
excess) peptide competitor molecules. Thioalcohol yield (A492) was quantified using 
MTS/PMS after 10 min incubation. Error bars represent standard deviation of three 
biological replicates. 
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5.5  Overexpression of DtpB transforms E. coli into an efficient Cys-
Gly-3M3SH biotransforming bacterium 
It was previously stated that wild-type E. coli K-12 is a poor biotransformer of the 
physiological malodour precursor molecule Cys-Gly-3M3SH. If E. coli is to be a useful 
model organism for malodour production analysis, it is required to biotransform 
physiologically relevant malodour precursor molecules, particularly Cys-Gly-3M3SH. To 
assess whether overexpression of Dtp transport proteins could transform E. coli into a 
Cys-Gly-3M3SH biotransforming bacterium, biotransformation assays were carried out 
with Dtp-overexpressing strains.  
WT pDtpB was able to efficiently convert Cys-Gly-3M3SH into 3M3SH following 5 h 
incubation (Fig, 5.5A). This phenotype was exclusive to WT pDtpB, as neither WT pDtpA, 
WT pDtpC nor WT pDtpD were able to biotransform Cys-Gly-3M3SH. The final 3M3SH 
yield obtained from WT pDtpB (A412 = 0.166) is only 28% less than that obtained from S. 
hominis B10 over the same time period. Intracellular biotransformation of Cys-Gly-3M3SH 
is also dependent on TnaA, as ∆tnaA overexpressing DtpB reaches only negligible 
3M3SH yield (Fig. 5.5.B). This is surprising, given the structural dissimilarity between Cys-
Gly-3M3SH and the biological substrate of TnaA, L-tryptophan. It was also observed that 
CCCP was able to inhibit Cys-Gly-3M3SH biotransformation in WT pDtpB, again, 
confirming that a proton gradient is required to transport the substrate into the cytoplasm 
of E. coli. 
Overall, it was demonstrated here that E. coli K-12 could be converted into a Cys-Gly-
3M3SH biotransforming strain by overexpression of DtpB and also shown that Cys-Gly-
3M3SH biotransformation is dependent upon TnaA.  
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Figure 5.5. Biotransformation of Cys-Gly-3M3SH by (A) Dtp protein-overexpressing E. 
coli and (B) E. coli WT, WT pDtpB, WT pDtpB and ∆tnaA pDtpB in the presence of 100 
µM CCCP. Thioalcohol yield (A412) was quantified using DTNB after 5 h incubation. 
Error bars represent standard deviation of three biological replicates. 
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5.6  Discussion 
Through the work described in this chapter, it is possible to offer a model of malodour 
precursor biotransformation in E. coli, which is detailed in Fig. 5.6. The model suggests 
that Cys-Gly-malodour precursor molecules are transported by DtpB and intracellularly 
catabolised either solely by TnaA, or by a combination of a dipeptidase and TnaA, as 
discussed. The liberated thioalcohol is then excreted from the cell, likely via passive 
diffusion across the membrane into the periplasm and then ultimately to the extracellular 
environment. 
 
It was demonstrated that E. coli is an efficient biotransformer of the model malodour 
precursor substrate S-Benzyl-L-cysteinylglycine. The TLC assay (Fig. 5.1B) shows that S-
Benzyl-L-cysteinylglycine was completely depleted in the buffer medium between 2 and 3 
h after incubation, although the time course of S-Benzyl-L-cysteinylglycine 
biotransformation shows that maximum benzyl-mercaptan yield is not reached until 
approximately 4.5 h. The prolonged time required to fully biotransform the substrate 
following uptake may be due to an overload of substrate inside the cell, as the cells may 
transport S-Benzyl-L-cysteinylglycine faster than they can catabolise it, effectively creating 
a substrate backlog which takes, in this case, 90 minutes to overcome. It was 
demonstrated that S-Benzyl-L-cysteinylglycine is transported by DtpB, with a dtpB 
knockout strain, ∆dtpB, producing only 40% of the benzyl-mercaptan yield compared to 
wild-type (Fig. 5.3). The ∆dtpB strain could be complemented when dtpB was 
overexpressed on a high copy number plasmid with an inducible promoter. 
Overexpression of dtpB converted E. coli into a highly efficient biotransformer not only of 
S-Benzyl-L-cysteinylglycine, but also the physiological malodour precursor substrate, Cys-
Gly-3M3SH. This confirmed that in E. coli, dipeptide-based malodour precursor molecules 
are transported by a protein that recognises the dipeptide moiety of the molecule. It is 
interesting that DtpB should have such a unique function, which was not attributable to 
any other Dtp protein. This suggests a role for DtpB in uptake of unusual peptide-based 
molecules which may explain why no clear phenotype was observed for ∆dtpB during the 
growth phenotype analyses outlined in chapter 4. However, DtpB has been shown to 
transport several simple, non-modified dipeptide molecules including the glycine 
containing dipeptides glycylaspartate (Gly-Asp), lysylglycine (Lys-Gly) and the non-
hydrolysable glycycsarcosine (Gly-Sar) (Harder et al., 2008). This suggests that the 
variety of substrates that DtpB is able to recognise and transport ranges from xenopeptide 
substrates such as S-Benzyl-L-cysteinylglycine and Cys-Gly-3M3SH to conventional 
dipeptides such as those cited by Harder. 
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Figure 5.6. Proposed model of malodour precursor substrate biotransformation by 
E. coli K-12. Cys-Gly-malodour precursor (S-Benzyl-L-cysteinylglycine or Cys-Gly-
3M3SH (shown here)) are transported into the cytoplasm via DtpB. A thiol precursor 
dipeptidase may initially act to cleave glycine from the substrate (displayed in red 
brackets), liberating Cys-malodour precursor prior to further catabolism by TnaA. 
Alternatively, TnaA is able to directly biotransform the Cys-Gly-malodour precursor 
into glycine, ammonia, pyruvate and thioalcohol. The thioalcohol molecule then 
diffuses across the membrane. 
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It may be the case that the Dtp proteins in E. coli (and other members of the 
Enterobacteriaceae) have evolved unique substrate specificities, each playing an 
individual role in specific peptide or peptide-based molecular transport, with some level of 
substrate specificity overlap, as discussed in chapter 4. This would allow the bacterium to 
transport a larger number of peptide-based molecules, increasing the overall pool of 
available growth substrates, potentially conferring a fitness advantage to an individual 
bacterium in a mixed bacterial population. 
It is interesting to note that overexpression of DtpB conferred onto E. coli the ability to 
uptake and biotransform Cys-Gly-3M3SH, a process that wild-type E. coli is unable to 
carry out. Clearly, the inability of E. coli to catabolise Cys-Gly-3M3SH is limited at the level 
of transport and the bacterium possesses the necessary intracellular machinery to 
biotransform the substrate. This indirectly suggests that under growth in LB medium, 
constitutive expression of dtpB is low and that expression of this gene may be induced by 
substrates of the transporter. This would be consistent with the biological substrates of 
other transporters in E. coli which also activate expression of their cognate transporters, 
for example L-arabinose, which activates expression of the L-arabinose symporter araE 
(Daruwalla et al., 1981). 
When the mechanism of intracellular S-Benzyl-L-cysteinylglycine catabolism was 
analysed in more detail, it was surprising that mutants of MetC and MalY, the two 
characterised C-S- β-lyases of E. coli displayed no reduced S-Benzyl-L-cysteinylglycine 
catabolism, given that corynebacterial homologues of MetC are active against S-benzyl-
containing substrates (James et al., 2013). Further analysis revealed that S-Benzyl-L-
cysteinylglycine biotransformation was dependent upon TnaA, the cellular tryptophanase 
of E. coli. TnaA not only degrades tryptophan, but is also one of the most important 
intracellular cysteine desulfhydrase enzymes in the cell (Awano et al., 2003), playing a 
role in intracellular L-cysteine degradation. Previous studies on TnaA revealed that it is 
also able to catalyse the breakdown of S-Benzyl-L-cysteine (Watanabe & Snell, 1977). 
Remarkably, the Km of TnaA for S-Benzyl-L-cysteine is 4-fold lower (0.065 mM) than its 
natural substrate, L-tryptophan (0.3 mM) and both substrates share a similar kcat (5.2 ± 0.4 
s-1 for S-Benzyl-L-cysteine compared to 6.8 s-1 for L-tryptophan) (Phillips et al., 1991). It is 
therefore unsurprising that TnaA is also required for intracellular biotransformation of S-
Benzyl-L-cysteinylglycine, but perhaps more surprising that the same enzyme is required 
for catabolism of Cys-Gly-3M3SH. Given the disparity in structural similarity between the 
hydroxyalkyl groups of S-Benzyl-L-cysteinylglycine and Cys-Gly-3M3SH, it is surprising 
that both can be accommodated and correctly orientated in the active site of TnaA, 
although Watanabe & Snell (1977) demonstrated that TnaA catalyses the breakdown of a 
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wide spectrum of structurally dissimilar substrates. Structurally, TnaA is a homotetramer 
formed of two catalytic dimers with each individual domain consisting of a small and large 
subunit (London & Goldberg, 1972). The first crystal structure of the E. coli apoenzyme 
was solved by Ku et al. (2006) but to date, no holoenzyme structure is available so it is 
difficult to accurately propose how malodour precursor molecules would be orientated in 
the active site of the enzyme. However, structural data of the apoenzyme with L-
tryptophan modelled into the active site (Ku et al., 2006) combined with previous 
biochemical studies (Phillips et al., 2002), suggests that the indole ring of L-tryptophan is 
coordinated by His463 from one subunit of the catalytic dimer and Tyr74 from the other. 
This proposal is based on reports that mutations in either of these residues leads to at 
least a 3000-fold reduction in tryptophanase activity (Phillips et al., 2002). The α-amino 
group of L-tryptophan is proposed to form an imine bond with the lysine-stabilised PLP 
molecule, a function that could feasibly be achieved by the α-amino group of the Cys-Gly 
dipeptide moiety of the malodour precursor molecule. The proposed model of substrate 
orientation in the active site of TnaA is consistent with this enzyme possessing the ability 
to catalyse the biotransformation of S-Benzyl-L-cysteinylglycine. In this instance, the 
benzyl ring of this substrate would be orientated by His463 and Tyr74, although the 
importance of these catalytic residues for β-elimination reactions of non-physiological 
substrates such as S-ethyl-L-cysteine appears to be less important than for L-tryptophan 
(Phillips et al., 2002). However, the observation that TnaA is required to biotransform Cys-
Gly-3M3SH is puzzling as the orientation of the hydroxyalkyl moiety of this molecule in the 
active site of TnaA is difficult to determine. Nonetheless, given that TnaA is promiscuous 
in terms of substrate specificity, it may be that the structural flexibility of the enzyme, as 
demonstrated previously (Tsesin et al., 2007), directly permits the orientation and 
subsequent catabolism of structurally diverse substrates within the active site. 
While TnaA appears to be crucial for malodour precursor biotransformation in E. coli, it 
cannot be responsible for the same process in the high Cys-Gly-3M3SH biotransforming 
Staphylococcus species, as there is no TnaA orthologue in the Staphylococcus genus as 
a whole.  
It also remains unclear whether, in E. coli, an initial dipeptidase step is required to liberate 
the Cys-conjugate of the dipeptide precursor molecule prior to catabolism by TnaA, or 
whether TnaA is able to facilitate the biotransformation of the complete dipeptide 
conjugate. These questions will remain unanswered until further biochemical studies are 
undertaken on TnaA using this newly identified class of substrates.  
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Several dipeptide molecules were shown to inhibit S-Benzyl-L-cysteinylglycine 
biotransformation in E. coli (Fig. 5.4.3). Ala-Ala and Tyr-Ala were particularly effective in 
whole cell and whole cell lysate assays but an additional dipeptide, Ala-Tyr, inhibited S-
Benzyl-L-cysteinylglycine biotransformation only in whole cell lysate assays. In a similar 
vein to the competitor assays undertaken with S. hominis B10, it is unclear whether this 
inhibition is at the level of substrate transport or intracellular catabolism, although it 
appears that Ala-Tyr limits S-Benzyl-L-cysteinylglycine by inhibiting an important 
intracellular enzymatic process, as it was only effective in whole cell lysate assays. 
Competitive inhibition of TnaA by dipeptides has not been demonstrated, despite an 
abundance of amino acids and their structural analogues being able to efficiently prevent 
L-tryptophan catabolism to indole by this enzyme (Watanabe & Snell, 1977). This may 
suggest that dipeptides such as Ala-Tyr inhibit the dipeptidase enzyme which may 
catalyse a putative first step in S-Benzyl-L-cysteinylglycine biotransformation; cleavage of 
the glycine residue to liberate S-Benzyl-L-cysteine which is potentially the genuine 
substrate of TnaA. 
Identification of the transport route along with insight into the intracellular catabolic 
capabilities of E. coli in terms of Cys-Gly-3M3SH biotransformation allows E. coli to be 
used as a model organism to study thioalcohol-based malodour. Previously, C. jeikeium 
has been used as a model Corynebacterium sp. (Troccaz et al., 2009), owing mainly to its 
efficiency in biotransforming the model malodour substrate S-Benzyl-L-cysteine, as 
outlined in Fig. 5.2A. However, as previously discussed, C. jeikieum is unable to 
biotransform Cys-Gly-3M3SH, making it a poor model organism in this respect. Using E. 
coli as a model organism to study this process has an obvious benefit compared to 
staphylococcal or corynebacterial equivalents in that E. coli represents one of the most 
genetically well characterised and tractable bacterial species. This allows multiple gene 
deletions to be made in the host to indirectly study the role of the staphylococcal 
homologues in malodour precursor biotransformation. It also opens up the possibility to 
clone into E. coli staphylococcal genes with putative roles in malodour precursor 
biotransformation in order to test their activity directly. Without the discovery that 
overexpression of dtpB is an essential step in allowing E. coli to biotransform Cys-Gly-
3M3SH, the concept of E. coli as a model host for this biochemical process could not have 
been proposed.  
This work allows provides a proof-of-principle that a gene encoding a transport protein can 
be cloned into pBADcLIC2005 and overexpressed in E. coli, resulting in a gain-of-function, 
as seen here with Cys-Gly-3M3SH biotransformation by overexpression of dtpB. This 
principle can be taken forward by identifying putative Cys-Gly-3M3SH transporters from S. 
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hominis with a view to clone and overexpress them in wild-type E. coli. Any transporter 
that has intrinsic Cys-Gly-3M3SH transport ability will, in principal, convert E. coli into a 
Cys-Gly-3M3SH biotransformer.    
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Introduction and aims 
It was observed that when overexpressed in E. coli, the peptide symporter DtpB 
transforms this organism into an efficient biotransformer of Cys-Gly-3M3SH. This property 
can be exploited by cloning putative Cys-Gly-3M3SH transporters from the skin-isolated 
S. hominis B10 and recombinantly expressing these proteins in E. coli. It is foreseen that 
this will confer a gain-of-function phenotype, similar to that observed when DtpB is 
overexpressed. As no direct orthologue of DtpB is evident in S. hominis, an attempt will be 
made to identify the Cys-Gly-3M3SH transporter in this organism initially by in silico 
analysis. Following this, molecular cloning of the putative transporter gene(s) and 
recombinant expression in E. coli will be performed. 
In E. coli, Cys-Gly-3M3SH is intracellularly catabolised, in part, by TnaA. This was directly 
demonstrated when a ∆tnaA mutant failed to produce malodour (section 5.2). However, 
despite a C-S- β-lyase having been cloned and recombinantly expressed (Troccaz et al., 
2008), the intracellular enzymes involved in Cys-Gly-3M3SH biotransformation in S. 
hominis have not been identified. Therefore, as with identification of the Cys-Gly-3M3SH 
transporter, a similar approach will be taken to identify and characterise the putative C-S- 
β-lyase gene in S. hominis. 
Specific aims 
• To carry out an in silico audit of molecular symporters in S. hominis. 
 
• To clone genes from S. hominis that are putatively involved in Cys-Gly-3M3SH 
transport and use these constructs to complement Cys-Gly-3M3SH 
biotransformation deficient E. coli TD-Pep mutants.  
 
• To identify and clone a putative Cys-Gly-3M3SH biotransforming C-S- β-lyase from 
S. hominis B10 and recombinantly express and functionally complement an E. coli 
∆tnaA strain. 
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6.1  Bioinformatic analysis of the secondary transporter (symporter) 
repertoire of S. hominis SK119 and identification of C-S- β-lyase 
In the model organism E. coli, Cys-Gly-3M3SH uptake is dependent upon the peptide 
symporter, DtpB. However, there is no clear orthologue of DtpB in S. hominis. For this 
reason, a list of all symport proteins of S. hominis SK119 was compiled in order to give a 
complete picture of molecular symport in this bacterium and to aid in identifying the Cys-
Gly-3M3SH transporter, which, as in E. coli, was postulated to be a peptide transporter. S. 
hominis SK119 was used for the bioinformatic analysis as it represents a genome 
sequenced S. hominis strain, originally isolated from human skin (Tatusova et al., 2014). 
Unfortunately, no genome sequence is available for the skin isolate S. hominis B10. 
Although SK119 was not characterised biochemically for Cys-Gly-3M3SH 
biotransformation activity, it is strongly hypothesised that this strain, as is the case with 
90% of other S. hominis strains tested (see section 3.6), would have the molecular 
capacity to produce thioalcohol malodour.   
51 annotated symporters were identified in S. hominis SK119 (Table 6.1). Within this list, 
there is a single annotated peptide symporter, STAHO0001_1446 (NCBI: EEK12089.1) 
and another symporter, STAHO0001_0415 (NCBI: EEK11635.1), which, following a more 
detailed substrate specificity analysis was also identified as a peptide transporter. The 
genome context of these two genes is shown in Fig. 6.1A. It was anticipated that, as in E. 
coli, the inability of a particular Staphylococcus species to biotransform Cys-Gly-3M3SH 
would be limited at the level of transport. If this hypothesis were correct, then bacteria that 
could biotransform Cys-Gly-3M3SH, S. hominis, S. lugdunensis and S. haemolyticus (plus 
potentially other staphylococci that were not included in the original screen) would 
possess a peptide transporter that was absent from non-Cys-Gly-3M3SH biotransforming 
staphylococci. Further analysis revealed that STAHO0001_0415 is present only in S. 
hominis and S. haemolyticus, whereas STAH0001_1446 is present in all sequenced 
staphylococci and therefore likely to participate in general peptide uptake. Although the 
candidate Cys-Gly-3M3SH transporter STAHO0001_0415 was not present in S. 
lugdunensis, it represented the most likely transporter of Cys-Gly-3M3SH and therefore 
became the focus of subsequent experimental analysis. STAHO0001_1446 was also 
taken forward as a control. 
The BioCyc Database Collection was also used to identify the putative C-S- β-lyase 
enzyme that was hypothesised to be involved in Cys-Gly-3M3SH catabolism in S. 
hominis. A single annotated C-S- β-lyase gene, STAHO0001_2140, was identified through 
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analysis of the S. hominis SK119 genome. The genome context of this gene is shown in 
Fig. 6.1B. With no prior knowledge of the relative activity of staphylococcal C-S- β-lyase 
proteins in terms of malodour precursor biotransformation, STAHO0001_2140 
represented an appropriate candidate to test for activity against Cys-Gly-3M3SH.   
In summary, bioinformatics-based analysis identified two candidate Cys-Gly-3M3SH 
transporters in the model S. hominis strain SK119, along with a putative C-S- β-lyase 
gene with potential malodour precursor biotransformation activity. These three candidates 
were taken forward for experimental characterisation.  
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Table 6.1. Metabolite symporters of S. hominis SK119 as identified using BioCyc Database 
Collection. Genes identified in this analysis were annotated as either a ‘permease’ or 
‘transporter’ and are encoded by a single chromosomal gene. STAHO0001_XXXX is the 
BioCyc locus identifier and the EEK number represents the NCBI identifier. The two putative 
Cys-Gly-3M3SH transporters, STAHO0001_0415 and STAHO0001_1446 are highlighted in 
yellow. 
173 


 


 
 


  
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Genome context of (A) STAHO0001_1446 (i) and STAHO0001_0415 (ii) and (B) 
STAHO0001_2140. The genome context was reproduced from the original BioCyc graphical 
representation at each respective locus. Not to scale. 
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6.2  Cloning, expression and characterisation of S. hominis B10 
peptide transporters 
S. hominis B10 was used as the parental strain for gene cloning as it represents a direct 
skin-isolated S. hominis strain. With no available genome sequence for S. hominis B10, 
degenerate primers were designed for each gene using the genome sequence of S. 
hominis SK119 as a template. 
Both STAHO0001_0415 and STAHO0001_1446 were amplified successfully from S. 
hominis B10. These genes were cloned into pBADcLIC2005 and named pSH0415 and 
pSH1446, linking them to their specific S. hominis gene locus identifiers. Wild-type E. coli 
K-12 was transformed with pSH0415 and pSH1446. Malodour precursor biotransformation 
assays were repeated with these new strains to assess if a gain-of-function phenotype 
was conferred. 
The ability of STAHO0001_1446 and STAHO0001_0415 to convert wild-type E. coli from 
a poor to an efficient biotransformer of S-Benzyl-L-cysteinylglycine was assessed. 
Overexpression of STAHO0001_0415 improved the ability of E. coli to metabolise S-
Benzyl-L-cysteinylglycine (Fig. 6.2A). However, there was no observable phenotype when 
STAHO0001_1446 was overexpressed, suggesting that this protein is not involved in the 
transport of this molecule.  
In contrast, when uptake of Cys-Gly-3M3SH was studied, no gain-of-function was 
attributable to overexpression of STAHO0001_0415, confirming that, despite showing an 
affinity for S-Benzyl-L-cysteinylglycine, this transporter does not transport Cys-Gly-
3M3SH.  However, Cys-Gly-3M3SH biotransformation was dramatically improved when 
SHATO0001_1446 was overexpressed (Fig. 6.2B), with cells producing a total 3M3SH 
yield 2-fold higher than when overexpressing dtpB following 4 h incubation, suggesting 
that STAHO0001_1446 has a high affinity for Cys-Gly-3M3SH.  
Although the cloned inserts were only sequenced following integration into 
pBADcLIC2005 and not directly following PCR amplification, the observed activity of both 
constructs against malodour precursor substrates implies that the cloned genes are 
expressed and functional in the E. coli system. 
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Overall, it was established that the protein product of the S. hominis B10 gene 
STAHO0001_0415 is responsible for S-Benzyl-L-cysteinylglycine uptake, whereas 
STAHO0001_1446 is responsible for uptake of the physiological malodour precursor Cys-
Gly-3M3SH. All sequenced staphylococci have an orthologue of STAHO0001_1446, 
suggesting that all species are able to uptake Cys-Gly-3M3SH. Logically, this suggests 
that the ability to biotransform Cys-Gly-3M3SH in staphylococci is limited not by transport 
of the substrate into the cell, but at the level of intracellular substrate biotransformation.  
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Figure 6.2. Biotransformation of (A) S-Benzyl-L-cysteinylglycine and (B) Cys-Gly-
3M3SH by E. coli overexpressing STAHO0001_1446 (pSH1446) and 
STAHO0001_0415 (pSH0415). E. coli overexpressing dtpB (pDtpB) is shown for 
reference. ‘Empty vector’ refers to E. coli expressing pBADcLIC2005 with no gene 
insertion. Cultures containing strains harbouring plasmids were pre-induced with 
0.0001% L-arabinose overnight. Thioalcohol yield (A412) was quantified using DTNB 
after 30 min incubation for S-Benzyl-L-cysteinylglycine and 4 h (blue bars) and 24 h 
incubation (green bars) for Cys-Gly-3M3SH. Error bars represent standard deviation of 
three biological replicates. 
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6.3  Cloning, expression and characterisation of S. hominis B10 C-
S- β-lyase 
Given that the ability to biotransform Cys-Gly-3M3SH in staphylococci is not limited by the 
ability to transport the substrate into the cell, but at the level of intracellular substrate 
biotransformation, characterisation of a C-S- β-lyase protein identified originally in S. 
hominis SK119 was carried out.  
STAHO0001_2140, the candidate C-S- β-lyase from S. hominis SK119, was amplified 
from S. hominis B10 and cloned into pBADcLIC2005.  E. coli strain ∆tnaA was 
transformed with the resulting plasmid, pSH2140, and malodour precursor 
biotransformation assays were repeated using model malodour substrates with the new 
strain to assess for complementation of TnaA. 
The ability of STAHO0001_2140 to functionally complement ∆tnaA was assessed by S-
Benzyl-L-cysteine and S-Benzyl-L-cysteinylglycine biotransformation assays. It was 
observed that STAHO0001_2140 could complement the tnaA mutation in S-Benzyl-L-
cysteine biotransformation assays (Fig. 6.3A) but not in S-Benzyl-L-cysteinylglycine 
assays (Fig. 6.3B). While STAHO0001_2140 cannot catabolise S-Benzyl-L-
cysteinylglycine, logically, it suggests that TnaA does have this ability. Therefore, TnaA 
may either have intrinsic dipeptidase activity, or have the ability to catalyse a β-elimination 
reaction directly from S-Benzyl-L-cysteinylglycine, liberating benzyl-mercaptan without the 
requirement to first cleave glycine. The previously suggested hypothesis that an additional 
enzyme is required to liberate S-Benzyl-L-cysteine from S-Benzyl-L-cysteinylglycine prior 
to liberation of benzyl-mercaptan by TnaA in E. coli appears unlikely.  
In summary, when expressed in E. coli ∆tnaA, STAHO00001_2140 is unable to 
biotransform S-Benzyl-L-cysteinylglycine, suggesting that TnaA can directly biotransform 
this substrate. This also suggests that STAHO0001_2140 is not responsible for 
biotransformation of the physiological malodour precursor Cys-Gly-3M3SH and a different 
protein(s) with C-S- β-lyase activity are likely to carry out this reaction in S. hominis. It was 
not possible to assess biotransformation of Cys-Gly-3M3SH by STAHO0001_2140, as 
biotransformation of this substrate in E. coli requires overexpression of DtpB (Fig. 5.5A), a 
feature that could not be achieved in E. coli ∆tnaA due to plasmid incompatibility issues. 

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Figure 6.3. Biotransformation of (A) S-Benzyl-L-cysteine and (B) S-Benzyl-L-
cysteinylglycine by ∆tnaA E. coli expressing STAHO0001_2140. Cultures containing 
strains harbouring plasmids were pre-induced with 0.0001% L-arabinose overnight. 
Thioalcohol yield (A412) was quantified using DTNB after 2 h incubation (blue bars) and 
4 h incubation (green bars). Error bars represent standard deviation of three biological 
replicates. 
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6.4  Bioinformatic-based analysis of malodour precursor catabolic 
genes in staphylococci 
Following preliminary characterisation of STAHO0001_2140, which implied that this 
protein could not directly biotransform the model dipeptide malodour substrate S-Benzyl-
L-cysteinylglycine, an attempt was made to identify the gene(s) responsible for malodour 
precursor biotransformation. Due to time constraints, a bioinformatic-based 
characterisation was the only feasible option available. The protein sequence of the 
characterised C-S- β-lyase from C. jeikeium K411 was used as a BLAST template to 
search for homologous proteins in staphylococci, particularly S. hominis, S. haemolyticus 
and S. lugdunensis.  
The sequences of candidate staphylococcal C-S- lyase proteins were compiled and the 
phylogenetic relationship between these proteins is displayed in Fig. 6.4.1. The majority of 
staphylococci have three C-S- lyase-type proteins, one of which from each species forms 
a clade of proteins orthologous to the partially characterised protein STAHO0001_2140. 
Of the other two clades of C-S- lyase-type proteins, one was homologous to the MetC 
family (see section 1.5.3) and the other was annotated as a cystathionine gamma-
lyase/synthase. Interestingly however, an additional protein (forming a fourth C-S- lyase-
type protein clade) was identified in S. hominis C80 (EFS20384.1), S. hominis SK119 
(EEK11697.1), S. lugdunensis HKU-09-01 (YP_003470502.1) and S. haemolyticus 
JCSC1435 (YP_252136.1), and also in other strains of these three species (not shown). 
These four proteins are all annotated as aminotransferases, although this arbitrary 
annotation is likely to be incorrect as it is common for experimentally characterised C-S- 
β-lyase proteins to be incorrectly annotated as aminotransferases in the first instance 
such as PatB from B. subtilis, for example (Auger et al., 2005). When EEK11697.1 was 
used as a BLAST query, it was clear that this protein shares no orthology with any other 
protein across the bacterial kingdom (Fig. 6.4.2A). The closest non- S. hominis, S. 
lugdunensis or S. haemolyticus match is from Eubacterium acidaminophilum, an obligate 
anaerobic amino-acid degrading bacterium originally isolated from black mud samples 
(Zindel et al., 1988). Multiple protein domains are present in EEK11697.1. The majority 
relate to aminotransferase activity, for example AAT_like, Aminotran_1_2 and 
Aminotran_3 domains were all detected, along with two C-S- lyase activity domains such 
as MalY and C-S-lyase_PatB (Fig. 6.4.2B). 
The genome context of the protein is similar in all 3 species, although in S. hominis SK119 
and S. haemolyticus JCSC1435, the putative Cys-Gly-3M3SH biotransforming enzyme is 
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located in an operon with a small, 135 amino acid-long hypothetical protein. This small 
protein in absent from the genome of S. lugdunensis HKU-09-01, suggesting that it is not 
essential for Cys-Gly-3M3SH biotransformation, assuming that these genome sequenced 
strains are all efficient biotransformers of Cys-Gly-3M3SH. When this hypothetical protein 
is used as a BLAST query, there appear to be no orthologues in any organism apart from 
S. hominis and S. haemolyticus (data not shown). The only functional domain present is 
annotated as COG2128, which is functionally unassigned. The closest matching protein 
with an annotated function is WP_0100947466.1fromOrnithinibacillus scapharcae, which 
is annotated as an alkylhydroxyperoxidase. Without access to the specific genome-
sequenced Staphylococcus isolates it is difficult to make strong predictions regarding the 
role of the putative alkylhydroxyperoxidase in Cys-Gly-3M3SH biotransformation, if any, 
particularly as it is not present in S. lugdunensis. 
Overall, through bioinformatic-based analysis, a putative Cys-Gly-3M3SH biotransforming 
protein has been identified in S. hominis, S. lugdunensis and S. haemolyticus. This protein 
appears to be unique to these three organisms as no orthologous protein was identified in 
any other bacteria. This suggests that these proteins likely play a unique role in the cell, 
possibly in Cys-Gly-3M3SH biotransformation. 
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Figure 6.4.1. Rooted phylogenetic tree showing the relationship between C-S- lyase type 
proteins in staphylococci. Clades of orthologous staphylococci proteins are coloured 
individually with the unique clade of putative Cys-Gly-3M3SH biotransforming proteins 
coloured red. Examples of experimentally characterised C-S- lyase proteins from E. coli, 
Bacillus spp. and L. lactis are included for reference. Multiple sequence alignment and 
phylogenetic tree building was carried out using ClustalX2. 
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Figure 6.4.2. (A) BLAST search using the protein sequence of EEK11697.1 as a query 
searching for homologous proteins in the bacterial kingdom (B) Identification of multiple 
functional domains of the protein EEK11697.1 via the NCBI domain analysis database. 
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6.5  Discussion 
In this chapter, two putative Cys-Gly-3M3SH transporters, STAHO0001_1446 and 
STAHO0001_0415 were identified based on analysis of the S. hominis SK119 genome. 
Only peptide transporters were studied as it had been previously demonstrated that in E. 
coli, a dedicated peptide transporter was responsible for uptake of Cys-Gly-3M3SH. 
Neither STAHO0001_1446 nor STAHO0001_0415 had been experimentally characterised 
and little is known about peptide transport in general in S. hominis, presumably due to the 
clinical insignificance of this species in relation to the important clinical pathogen, S. 
aureus. Overexpressed STAHO0001_1446 from S. hominis B10 transformed wild-type E. 
coli into an efficient biotransformer of Cys-Gly-3M3SH, demonstrating that the 
physiological malodour precursor substrate is transported with high capacity by this 
protein. Given that it was demonstrated in chapter 5 that the E. coli PTR family transporter 
DtpB was responsible for Cys-Gly-3M3SH, it is unsurprising that STAHO0001_1446 is 
also member of the same transporter family. An orthologue of STAHO0001_1446 is 
present in all sequenced Staphylococcus spp. and consequently it can be hypothesised 
that all staphylococci have the ability to transport Cys-Gly-3M3SH across the cell 
membrane, but only a limited number such as those identified here as S. hominis, S. 
haemolyticus and S. lugdunensis possess the necessary intracellular enzymes required to 
biotransform the substrate into thioalcohol product. Knowledge of peptide transport in 
staphylococci is mainly limited to analyses of S. aureus. Perry & Abraham (1979) used a 
competitive inhibition assay to show that a wide range of di- and tripeptides are taken up 
by this organism, although the authors acknowledge that multiple peptide transport 
systems are likely to exist and so the exact route for general peptide uptake in S. aureus 
remained uncertain. A subsequent study by Perry (1980) similarly identified several di- 
and tripeptide substrates for S. aureus that were able to reduce the bactericidal effects of 
the peptide antibiotic bacilysin, with Ala-Ala-Ala being particularly effective among the 
chosen library of competitors. Interestingly, blocking either the N- or C-terminus of Ala-
Ala-Ala with an acetyl methyl group, respectively, resulted in significant loss of 
antagonistic effect, suggesting that the general peptide transport system of S. aureus 
requires unsubstituted carboxy- and amino-termini to facilitate substrate entry into the cell. 
This structural requirement of peptide substrates is similar to that of the high affinity dpp 
and opp peptide transport systems of E. coli, both of which require the presence of an 
unsubstituted α–amino group (Payne, 1971), and for dpp, the presence of an 
unsubstituted terminal carboxyl-group (Payne, 1968). It was later demonstrated that S. 
aureus NCTC8325 possesses four Opp-like proteins that are able to transport peptides 
ranging in size from 3 to 8 amino acids in length (Hiron et al., 2007). Interestingly 
however, dipeptide transport in this organism is driven solely by DtpT, the S. aureus 
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orthologue of S. hominis STAHO0001_1446. With most staphylococci possessing an 
orthologue of STAHO0001_1446, it is likely that in staphylococci, dipeptide transport is 
driven solely by this transporter. Logically, this suggests that the substrate specificity of 
this transporter must be relatively wide-ranging as staphylococci do not appear to possess 
an alternative route for dipeptide uptake. Hiron et al. (2007) also demonstrated that DtpT 
of S. aureus NCTC8325 is solely responsible for the uptake of several tripeptides, 
including Gly-Gly-Gln and Lys-Gly-Gly, suggesting that transport of the dipeptide 
malodour precursor substrate Cys-Gly-3M3SH would not be excluded from the binding 
cavity of DtpT based on size, as confirmed here when STAHO0001_1446 was shown to 
actively transport this substrate when overexpressed in E. coli.  
In terms of intracellular catabolism of Cys-Gly-3M3SH, it was demonstrated by Emter & 
Natsch (2008) that Corynebacterium sp. Ax20 possesses a novel dipeptidase (TpdA) that 
is able to cleave the glycine residue from Cys-Gly-3M3SH to liberate Cys-3M3SH. The 
group further demonstrated that liberated Cys-3M3SH is a substrate for the β-lyase of the 
same organism, confirming that in vitro, Corynebacterium sp. Ax20 employs a two-
enzyme Cys-Gly-3M3SH biotransformation process to liberate 3M3SH. Orthologues of 
tpdA are not widespread among the bacterial kingdom and there are no clear orthologues 
in staphylococci. Therefore, S. hominis, S. haemolyticus and S. lugdunensis must employ 
a different enzyme or enzymes in order to biotransform malodour precursor molecules. In 
disagreement with the observation by Emter & Natsch, it was demonstrated here that 
recombinant C-S- β-lyase from S. hominis B10 (STAHO0001_2140) was only able to fully 
complement ∆tnaA in biotransformation of S-Benzyl-L-cysteine and not S-Benzyl-L-
cysteinylglycine (Fig. 6.3). This indirectly suggests that in contrast to Corynebacterium sp. 
Ax20, wild-type E. coli, employs only a single enzyme, TnaA, for biotransformation of 
dipeptide malodour precursor molecules such as S-Benzyl-L-cysteinylglycine. This 
proposal corresponds to observations made by Starkenmann et al. (2005), on studies 
relating to the high Cys-Gly-3M3SH biotransforming bacterium, S. haemolyticus. 
Starkenmann postulates that a single enzyme is responsible for Cys-Gly-3M3SH 
biotransformation in S. haemolyticus. In the 2005 study, it was demonstrated that S. 
haemolyticus is able to accomplish Cys-Gly-3M3SH biotransformation (75% product yield) 
more efficiently than biotransformation of the smaller malodour precursor molecule, Cys-
3M3SH (25% product yield). This result suggested to Starkenmann that S. haemolyticus 
possesses a novel enzyme that is able to directly catabolise Cys-Gly-3M3SH. This is 
because dual-step biotransformation of Cys- and Cys-Gly-3M3SH should yield an 
equivalent amount of 3M3SH in both cases as the C-S- β-lyase step is dependent upon 
the initial dipeptidase step. This is an attractive hypothesis, however, a simpler 
explanation relates to differences in the transport rate of Cys-Gly-3M3SH, which is 
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actively transported into the cell by STAHO0001_1446 (in S. hominis), compared to Cys-
3M3SH which, being a smaller molecule, is more likely to passively diffuse into the cell. 
This would lead to a slower biotransformation rate of Cys-3M3SH and lower thioalcohol 
yield, possibly explaining why Starkenmann observed lower 3M3SH yield from S. 
haemolyticus biotransformation of Cys-3M3SH compared to Cys-Gly-3M3SH. 
Following on from this initial observation by Starkenmann, Troccaz et al. (2008), cloned 
the putative Cys-Gly-3M3SH C-S- β-lyase from S. haemolyticus, expressed the 
recombinant enzyme and characterised its biochemical activity against common C-S- β-
lyase substrates along with malodour precursor molecules. Curiously, the recombinant 
enzyme showed little activity against Cys-Gly-3M3SH (0.01% activity) or Cys-3M3SH 
(0.22% activity), relative to activity against the natural C-S- β-lyase substrates, L-
cystathionine. It therefore appears that a different enzyme is responsible for 
biotransformation of Cys-Gly-3M3SH in S. haemolyticus, possibly the orthologue of the S. 
hominis gene STAHO0001_0481, as identified in Fig. 6.4.1. 
STAHO0001_0481 from S. hominis SK119 represents a gene encoding a novel enzyme 
in the respect that an orthologue can only be identified in those other bacteria able to 
biotransform Cys-Gly-3M3SH: S. haemolyticus and S. lugdunensis. Both S. hominis 
STAHO0001_0481 and E. coli TnaA are part of the AAT_I (aspartate aminotransferase 
fold type I) superfamily, suggesting that although they share little sequence similarity at 
the amino acid level, there is some common domain architecture between the two 
proteins, which may lead to overlapping functionalities in terms of malodour precursor 
biotransformation. 
In summary, a S. hominis peptide transporter, STAHO0001_1446, has been identified, 
experimentally characterised and shown to transport the physiological malodour precursor 
molecule, Cys-Gly-3M3SH. A strong bioinformatics-based hypothesis has also been 
proposed which suggests that once internalised by STAHO0001_1446, Cys-Gly-3M3SH is 
catabolised by a novel aminotransferase-like protein, STAHO0001_0481, which is only 
present in those staphylococci that show strong Cys-Gly-3M3SH biotransformation activity 
(S. hominis, S. lugdunensis and S. haemolyticus). These findings represent novel insights 
into the molecular mechanism of thioalcohol-based malodour by members of the axillary 
microbiota and open up the possibility of employing novel strategies to directly target 
specific proteins involved in catabolism of such precursor substrates in order to reduce the 
formation of axillary malodour. 
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In this study, E. coli was used as a model organism to study thioalcohol-conjugated 
malodour precursor biotransformation. A series of peptide transporter-deficient (TD-Pep) 
E. coli strains were created and phenotypically characterised. This revealed an interesting 
pattern of substrate recognition for the lesser-studied PTR-family transporters, DtpA, 
DtpB, DtpC and DtpD. Strong phenotypic growth defects were observed when multiple 
PTR transporters were mutated and the strains subsequently grown on peptide-containing 
media, suggesting that the overall contribution of these transporters to growth on peptides 
is likely to be more important that previously suggested. A strong phenotype was 
particularly apparent when ∆dtpA ∆dtpB ∆dtpC ∆dtpD (∆DB5) was grown on Ala-Ala as 
the sole source of nitrogen, suggesting that multiple PTR proteins are able to recognise 
and transport this simple dipeptide substrate. Additionally, dipeptide-conjugated malodour 
precursor compounds were also transported by the PTR transporter DtpB which 
represents a novel phenotype for a member of this family. It also suggests that the 
substrate specificity of PTR transporters, particularly DtpB, is dynamic and able to 
accommodate structurally diverse molecules. This observation potentially re-opens the 
possibility of designing novel antimicrobials that are specifically targeted for uptake by 
these proteins, rather than following the earlier proposal of targeting such compounds to 
the Dpp and Opp systems (Ames et al., 1973, Diddens et al., 1976). Although to do this, a 
comprehensive analysis of the entire substrate specificity of the PTR transporters would 
have to be carried out, perhaps by designing a high-throughput substrate screening 
method.  
The more widely characterised ABC peptide transporters Opp and Dpp were also studied 
and the findings generally supported previous literature suggesting that Opp is a general 
oligopeptide transporter (Hiles et al., 1987, Naider & Becker, 1975). The ability of both 
Opp and Dpp to transport dipeptides was also reinforced when a double mutant, ∆dppC 
∆oppC (∆DB1) displayed a weaker growth rate on Ala-Phe as the sole source of nitrogen, 
compared to either single mutant strain alone. No phenotype was observed for dpp or opp 
mutants when required to transport dipeptide-conjugated malodour precursor molecules, 
again reinforcing the importance of E. coli Dtp transporters.  
Specifically regarding the biochemical basis of axillary malodour, this project has 
assessed, in detail, the relative contribution of multiple axillary-isolated bacterial species 
to thioalcohol-based malodour. Whole cell Cys-Gly-3M3SH biotransformation assays 
revealed that three Staphylococcus species, S. hominis, S. lugdunensis and S. 
haemolyticus were the most active biotransformers of this substrate and generated a 
significantly greater thioalcohol yield than other Staphylococcus spp. or any 
corynebacteria. This discovery casts doubt on to previous observations that 
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corynebacteria, particularly C. tuberculostearicum, contribute to thioalcohol-based 
malodour (Jackman & Noble, 1983, Taylor et al., 2003, James et al., 2013), given that in 
this study, 8 out of 8 C. tuberculostearicum isolates were unable to generate 3M3SH. 
These findings also raise questions about the overall contribution of the genus 
Corynebacterium to typical axillary malodour, given that the most prevalent 
Corynebacterium spp. within the axillary microbiota, C. tuberculostearicum and C. 
mucifaciens (Taylor et al., 2003) are not involved in either thioalcohol- or VFA-associated 
malodour (James et al., 2013), the two major axillary odour pathways. It is possible that a 
Corynebacterium-dense axilla is associated with but not causal to the high-odour axilla 
phenotype. This mis-association could be ubiquitous for several reasons. Firstly, the 
relative abundance of different Staphylococcus species in a malodorous axilla has never 
been investigated, so it is possible that high corynebacterial numbers drive up the relative 
proportion of thioalcohol-producing staphylococci such as S. hominis, S. lugdunensis and 
S. haemolyticus. This would effectively lead to a case of mistaken identity, whereby 
corynebacteria are wrongly linked to malodour. Conversely, in a staphylococcal 
dominated axilla, where the most prevalent species is likely to be S. epidermidis (Kloos & 
Musselwhite, 1975), the S. hominis, S. lugdunensis and S. haemolyticus population may 
be much lower resulting in a non-malodour phenotype. This would lead to what is 
observed in literature, whereby the genus Staphylococcus is not correlated with axillary 
malodour (Taylor et al., 2003). It is also feasible but unlikely that corynebacteria are able 
to biotransform a yet to be identified malodour molecule with particularly high olfactory 
impact. Clearly there is a requirement to quantify the axillary microbiota at the species 
level. With the advent of high-throughput DNA sequencing it would be feasible to adopt a 
metagenomic approach to sequence and delineate the relative abundance of individual 
bacterial species across a statistically significant number of axillae. It would also be 
interesting to note any evolutionary-associated patterns, for example, do individuals that 
are unable to secrete Cys-Gly-3M3SH due to the ABCC11 mutation (Martin et al., 2010) 
carry a lower percentage of S. hominis than individuals with a functional ABCC11 allele? 
Similarly, is there a relationship between the abundance of S hominis in the axilla and the 
amount of 3M3SH produced? 
Also in this work, the biochemical basis of Cys-Gly-3M3SH biotransformation in S. 
hominis has been characterised, with uptake of the molecule in this bacterium mediated 
by a general staphylococcal transport protein, STAHO0001_1446. This transporter, a 
member of the PTR family, is present in all sequenced staphylococci. The partially-
characterised orthologue in S. aureus participates in general peptide uptake (Perry, 1980). 
Evidently, the substrate specificity of STAHO0001_1446 is dynamic enough to bind and 
transport dipeptide analogues and, similar to most characterised peptide transporters, 
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likely recognises the peptide backbone of the molecule rather than the side chain. It would 
be interesting to elucidate whether STAHO0001_1446 has evolved to specifically 
recognise and transport Cys-Gly-3M3SH, or whether Cys-Gly-3M3SH transport can be 
mediated by STAHO0001_1446 orthologues from a parent strain that does not 
biotransform Cys-Gly-3M3SH, such as S. aureus. This would be a relatively simple 
experiment to carry out and would only require cloning of the orthologous S. aureus gene 
and expression in E. coli followed by a Cys-Gly-3M3SH biotransformation assay to assess 
functional complementation. It would be appealing to determine whether 
STAHO0001_1446 is also able to recognise and transport the minor thioalcohol-
conjugated precursor, Cys-3M3SH. Despite being present in apocrine secretions at 
relatively low abundance compared to Cys-Gly-3M3SH (Emter & Natsch, 2008), the 
bacterium would certainly benefit if the same transporter could import both molecules, 
although this is unlikely to be the case given the absence of a peptide bond in Cys-
3M3SH. 
In addition to characterising the transport mechanism of Cys-Gly-3M3SH in physiologically 
relevant bacteria, a hypothesis was proposed describing the most likely route of 
intracellular substrate catabolism. It was suggested that the ability to biotransform Cys-
Gly-3M3SH was limited at the level of intracellular catabolism, given that all staphylococci, 
in theory, have the ability to transport this molecule. Using in silico analysis, a unique 
aminotransferase-like protein with C-S- β-lyase activity was identified and is only present 
in those Staphylococcus species able to biotransform Cys-Gly-3M3SH. Following this 
observation, the immediate experimental objective would be to clone this gene from S. 
hominis and assess its ability to convert a non-Cys-Gly-3M3SH biotransforming 
Staphylococcus sp. into a thioalcohol producing strain. This could be achieved using a 
Staphylococcus/E. coli shuttle vector and would categorically demonstrate that Cys-Gly-
3M3SH biotransformation is limited by an inability of most Staphylococcus spp. to 
intracellularly catabolise the substrate. 
The effectiveness of using model substrates to characterise important physiological 
processes was questioned when it was demonstrated that the pattern of biotransformation 
of the model thioalcohol-conjugated dipeptide substrate S-Benzyl-L-cysteinylglycine by 
individual bacterial species was completely different to that of the physiological substrate 
Cys-Gly-3M3SH. From the bioinformatic-based analysis, this difference likely stems from 
the specific enzymes involved in the biotransformation of these substrates. S-Benzyl-L-
cysteinylglycine is likely metabolised by a general cystathionase-type C-S- β-lyase 
whereas Cys-Gly-3M3SH is hypothesised to be broken down by the unique bacterial lyase 
only present in S. hominis, S. lugdunensis and S. haemolyticus. For this reason, general 
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C-S- β-lyase activity can no longer be used a sufficient measure of Cys-Gly-3M3SH 
biotransformation ability.    
Human body odour has been subjectively described for centuries but with significant 
technological advancement over the previous decades, the microbial, molecular and 
biochemical origins of body odour are becoming apparent. Historically, body odour is likely 
to have served as a specific and necessary olfactory cue but as modern society evolved it 
became an unpleasant and undesirable facet of human evolution. This work provides 
significant molecular and biochemical evidence for the route to thioalcohol-based odour in 
the human axilla.  
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Abbreviations 
 
3M2H    (E)-3-methyl-2-hexenoic acid 
3M3SH   3-methyl-3-sulfanylhexanol 
Axxx    Optical absorbance at stated wavelength of light 
ABC    ATP-binding cassette 
AHAS    Acetohydroxy acid synthase 
Amp    Ampicillin 
ASOB1   Apocrine Secretion Odor-Binding protein 1 
ASOB2   Apocrine Secretion Odor-Binding protein 2 
BLAST    Basic Local Alignment Search Tool 
Cam    Chloramphenicol 
CCCP    Carbonyl cyanide m-chlorophenyl hydrazone 
Cys-Gly-3M3SH  (S)-(1-(2-hydroxyethyl)-1-methylbutyl)-L-cysteinylglycine 
C-S- β-lyase   Carbon-sulphur (usually cystathionine)- beta-lyase 
dATP    Deoxyadenosine triphosphate  
dCTP    Deoxycytosine triphosphate  
dGTP    Deoxyguanosine triphosphate  
dH2O    Distilled water 
DTNB    5,5'-dithiobis-(2-nitrobenzoic acid) 
dTTP    Deoxythymidine triphosphate  
DHT    5α-dihydrotestosterone 
GC-MS   Gas chromotography-mass spectrometry 
HMHA    3-hydroxy-3-methylhexanoic acid 
HPLC    High-performance liquid chromatography 
HPLC/GC High-performance liquid chromatography coupled to gas 
chromatography 
LIC    Ligation-independent cloning 
LB    Luria-Bertani 
LC-MS    Liquid chromatography-mass spectrometry 
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MHC    Major histocompatibility complex 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) 
NCBI National Center for Biotechnology Information 
NTB- 2-nitro-5-thiobenzoate 
OBP    Odorant binding protein 
OD    Optical density 
POT    Proton-dependent oligopeptide transporter 
ppb    Parts per billion 
PCR    Polymerase chain reaction 
PMS    Phenazine methosulfate 
Psi    Parts per square inch 
Rpm    Revolutions per minute 
SOC    Super optimal broth with catabolite repression 
TD Pep   Peptide transporter-deficient E. coli 
TLC    Thin layer chromatography 
TSAT    Tryptone soy broth with tween (agar) 
TSBT    Tryptone soy broth with tween 
MRM    Minimal recovery medium 
sp.    Species (singular) 
spp.     Species (plural) 
WT    Wild-type 
w/v    Weight to volume ratio 
VFA    Volatile fatty acid 
v/v    Volume to volume ratio 
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